<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="17814"><DrugName>pregabalin</DrugName><DrugNamesKey><Name id="42982505">Lyrica</Name><Name id="43103957">Lyrica Capsules</Name><Name id="43103958">Lyrica OD Tablets</Name><Name id="42752264">pregabalin</Name></DrugNamesKey><DrugSynonyms><Name><Value>pregabalin</Value><Types><Type>INN</Type></Types></Name><Name><Value>CI-1008</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>PGB</Value></Name><Name><Value>PD-144723</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>S-isobutylGABA</Value></Name><Name><Value>Lyrica</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Lyrica Capsules</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Lyrica OD Tablets</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>148553-50-8</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="20787">Warner-Lambert Co</CompanyOriginator><CompaniesPrimary><Company id="18767">Pfizer Inc</Company></CompaniesPrimary><CompaniesSecondary><Company id="20787">Warner-Lambert Co</Company><Company id="20805">Parke-Davis &amp; Co</Company></CompaniesSecondary><CrossReferences><SourceEntity id="17814" type="Drug"><TargetEntity id="194644" type="siDrug">Pregabalin</TargetEntity></SourceEntity><SourceEntity id="18767" type="Company"><TargetEntity id="4295904722" type="organizationId">Pfizer Inc</TargetEntity></SourceEntity><SourceEntity id="20787" type="Company"><TargetEntity id="5000822663" type="organizationId">Warner Lambert Co</TargetEntity></SourceEntity><SourceEntity id="20805" type="Company"><TargetEntity id="5000120321" type="organizationId">Parke Davis &amp; Company LLC</TargetEntity></SourceEntity><SourceEntity id="119" type="ciIndication"><TargetEntity id="G40" type="ICD10"></TargetEntity><TargetEntity id="345" type="ICD9"></TargetEntity><TargetEntity id="10015037" type="MEDDRA"></TargetEntity><TargetEntity id="D004827" type="MeSH"></TargetEntity><TargetEntity id="-2005570698" type="omicsDisease"></TargetEntity><TargetEntity id="115" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1295" type="ciIndication"><TargetEntity id="10029223" type="MEDDRA"></TargetEntity><TargetEntity id="D009437" type="MeSH"></TargetEntity><TargetEntity id="-533466818" type="omicsDisease"></TargetEntity><TargetEntity id="14" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1774" type="ciIndication"><TargetEntity id="G25.81" type="ICD10"></TargetEntity><TargetEntity id="10058920" type="MEDDRA"></TargetEntity><TargetEntity id="D012148" type="MeSH"></TargetEntity><TargetEntity id="-918624478" type="omicsDisease"></TargetEntity><TargetEntity id="135" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1937" type="ciIndication"><TargetEntity id="F41.1" type="ICD10"></TargetEntity><TargetEntity id="10018075" type="MEDDRA"></TargetEntity><TargetEntity id="32" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="20" type="ciIndication"><TargetEntity id="10033371" type="MEDDRA"></TargetEntity><TargetEntity id="D010146" type="MeSH"></TargetEntity><TargetEntity id="-1585850437" type="omicsDisease"></TargetEntity><TargetEntity id="1" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2527" type="ciIndication"><TargetEntity id="M79.7" type="ICD10"></TargetEntity><TargetEntity id="10048439" type="MEDDRA"></TargetEntity><TargetEntity id="D005356" type="MeSH"></TargetEntity><TargetEntity id="-1947347836" type="omicsDisease"></TargetEntity><TargetEntity id="1156" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2618" type="ciIndication"><TargetEntity id="10064332" type="MEDDRA"></TargetEntity><TargetEntity id="D020918" type="MeSH"></TargetEntity><TargetEntity id="83452" type="ORPHANET"></TargetEntity><TargetEntity id="-450428058" type="omicsDisease"></TargetEntity><TargetEntity id="2593" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2992" type="ciIndication"><TargetEntity id="10018659" type="MEDDRA"></TargetEntity><TargetEntity id="D004830" type="MeSH"></TargetEntity><TargetEntity id="-4977642" type="omicsDisease"></TargetEntity><TargetEntity id="118" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3300" type="ciIndication"><TargetEntity id="10036376" type="MEDDRA"></TargetEntity><TargetEntity id="D051474" type="MeSH"></TargetEntity><TargetEntity id="-1650985330" type="omicsDisease"></TargetEntity><TargetEntity id="17" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="724" type="ciIndication"><TargetEntity id="F60.2" type="ICD10"></TargetEntity><TargetEntity id="301.7" type="ICD9"></TargetEntity><TargetEntity id="10002822" type="MEDDRA"></TargetEntity><TargetEntity id="D000987" type="MeSH"></TargetEntity></SourceEntity><SourceEntity id="173" type="Action"><TargetEntity id="961" type="Mechanism">GABAergic Transmission Enhancers</TargetEntity></SourceEntity><SourceEntity id="17247" type="Action"><TargetEntity id="5227" type="Mechanism">GABA(A) Receptor Subunit delta Positive Allosteric Modulators</TargetEntity></SourceEntity><SourceEntity id="17217" type="Action"><TargetEntity id="5031" type="Mechanism">GABA(A) Receptor Subunit alpha-2 (GABRA2) Positive Allosteric Modulators</TargetEntity><TargetEntity id="5343" type="Mechanism">GABA(A) Receptor Subunit alpha-2 Agonists</TargetEntity></SourceEntity><SourceEntity id="PTGT-04258" type="ciTarget"><TargetEntity id="142633925925553" type="siTarget">Gamma-aminobutyric acid receptor subunit alpha-2</TargetEntity><TargetEntity id="-1607876260" type="omicsTarget"></TargetEntity></SourceEntity><SourceEntity id="PTGT-04268" type="ciTarget"><TargetEntity id="132299613025633" type="siTarget">Gamma-aminobutyric acid receptor subunit delta</TargetEntity><TargetEntity id="-247099015" type="omicsTarget"></TargetEntity></SourceEntity><SourceEntity id="PTGT-09179" type="ciTarget"><TargetEntity id="107731" type="siTarget">Voltage-Gated Calcium Channel alpha-2/delta (nonspecified subtype)</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Epilepsy - EU - Sep-2004</FirstLaunched><FirstLaunched>Epilepsy - UK - Sep-2004</FirstLaunched><FirstLaunched>Neuropathic pain - EU - Sep-2004</FirstLaunched><FirstLaunched>Neuropathic pain - UK - Sep-2004</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="119">Epilepsy</Indication><Indication id="1295">Neuropathic pain</Indication><Indication id="1937">Generalized anxiety disorder</Indication><Indication id="20">Pain</Indication><Indication id="2527">Fibromyalgia</Indication><Indication id="2992">Tonic clonic epilepsy</Indication><Indication id="3300">Postherpetic neuralgia</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="1774">Restless legs syndrome</Indication><Indication id="2618">Complex regional pain syndrome</Indication><Indication id="724">Antisocial personality disorder</Indication></IndicationsSecondary><ActionsPrimary><Action id="17247">GABA A receptor delta subunit stimulator</Action><Action id="50960">CACNA2D calcium channel subunit modulator</Action><Action id="17217">GABA A receptor alpha-2 subunit stimulator</Action><Action id="173">GABA receptor agonist</Action></ActionsPrimary><ActionsSecondary><Action id="2946">Analgesic</Action><Action id="70">Anticonvulsant agent</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology><Technology id="586">Capsule formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="902">Orally disintegrating tablet</Technology></Technologies><EphmraCodes><Ephmra><Code>N2</Code><Name>ANALGESICS</Name></Ephmra><Ephmra><Code>N3</Code><Name>ANTI-EPILEPTICS</Name></Ephmra></EphmraCodes><LastModificationDate>2019-06-28T11:24:26.000Z</LastModificationDate><ChangeDateLast>2019-05-30T00:00:00.000Z</ChangeDateLast><AddedDate>1998-05-06T16:36:11.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="18767" linkType="Company"&gt;&lt;/ulink&gt;Pregabalin  (Lyrica; Lyrica Capsules;  Lyrica OD Tablets), a GABA alpha-2-delta subunit agonist, has been developed and launched by &lt;ulink linkID="18767" linkType="Company"&gt;Pfizer&lt;/ulink&gt; (formerly &lt;ulink linkID="20787" linkType="Company"&gt;Warner-Lambert&lt;/ulink&gt;). In the US, the product is indicated for neuropathic pain associated with diabetic peripheral neuropathy (DPN); postherpetic neuralgia (PHN); adjunctive therapy for the treatment of partial onset seizures in patients four years of age and older;  fibromyalgia (FM); and neuropathic pain associated with spinal cord injury [&lt;ulink linkID="645906" linkType="Reference"&gt;645906&lt;/ulink&gt;]. In the EU, the product is indicated for the treatment of peripheral and central neuropathic pain in adults, as adjunctive therapy in adults with partial seizures with or without secondary generalization, and for the treatment of generalized anxiety disorder (GAD) in adults [&lt;ulink linkID="1006017" linkType="Reference"&gt;1006017&lt;/ulink&gt;].    The drug is indicated in Japan for neuropathic pain and for pain associated with fibromyalgia [&lt;ulink linkID="1387181" linkType="Reference"&gt;1387181&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In September 2004, pregabalin was launched for  pain  and as an add-on treatment for epilepsy in the UK; by October 2004, in Germany, and in February 2005, in Sweden  [&lt;ulink linkID="557408" linkType="Reference"&gt;557408&lt;/ulink&gt;],  [&lt;ulink linkID="569658" linkType="Reference"&gt;569658&lt;/ulink&gt;], [&lt;ulink linkID="1411310" linkType="Reference"&gt;1411310&lt;/ulink&gt;]; in September 2006, pregabalin was additionally approved in Europe for the treatment of central neuropathic pain [&lt;ulink linkID="691234" linkType="Reference"&gt;691234&lt;/ulink&gt;]. In September 2005, the product was launched in the US for  neuropathic pain associated with DPN and postherpetic neuralgia, and as adjunctive treatment for partial onset seizures in epileptic adults [&lt;ulink linkID="624422" linkType="Reference"&gt;624422&lt;/ulink&gt;]; in June 2012, the product was approved in the US for neuropathic pain due to spinal cord injury [&lt;ulink linkID="1303230" linkType="Reference"&gt;1303230&lt;/ulink&gt;]; in May 2018, the drug was approved in the US as adjunctive therapy for the treatment of partial onset seizures in patients four years of age and older [&lt;ulink linkID="2087279" linkType="Reference"&gt;2087279&lt;/ulink&gt;]. In June 2010, launch took place in Japan for postherpetic neuralgia  [&lt;ulink linkID="1107595" linkType="Reference"&gt;1107595&lt;/ulink&gt;]; in October 2010,  Japanese approval was granted to replace the indication of postherpetic neuralgia with the broader indication of peripheral neuropathic pain [&lt;ulink linkID="1142528" linkType="Reference"&gt;1142528&lt;/ulink&gt;]; in February 2013, Japanese approval was granted to replace the indication of peripheral neuropathic pain with broader neuropathic pain [&lt;ulink linkID="1387181" linkType="Reference"&gt;1387181&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By June 2007, pregabalin was launched for fibromyalgia in the US [&lt;ulink linkID="945397" linkType="Reference"&gt;945397&lt;/ulink&gt;].    In June 2012, the product was approved in Japan for the treatment of pain associated with fibromyalgia [&lt;ulink linkID="1303483" linkType="Reference"&gt;1303483&lt;/ulink&gt;]. In April 2009, the EU CHMP adopted a negative opinion over an extension to include fibromyalgia patients with   moderate-to-severe pain  [&lt;ulink linkID="1005285" linkType="Reference"&gt;1005285&lt;/ulink&gt;]. In July 2009, after a re-examination, the CHMP confirmed its decision [&lt;ulink linkID="1028135" linkType="Reference"&gt;1028135&lt;/ulink&gt;]; development for fibromyalgia in the EU is presumed to have been discontinued. &lt;/para&gt;&lt;para&gt;In March 2006, pregabalin was approved for GAD by the EC and was subsequently launched for this indication [&lt;ulink linkID="658057" linkType="Reference"&gt;658057&lt;/ulink&gt;]. The drug was issued a non-approval letter by the FDA for GAD in 2004 [&lt;ulink linkID="557410" linkType="Reference"&gt;557410&lt;/ulink&gt;]. By December 2009, Pfizer had resubmitted filings seeking US approval for pregabalin as both monotherapy and adjunctive therapy for GAD; however the FDA issued a Complete Response letter for GAD monotherapy at that time; the review for adjunctive therapy was ongoing [&lt;ulink linkID="1065711" linkType="Reference"&gt;1065711&lt;/ulink&gt;]. In January 2010, Pfizer withdrew the sNDA for adjunctive GAD [&lt;ulink linkID="1071167" linkType="Reference"&gt;1071167&lt;/ulink&gt;], [&lt;ulink linkID="1085323" linkType="Reference"&gt;1085323&lt;/ulink&gt;]. In December 2010, the NDA for monotherapy treatment of GAD was withdrawn [&lt;ulink linkID="1172256" linkType="Reference"&gt;1172256&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Development is also ongoing for other indications. In January 2014, a phase II trial for perioperative pain control after thoracotomy was initiated; in  March 2017, the study was completed [&lt;ulink linkID="1905723" linkType="Reference"&gt;1905723&lt;/ulink&gt;]. In February 2012, a phase III trial for primary generalized tonic-clonic seizures was initiated; in June 2019, the trial was ongoing [&lt;ulink linkID="1728755" linkType="Reference"&gt;1728755&lt;/ulink&gt;]. In April 2013, a further phase III trial for primary generalized tonic-clonic seizures was initiated [&lt;ulink linkID="1759804" linkType="Reference"&gt;1759804&lt;/ulink&gt;]; however, in May 2019, negative topline data were reported from the trial that was part of a post-marketing commitment  [&lt;ulink linkID="2155377" linkType="Reference"&gt;2155377&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2017, an orally disintegrating (OD) tablet formulation of pregabalin was launched in Japan for the treatment of neuropathic pain and pain associated with fibromyalgia [&lt;ulink linkID="1935992" linkType="Reference"&gt;1935992&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;Development was also previously undertaken in other settings. By December 2006, the drug was  in phase III  trials as a monotherapy  for epilepsy [&lt;ulink linkID="757356" linkType="Reference"&gt;757356&lt;/ulink&gt;];  however, by February 2012, development of pregabalin as a monotherapy  for epilepsy had been discontinued [&lt;ulink linkID="1267798" linkType="Reference"&gt;1267798&lt;/ulink&gt;]. In December 2008,  a phase III trial in  patients with restless leg syndrome (RLS) had begun [&lt;ulink linkID="819965" linkType="Reference"&gt;&lt;/ulink&gt;&lt;ulink linkID="1005943" linkType="Reference"&gt;1005943&lt;/ulink&gt;]; however, by September 2010, development for this indication had been discontinued [&lt;ulink linkID="1134713" linkType="Reference"&gt;1134713&lt;/ulink&gt;].  A phase III trial in post-traumatic peripheral neuropathic pain began in October 2012 [&lt;ulink linkID="1508008" linkType="Reference"&gt;1508008&lt;/ulink&gt;]; in November 2015, negative topline results from the study were reported [&lt;ulink linkID="1716101" linkType="Reference"&gt;1716101&lt;/ulink&gt;] and, by May 2016, Pfizer had discontinued  development of the drug for a  peripheral neuropathic pain indication [&lt;ulink linkID="1762214" linkType="Reference"&gt;1762214&lt;/ulink&gt;], presumed to be this one. In January 2016, an investigator-led phase II study on pegfilgrastim-induced bone pain was initiated in the US by &lt;ulink linkID="1041077" linkType="Company"&gt;UNC Lineberger Comprehensive Cancer Center&lt;/ulink&gt; in collaboration with Pfizer. However in July 2017, the trial was terminated due to low patient accrual [&lt;ulink linkID="2046634" linkType="Reference"&gt;2046634&lt;/ulink&gt;]. In April 2006, a phase II trial was initiated for complex regional pain syndrome.  The study was completed in June 2010 [&lt;ulink linkID="1771893" linkType="Reference"&gt;1771893&lt;/ulink&gt;]. However, no further development was reported since then. &lt;/para&gt;&lt;para&gt;Pfizer is also investigating a &lt;ulink linkID="64949" linkType="Drug"&gt;controlled-release formulation of pregabalin&lt;/ulink&gt;.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;Pregabalin is claimed in WO-09209560 (&lt;ulink linkID="20645" linkType="Company"&gt;Northwestern University&lt;/ulink&gt;). US equivalents relevant to pregabalin include &lt;ulink linkID="PA2998053" linkType="Patent"&gt;US-06197819&lt;/ulink&gt; covering the active ingredient (expires December 2018), &lt;ulink linkID="IN2171550" linkType="Patent"&gt;US-05563175&lt;/ulink&gt; covering a method for using pregabalin to treat seizure disorders (expired in  October 2013), and RE-041920 covering methods for using pregabalin to treat pain  (expires December 2018). Warner Lambert has a subsequent PCT application relating to its use in the treatment of pain; WO-09803167. The equivalent US patent is &lt;ulink linkID="IN2699135" linkType="Patent"&gt;US-06001876&lt;/ulink&gt; [&lt;ulink linkID="1267519" linkType="Reference"&gt;1267519&lt;/ulink&gt;]. By February 2018, Pfizer had  sought to obtain a 6-month patent-term extension for US pediatric exclusivity to June 2019   [&lt;ulink linkID="2007726" linkType="Reference"&gt;2007726&lt;/ulink&gt;], [&lt;ulink linkID="2001350" linkType="Reference"&gt;2001350&lt;/ulink&gt;].  In November 2018, the US FDA granted pediatric exclusivity, extending the period of US market exclusivity to June 30, 2019 [&lt;ulink linkID="2099354" linkType="Reference"&gt;2099354&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2019, &lt;ulink linkID="29387" linkType="Company"&gt;Dr Reddy's&lt;/ulink&gt; received tentative approval from the US FDA for its ANDA seeking approval  for  generic pregabalin capsules [&lt;ulink linkID="2132711" linkType="Reference"&gt;2132711&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2017, &lt;ulink linkID="1030330" linkType="Company"&gt;Zhejiang Huahai Pharmaceutical Group&lt;/ulink&gt; received a tentative FDA approval for its generic pregabalin capsules (25, 50, 75, 100, 150, 200, 225 and 300 mg). However, it could not market the generic prior to the expiration of the basic patent in December 2018 [&lt;ulink linkID="1991365" linkType="Reference"&gt;1991365&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May and June 2011, respectively, &lt;ulink linkID="22353" linkType="Company"&gt;Apotex&lt;/ulink&gt; filed ANDA's for generic pregabalin oral solution and capsules, asserting the invalidity and non-infringement of the basic patent and the seizure patent that expires in 2013. Pfizer filed suit against Apotex in July 2011  [&lt;ulink linkID="1267519" linkType="Reference"&gt;1267519&lt;/ulink&gt;]. In January 2015, the District Court entered a stipulated dismissal, thus Apotex could not obtain approval for, or market, its generic prior to the expiration of the basic patent in December 2018 [&lt;ulink linkID="1642228" linkType="Reference"&gt;1642228&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By August 2010, Alphapharm (a subsidiary of &lt;ulink linkID="18439" linkType="Company"&gt;Mylan&lt;/ulink&gt;), &lt;ulink linkID="20348" linkType="Company"&gt;Teva&lt;/ulink&gt;, &lt;ulink linkID="27614" linkType="Company"&gt;Wockhardt&lt;/ulink&gt;, Cobalt (a subsidiary of &lt;ulink linkID="21717" linkType="Company"&gt;Watson Pharmaceuticals&lt;/ulink&gt;), &lt;ulink linkID="27561" linkType="Company"&gt;Sun Pharmaceuticals&lt;/ulink&gt; and &lt;ulink linkID="21932" linkType="Company"&gt;Lupin&lt;/ulink&gt;, had all submitted ANDA's to the FDA for generic pregabalin [&lt;ulink linkID="1125252" linkType="Reference"&gt;1125252&lt;/ulink&gt;]. By November 2010, &lt;ulink linkID="1034299" linkType="Company"&gt;Novel Laboratories&lt;/ulink&gt; had filed an ANDA for a generic versions of pregabalin oral solution, asserting the invalidity and/or infringement of  three of Pfizer's pregabalin patents. In October 2010 and January 2011, respectively, Pfizer filed actions against Lupin and Novel [&lt;ulink linkID="1172256" linkType="Reference"&gt;1172256&lt;/ulink&gt;]. In August 2011, Teva received tentative FDA approval for its generic pregabalin capsules (25, 50, 75, 100, 150, 200, 225 and 300 mg) [&lt;ulink linkID="1271741" linkType="Reference"&gt;1271741&lt;/ulink&gt;]; final FDA approval was granted in July 2012 [&lt;ulink linkID="1349435" linkType="Reference"&gt;1349435&lt;/ulink&gt;]. In October 2011, &lt;ulink linkID="29955" linkType="Company"&gt;Alembic Pharmaceuticals&lt;/ulink&gt; filed an ANDA for generic pregabalin capsules, asserting the invalidity of the basic patent. In December 2011, Pfizer filed suit in the US District Court against Alembic   [&lt;ulink linkID="1267519" linkType="Reference"&gt;1267519&lt;/ulink&gt;]. In July 2012, the FDA granted final approval for Watson and Lupin's generic versions of pregabalin capsules (25, 50, 75, 100, 150, 200, 225 and 300 mg) [&lt;ulink linkID="1306516" linkType="Reference"&gt;1306516&lt;/ulink&gt;], [&lt;ulink linkID="1349435" linkType="Reference"&gt;1349435&lt;/ulink&gt;]. In September 2012, Wockhardt received tentative FDA approval for its generic pregabalin capsules (25, 50, 75, 100, 150, 200, 225 and 300 mg) [&lt;ulink linkID="1349922" linkType="Reference"&gt;1349922&lt;/ulink&gt;]. In January 2013, Pfizer filed  an action against Wockhardt [&lt;ulink linkID="1393784" linkType="Reference"&gt;1393784&lt;/ulink&gt;]. In March 2013, Mylan received tentative FDA approval for its generic pregabalin capsules (25, 50, 75, 100, 150, 200, 225 and 300 mg) [&lt;ulink linkID="1448886" linkType="Reference"&gt;1448886&lt;/ulink&gt;]. In June 2013, Lupin received tentative FDA for its generic pregabalin oral solution (20 mg/ml) [&lt;ulink linkID="1413005" linkType="Reference"&gt;1413005&lt;/ulink&gt;]. In  May and June 2014, the District Court entered consent judgments against Novel, Alembic and Wockhardt, thus they could  not obtain approval, or market, their generics prior to the expiration of the basic patent in December 2018 [&lt;ulink linkID="1642228" linkType="Reference"&gt;1642228&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2010, Sandoz (now &lt;ulink linkID="23137" linkType="Company"&gt;Novartis&lt;/ulink&gt;) submitted a citizen petition to the FDA, requesting the agency to decline approvals of ANDAs for generic pregabalin if the labelling omitted or carved out seizure or pain indications, as essential safety information would be excluded. Sandoz's ANDA contained a Paragraph IV certification to two methods-of-use patents which covered these indications. In August 2010, the FDA rejected the petition stating that label carve outs could be modified to include the necessary safety information [&lt;ulink linkID="1125252" linkType="Reference"&gt;1125252&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2009, several generic manufacturers notified Pfizer that they had filed ANDAs with the FDA for generic pregabalin, challenging one or more of  three patents. In April 2009, Pfizer filed suits against the companies [&lt;ulink linkID="1085323" linkType="Reference"&gt;1085323&lt;/ulink&gt;], [&lt;ulink linkID="1309862" linkType="Reference"&gt;1309862&lt;/ulink&gt;]. In July 2012, a US District Court upheld the composition of matter patent   and pain and seizure use patents covering pregabalin capsules; the decision would therefore provide patent coverage to December 2018, pending appeal and further patent litigation [&lt;ulink linkID="1309862" linkType="Reference"&gt;1309862&lt;/ulink&gt;].  In August 2012, the generic manufacturers appealed the decision to the US Court of Appeals for the Federal Circuit [&lt;ulink linkID="1393784" linkType="Reference"&gt;1393784&lt;/ulink&gt;]. In February 2014, the Federal Circuit affirmed the decision [&lt;ulink linkID="1530944" linkType="Reference"&gt;1530944&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;The European application, &lt;ulink linkID="IN2471689" linkType="Patent"&gt;EP-00934061&lt;/ulink&gt;, which relates to the use of pregabalin in the treatment of pain expires in 2018. European regulatory exclusivity expired in  July 2014 [&lt;ulink linkID="1267519" linkType="Reference"&gt;1267519&lt;/ulink&gt;], [&lt;ulink linkID="1642228" linkType="Reference"&gt;1642228&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2018, &lt;ulink linkID="1177659" linkType="Company"&gt;EQL Pharma&lt;/ulink&gt;'s generic version of pregabalin was approved by the Swedish Medicines Agency; at that time, launch was expected in 2Q19 [&lt;ulink linkID="2105810" linkType="Reference"&gt;2105810&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In fiscal 4Q15, Dr Reddy's  launched its generic pregabalinin Europe [&lt;ulink linkID="1682104" linkType="Reference"&gt;1682104&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In October 2015, Pfizer stated that generic competition for pregabalin started in certain developed European markets in 1Q15 [&lt;ulink linkID="1711379" linkType="Reference"&gt;1711379&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2015, the EMA's CHMP recommended EU approval of Accord's generic version of pregabalin [&lt;ulink linkID="1673625" linkType="Reference"&gt;1673625&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2015, the EMA's CHMP recommended EU approval of &lt;ulink linkID="1007988" linkType="Company"&gt;Zentiva&lt;/ulink&gt;'s generic version of pregabalin capsules (25, 50, 75, 100, 150, 200, 225 and 300 mg) [&lt;ulink linkID="1663423" linkType="Reference"&gt;1663423&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2015, the EMA's CHMP recommended approval of &lt;ulink linkID="18439" linkType="Company"&gt;Mylan&lt;/ulink&gt; and &lt;ulink linkID="28696" linkType="Company"&gt;Sandoz&lt;/ulink&gt;'s generic versions of pregabalin capsules (25, 50, 75, 100, 150, 200, 225 and 300 mg) in the EU [&lt;ulink linkID="1654109" linkType="Reference"&gt;1654109&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;The Japanese basic product patent expires in 2022 [&lt;ulink linkID="1745372" linkType="Reference"&gt;1745372&lt;/ulink&gt;]; in February 2018, Pfizer noted that the Japanese method-of-use patent expiring in 2022 was subject to an invalidation action [&lt;ulink linkID="2007726" linkType="Reference"&gt;2007726&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;China&lt;/subtitle&gt;In May 2019, &lt;ulink linkID="1048457" linkType="Company"&gt;Jiangsu Nhwa Pharmaceutical&lt;/ulink&gt; filed an ANDA for its generic version of the drug in China [&lt;ulink linkID="2148060" linkType="Reference"&gt;2148060&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2019, &lt;ulink linkID="1153446" linkType="Company"&gt;Ningbo Menovo Pharmaceutical&lt;/ulink&gt; filed an ANDA for its generic version of the drug in China [&lt;ulink linkID="2107483" linkType="Reference"&gt;2107483&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;In February 2018, Pfizer noted that the product had a Peri-LOE status (either recently lost or anticipated to soon lose patent protection) in Russia, Turkey, Israel and Central Asia [&lt;ulink linkID="2007726" linkType="Reference"&gt;2007726&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2013, it was disclosed that Pfizer had exclusivity until August 14, 2017 in Korea. Until then, companies (including &lt;ulink linkID="15473" linkType="Company"&gt;CJ&lt;/ulink&gt;, &lt;ulink linkID="1040351" linkType="Company"&gt;Yooyoung&lt;/ulink&gt; and &lt;ulink linkID="1004564" linkType="Company"&gt;Hanlim&lt;/ulink&gt;) could market generic pregabalin    just as an adjunct therapy for partial seizures, but not for neuropathic pain and fibromyalgia [&lt;ulink linkID="1467517" linkType="Reference"&gt;1467517&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By February 2011, Pfizer had filed patent infringement actions in Canada against certain  manufacturers seeking approval to for generic versions of pregabalin capsules [&lt;ulink linkID="1172256" linkType="Reference"&gt;1172256&lt;/ulink&gt;]. In February 2013, the Canadian Federal Court denied the application to prevent approval of a pregabalin generic in Canada; shortly after, generic versions of the drug were launched in Canada [&lt;ulink linkID="1393784" linkType="Reference"&gt;1393784&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;&lt;subtitle&gt;Fibromyalgia&lt;/subtitle&gt;By April 2004, Pfizer stated its intention to proceed with an approval filing in  fibromyalgia [&lt;ulink linkID="645908" linkType="Reference"&gt;645908&lt;/ulink&gt;]. An sNDA had been filed for use in fibromyalgia in the US by May 2007 [&lt;ulink linkID="789608" linkType="Reference"&gt;789608&lt;/ulink&gt;]; this was approved in June 2007 [&lt;ulink linkID="807341" linkType="Reference"&gt;807341&lt;/ulink&gt;], [&lt;ulink linkID="807325" linkType="Reference"&gt;807325&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Anxiety&lt;/subtitle&gt;In October 2003, Pfizer submitted an NDA to the FDA seeking approval for generalized anxiety disorder (GAD) [&lt;ulink linkID="511220" linkType="Reference"&gt;511220&lt;/ulink&gt;]; by September 2004, the FDA had issued a non-approvable letter  [&lt;ulink linkID="557410" linkType="Reference"&gt;557410&lt;/ulink&gt;]. In July 2009, Pfizer resubmitted its data package for pregabalin as both monotherapy and adjunctive therapy for GAD; however, in December 2009, the FDA issued a Complete Response letter for GAD monotherapy, stating that the data contained in the NDA were insufficient. At that time, the review for adjunctive therapy was ongoing [&lt;ulink linkID="1065711" linkType="Reference"&gt;1065711&lt;/ulink&gt;]. In January 2010, Pfizer withdrew the sNDA for adjunctive GAD [&lt;ulink linkID="1071167" linkType="Reference"&gt;1071167&lt;/ulink&gt;], [&lt;ulink linkID="1085323" linkType="Reference"&gt;1085323&lt;/ulink&gt;]. In December 2010, the NDA for monotherapy treatment of GAD was withdrawn [&lt;ulink linkID="1172256" linkType="Reference"&gt;1172256&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Neuropathic pain&lt;/subtitle&gt;In October 2003, Pfizer filed for approval for the management of neuropathic pain associated with DPN and postherpetic neuralgia [&lt;ulink linkID="511220" linkType="Reference"&gt;511220&lt;/ulink&gt;]. By September 2004, the FDA had issued approvable letters for these indications [&lt;ulink linkID="557410" linkType="Reference"&gt;557410&lt;/ulink&gt;]. FDA approval was granted in December 2004 [&lt;ulink linkID="577995" linkType="Reference"&gt;577995&lt;/ulink&gt;]; launch occurred   in September 2005 [&lt;ulink linkID="624422" linkType="Reference"&gt;624422&lt;/ulink&gt;]. In February 2012, Pfizer filed for US approval for central neuropathic pain due to spinal cord injury [&lt;ulink linkID="1267519" linkType="Reference"&gt;1267519&lt;/ulink&gt;]. The indication was approved in June 2012 [&lt;ulink linkID="1303230" linkType="Reference"&gt;1303230&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Epilepsy&lt;/subtitle&gt;In October 2003, Pfizer submitted an NDA  for  pregabalin as an adjunctive therapy for partial seizures in patients with epilepsy [&lt;ulink linkID="511220" linkType="Reference"&gt;511220&lt;/ulink&gt;]. By September 2004  the FDA had issued an approvable letter for  adjunctive therapy in the treatment of partial seizures in adults [&lt;ulink linkID="557410" linkType="Reference"&gt;557410&lt;/ulink&gt;]. By January 2005, labeling negotiations with the FDA were ongoing [&lt;ulink linkID="611875" linkType="Reference"&gt;611875&lt;/ulink&gt;]; FDA approval was granted in June 2005 [&lt;ulink linkID="607051" linkType="Reference"&gt;607051&lt;/ulink&gt;].  In September 2005, pregabalin was launched  as adjunctive treatment for partial onset seizures in epileptic adults  [&lt;ulink linkID="624422" linkType="Reference"&gt;624422&lt;/ulink&gt;]. In May 2018, the drug was approved in the US as adjunctive therapy for the treatment of partial onset seizures in patients four years of age and older [&lt;ulink linkID="2087279" linkType="Reference"&gt;2087279&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;&lt;subtitle&gt;Fibromyalgia&lt;/subtitle&gt;In March 2008, an application was submitted in the EU for the treatment of fibromyalgia [&lt;ulink linkID="988354" linkType="Reference"&gt;988354&lt;/ulink&gt;]; in April 2009, the CHMP adopted a negative opinion to extend the drug's use to include fibromyalgia patients with   moderate-to-severe pain  [&lt;ulink linkID="1005285" linkType="Reference"&gt;1005285&lt;/ulink&gt;]. In July 2009, after a re-examination, the CHMP confirmed its decision [&lt;ulink linkID="1028135" linkType="Reference"&gt;1028135&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Anxiety&lt;/subtitle&gt;By July 2005, a supplemental filing had been submitted in the EU for use of pregabalin in the treatment of GAD [&lt;ulink linkID="613139" linkType="Reference"&gt;613139&lt;/ulink&gt;]. At that time, the drug was   launched in Switzerland [&lt;ulink linkID="1596623" linkType="Reference"&gt;1596623&lt;/ulink&gt;].  In January 2006, the CHMP adopted a positive opinion on approving the extended indication [&lt;ulink linkID="651064" linkType="Reference"&gt;651064&lt;/ulink&gt;]. It was approved for GAD by the EC in March 2006 and subsequently launched for this indication by December 2008 [&lt;ulink linkID="658057" linkType="Reference"&gt;658057&lt;/ulink&gt;], [&lt;ulink linkID="1006017" linkType="Reference"&gt;1006017&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Neuropathic pain&lt;/subtitle&gt;By April 2003, Pfizer had filed for approval for  the treatment of neuropathic pain  [&lt;ulink linkID="486607" linkType="reference"&gt;486607&lt;/ulink&gt;], [&lt;ulink linkID="499127" linkType="reference"&gt;499127&lt;/ulink&gt;]. In March 2004, the CPMP granted a positive opinion recommending marketing authorization of pregabalin in the EU for the treatment of neuropathic pain  [&lt;ulink linkID="528923" linkType="reference"&gt;528923&lt;/ulink&gt;]. In July 2004, pregabalin was approved in the EU for this indication [&lt;ulink linkID="547687" linkType="reference"&gt;547687&lt;/ulink&gt;], [&lt;ulink linkID="550187" linkType="Reference"&gt;550187&lt;/ulink&gt;]. In September 2004, pregabalin was launched for  pain  in the UK [&lt;ulink linkID="557408" linkType="Reference"&gt;557408&lt;/ulink&gt;]; and in Germany by October 2004 [&lt;ulink linkID="569658" linkType="Reference"&gt;569658&lt;/ulink&gt;]. In February 2005, the drug was launched in Sweden [&lt;ulink linkID="1411310" linkType="Reference"&gt;1411310&lt;/ulink&gt;]. In July 2005, it was launched in France [&lt;ulink linkID="1350697" linkType="Reference"&gt;1350697&lt;/ulink&gt;]. At that time, the drug was also launched in Switzerland [&lt;ulink linkID="1596623" linkType="Reference"&gt;1596623&lt;/ulink&gt;]. In October 2005, the drug was launched in Portugal [&lt;ulink linkID="1387703" linkType="Reference"&gt;1387703&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;In September 2006, the EC approved pregabalin for the treatment of central neuropathic pain, including nerve pain associated with conditions such as spinal cord injury, stroke, and multiple sclerosis [&lt;ulink linkID="691234" linkType="Reference"&gt;691234&lt;/ulink&gt;]. In March 2009, the CHMP adopted a positive opinion on the 5-year renewal application for pregabalin [&lt;ulink linkID="995541" linkType="Reference"&gt;995541&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Epilepsy&lt;/subtitle&gt;By April 2003, Pfizer had filed for approval in Europe for the use of pregabalin as an add-on treatment for epilepsy   [&lt;ulink linkID="486607" linkType="reference"&gt;486607&lt;/ulink&gt;], [&lt;ulink linkID="499127" linkType="reference"&gt;499127&lt;/ulink&gt;]. In March 2004, the CPMP granted a positive opinion recommending marketing authorization of pregabalin in the EU as an add-on therapy for partial seizures [&lt;ulink linkID="528923" linkType="reference"&gt;528923&lt;/ulink&gt;]. Pregabalin was approved in the EU for this indication in July 2004 [&lt;ulink linkID="547687" linkType="reference"&gt;547687&lt;/ulink&gt;], [&lt;ulink linkID="550187" linkType="Reference"&gt;550187&lt;/ulink&gt;]. In September 2004, pregabalin was launched as add-on treatment for epilepsy in the UK [&lt;ulink linkID="557408" linkType="Reference"&gt;557408&lt;/ulink&gt;]; and in Germany by October 2004 [&lt;ulink linkID="569658" linkType="Reference"&gt;569658&lt;/ulink&gt;]. In February 2005, the drug was launched in Sweden [&lt;ulink linkID="1411310" linkType="Reference"&gt;1411310&lt;/ulink&gt;]. In July 2005, it was launched in France [&lt;ulink linkID="1350697" linkType="Reference"&gt;1350697&lt;/ulink&gt;]. At that time, the drug was also launched in Switzerland [&lt;ulink linkID="1596623" linkType="Reference"&gt;1596623&lt;/ulink&gt;].  In October 2005, the drug was launched in Portugal [&lt;ulink linkID="1387703" linkType="Reference"&gt;1387703&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;&lt;subtitle&gt;Orally disintegrating tablet formulation&lt;/subtitle&gt;In February 2017, an OD tablet formulation (25, 75 and 150 mg) of pregabalin was approved in Japan [&lt;ulink linkID="1902049" linkType="Reference"&gt;1902049&lt;/ulink&gt;]. In June 2017, the OD tablet formulation (25, 75 and 150 mg) of pregabalin was launched in Japan for the treatment of neuropathic pain and pain associated with fibromyalgia [&lt;ulink linkID="1935992" linkType="Reference"&gt;1935992&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Fibromyalgia&lt;/subtitle&gt;In October 2011, a filing was submitted in Japan for fibromyalgia [&lt;ulink linkID="1267519" linkType="Reference"&gt;1267519&lt;/ulink&gt;]. In June 2012, the Pharmaceuticals Affairs and Food Sanitation Council's First Committee on New Drugs recommended approval of the drug [&lt;ulink linkID="1298980" linkType="Reference"&gt;1298980&lt;/ulink&gt;]. Later that month, the product was approved  for the treatment of pain associated with fibromyalgia [&lt;ulink linkID="1303483" linkType="Reference"&gt;1303483&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Neuropathic pain&lt;/subtitle&gt;In May 2008, the company filed an NDA in Japan for the treatment of pain associated with postherpetic neuralgia [&lt;ulink linkID="988354" linkType="Reference"&gt;988354&lt;/ulink&gt;]. In April 2010, the drug was approved in Japan for the treatment of  postherpetic neuralgia [&lt;ulink linkID="1091344" linkType="Reference"&gt;1091344&lt;/ulink&gt;]. In June 2010, pregabalin was launched; at that time, regulatory review for peripheral neuropathy indication was ongoing [&lt;ulink linkID="1107595" linkType="Reference"&gt;1107595&lt;/ulink&gt;]. In October 2010, approval was granted to replace the indication of postherpetic neuralgia with the broader peripheral neuropathic pain [&lt;ulink linkID="1142528" linkType="Reference"&gt;1142528&lt;/ulink&gt;]. In February 2013, approval was granted in Japan to replace the indication of peripheral neuropathic pain with the broader indication of neuropathic pain [&lt;ulink linkID="1387181" linkType="Reference"&gt;1387181&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;China&lt;/subtitle&gt;&lt;subtitle&gt;Fibromyalgia&lt;/subtitle&gt;In October 2018, the drug was approved  in China for the treatment of fibromyalgia [&lt;ulink linkID="2082742" linkType="Reference"&gt;2082742&lt;/ulink&gt;]. In March 2019, the drug was launched in China [&lt;ulink linkID="2130414" linkType="Reference"&gt;2130414&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Neuropathic pain&lt;/subtitle&gt;In July 2010, Lyrica was approved in China [&lt;ulink linkID="1270234" linkType="Reference"&gt;1270234&lt;/ulink&gt;]; it was assumed that the drug had been launched there shortly after for the treatment of neuropathic pain associated with  postherpetic neuralgia [&lt;ulink linkID="1269731" linkType="Reference"&gt;1269731&lt;/ulink&gt;], [&lt;ulink linkID="1270235" linkType="Reference"&gt;1270235&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;&lt;subtitle&gt;Canada&lt;/subtitle&gt;&lt;subtitle&gt;Fibromyalgia&lt;/subtitle&gt;In May 2009, the drug was approved in Canada [&lt;ulink linkID="1008646" linkType="Reference"&gt;1008646&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Neuropathic pain&lt;/subtitle&gt;By October 2004, Pfizer had filed a submission in Canada   [&lt;ulink linkID="565489" linkType="Reference"&gt;565489&lt;/ulink&gt;]; launch occurred in Canada in September 2005 [&lt;ulink linkID="623881" linkType="Reference"&gt;623881&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Latin America&lt;/subtitle&gt;By November 2012, the drug had been approved, and presumably launched, in Brazil as Lyrica for neuropathic pain,  epilepsy, GAD and fibromyalgia [&lt;ulink linkID="1647989" linkType="Reference"&gt;1647989&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Middle East and Africa&lt;/subtitle&gt;By February 2018, the drug had been launched in Turkey  [&lt;ulink linkID="2007726" linkType="Reference"&gt;2007726&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By February 2018, the drug had been launched in Israel  [&lt;ulink linkID="2007726" linkType="Reference"&gt;2007726&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Commonwealth of Independent States&lt;/subtitle&gt;By February 2018, the drug had been launched in Russia  [&lt;ulink linkID="2007726" linkType="Reference"&gt;2007726&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By February 2018, the drug had been launched in Central Asia countries   [&lt;ulink linkID="2007726" linkType="Reference"&gt;2007726&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Asia Pacific&lt;/subtitle&gt;&lt;subtitle&gt;Fibromyalgia&lt;/subtitle&gt;By December 2007, the drug was approved for fibromyalgia in Korea [&lt;ulink linkID="945907" linkType="Reference"&gt;945907&lt;/ulink&gt;]; in December 2008, the  drug was included in the list of reimbursed drugs as a second line treatment for fibromyalgia  [&lt;ulink linkID="975021" linkType="Reference"&gt;975021&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2009, pregabalin was approved in Taiwan for fibromyalgia; it was assumed that launch took place shortly after [&lt;ulink linkID="1524464" linkType="Reference"&gt;1524464&lt;/ulink&gt;], [&lt;ulink linkID="1514082" linkType="Reference"&gt;1514082&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Neuropathic pain&lt;/subtitle&gt;By October 2004, Pfizer had filed a submission in  Australia   [&lt;ulink linkID="565489" linkType="Reference"&gt;565489&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By July 2005, pregabalin was reported to have been approved in  Korea, and by February 2006, Pfizer expected to launch the drug in  Korea that year [&lt;ulink linkID="618341" linkType="Reference"&gt;618341&lt;/ulink&gt;], [&lt;ulink linkID="681076" linkType="Reference"&gt;681076&lt;/ulink&gt;]. It was presumed that the drug had been launched for pain in Korea in 2006 [&lt;ulink linkID="975021" linkType="Reference"&gt;975021&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In March 2009, pregabalin was approved in Taiwan for the management of neuropathic pain associated with DPN, postherpetic neuralgia and spinal cord injury; it was assumed that launch took place shortly after [&lt;ulink linkID="1524464" linkType="Reference"&gt;1524464&lt;/ulink&gt;], [&lt;ulink linkID="1514082" linkType="Reference"&gt;1514082&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Epilepsy&lt;/subtitle&gt;By July 2005, pregabalin was reported to have been approved in  Korea, and by February 2006, Pfizer expected to launch the drug in  Korea that year [&lt;ulink linkID="618341" linkType="Reference"&gt;618341&lt;/ulink&gt;], [&lt;ulink linkID="681076" linkType="Reference"&gt;681076&lt;/ulink&gt;]. It was presumed that the drug had been launched for epilepsy in Korea in 2006 [&lt;ulink linkID="975021" linkType="Reference"&gt;975021&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2009, pregabalin was approved in Taiwan as an add-on treatment for epilepsy; it was assumed that launch took place shortly after [&lt;ulink linkID="1524464" linkType="Reference"&gt;1524464&lt;/ulink&gt;], [&lt;ulink linkID="1514082" linkType="Reference"&gt;1514082&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;SAFETY INFORMATION&lt;/subtitle&gt;In July 2008, an FDA advisory committee agreed with the FDA's finding of a potential increased signal regarding suicidal thoughts and behavior for the certain epilepsy drugs, including pregabalin. However, the committee determined that the available data did not warrant black box labeling, which had been recommended by the FDA. In March 2009, Pfizer was collaborating with the FDA to update the drug's labeling [&lt;ulink linkID="1010980" linkType="Reference"&gt;1010980&lt;/ulink&gt;]. In July 2012, the Pharmaceutical and Food Safety Bureau in Japan requested the package insert be amended to include warnings regarding  the operation of motor vehicles, due to the risk of accident [&lt;ulink linkID="1342144" linkType="Reference"&gt;1342144&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Postmarketing><displayLabel>Postmarketing</displayLabel><value>&lt;Postmarketing&gt;&lt;para&gt;&lt;subtitle&gt;Fibromyalgia&lt;/subtitle&gt;In March 2015, topline data were reported data from a 15-week, double-blind, randomized, placebo-controlled, phase IV study evaluating the safety and efficacy of pregabalin capsules for fibromyalgia in adolescents aged 12 to 17 years (n = 107) in the US, Europe and Asia, which showed that the primary endpoint of the trial was not met. Pregabalin did not achieve a statistically significant difference in mean pain score (0.66 points) compared with placebo (improvement from baseline of 1.60 versus 094 points). The safety profile of pregabalin in adolescents was consistent with that of clinical studies in adults. At that time, further analysis was ongoing [&lt;ulink linkID="1641304" linkType="Reference"&gt;1641304&lt;/ulink&gt;]. In November 2015, further clinical data were presented at the 79th ACR Annual Meeting in San Francisco, CA. The trend towards improvement in mean pain score from baseline (primary endpoint) was not statistically significant with pregabalin when compared with placebo. Pregabalin showed a significant improvement in mean pain score (secondary endpoint) when compared with placebo in 10 out of 15 weeks  [&lt;ulink linkID="1709822" linkType="Reference"&gt;1709822&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2012, data from an exploratory, double-blind, crossover, functional magnetic resonance imaging (fMRI) study assessing the mechanism of action of pregabalin Â in women (n = 17) with fibromyalgia were presented at the American Pain Society Annual Meeting in Honolulu, HI. The fMRI images showed that pregabalin reduced visual activation or sensory stimulation that activates pain and affects related regions in the brain in fibromyalgia patients. Additional fMRI analyses found that pregabalin affected grey matter density in regions of the brain involved in pain processing. Previous results from the study also found that glutamate in fibromyalgia patients was reduced in areas of the central nervous system associated with processing pain [&lt;ulink linkID="1292415" linkType="Reference"&gt;1292415&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2008, data from a retrospective, pooled analysis were presented at the AAN annual meeting in Chicago, IL. The analysis demonstrated that pregabalin was more effective than placebo in reducing pain in fibromyalgia patients. A pain reduction of 2.08 on the pain scale was observed in patients receiving 600 mg pregabalin, a reduction of 2.01 at 450 mg, a reduction of 1.76 at 300 mg, 150 mg had a reduction of 1.37 and placebo had a reduction of 1.25 [&lt;ulink linkID="897548" linkType="Reference"&gt;897548&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Anxiety&lt;/subtitle&gt;In August 2012, a parallel assignment, double blind, placebo controlled, randomized, phase IV study (&lt;ulink linkID="83506" linkType="Protocol"&gt;NCT01496690&lt;/ulink&gt; ; Eudra CT nr 2010-024488-42, N-20100097; PACS) was initiated in Germany, to assess the safety and efficacy of the drug for anxiety-comorbidity in patients (n  = 70) with schizophrenia. At that time, the study was expected to complete in February 2016 [&lt;ulink linkID="1638221" linkType="Reference"&gt;1638221&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2009, a randomized, double-blind, parallel-group, phase IV trial (&lt;ulink linkID="31457" linkType="Protocol"&gt;NCT00624780&lt;/ulink&gt;; A0081147) was initiated in patients (n = 621) with GAD in Argentina, Czech Republic, Finland, India and Lithuania. Patients were randomized to receive pregabalin 150 to 300 mg bid, pregabalin 450 to 600 mg bid, &lt;ulink linkID="44362" linkType="Drug"&gt;lorazepam&lt;/ulink&gt; 3 to 4 mg bid or placebo. The primary endpoints were Hamilton Anxiety Scale, Clinical Global Impression-Severity Scale and Clinical Global Impression-Improvement Scale scores at 3 and 6 months, as well as adverse events (measured by the Physicians Withdrawal Checklist), rebound anxiety (measured by the Hamilton Anxiety Scale), and discontinuation-emergent signs and symptoms at 3 and 6 months. The study was completed in April 2012 [&lt;ulink linkID="1005987" linkType="Reference"&gt;1005987&lt;/ulink&gt;]. In July 2012, top-line data from the EU post-authorization study were reported; drug discontinuation symptoms were low after tapering pregabalin treatment following 3 and 6 months [&lt;ulink linkID="1310462" linkType="Reference"&gt;1310462&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Neuropathic pain&lt;/subtitle&gt;In June 2017, data from German Observational Study were presented from 2,642 DPN patients at the Sixth International Congress on Neuropathic Pain in Gothenburg, Sweden. Improved pain severity categories was observed in 96.2 and 92.9% with 2 or more dose changes and 90.3 and 92.0% with 0 or 1 dose changes, respectively in patients with moderate and severe baseline pain. Patient satisfaction with tolerability (âsatisfied/very satisfiedâ) was similar across baseline pain category, regardless of number of titrations or degree of improvement suggested that tolerability did not influence treatment response patterns [&lt;ulink linkID="1951639" linkType="Reference"&gt;1951639&lt;/ulink&gt;].   &lt;/para&gt;&lt;para&gt;In June 2017, clinical data from two Chinese and four International placebo-controlled studies in 1181 postherpetic neuralgia patients were presented at the Sixth International Congress on Neuropathic Pain in Gothenburg, Sweden. Treatment with pregabalin resulted in significant improvement in mean pain score versus placebo in Chinese (least square mean difference â0.8; p &amp;lt; 0.0001) and International patients (-1.4; p &amp;lt; 0.0001). Chinese and International patients treated with pregabalin versus placebo showed significant improvement in 30 (53.5 versus 31.9%, p = 0.007 and 40.6 versus 19.3%, p &amp;lt; 0.0001) and 50% (30.2 versus 11.3%, p = 0.0007, and 28.2 versus 12.4%, p &amp;lt; 0.0001) responder rates, and Patient Global Impression of Change responder rates (42.4 versus 17.7%, p &amp;lt; 0.0001; and 36.1 versus16.4%, p &amp;lt; 0.0001). Between patients groups, AE profiles of pregabalin versus placebo were comparable, but rates were somewhat higher in International patients [&lt;ulink linkID="1951651" linkType="Reference"&gt;1951651&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2012, a post hoc analysis of 15 clinical studies was presented at the 31st Annual APS Meeting in Honolulu, HI. In patients with post-herpetic neuralgia and diabetic peripheral neuropathy receiving pregabalin, there was a significant reduction in sleep interference scores, compared with placebo. In 91% of these drug-treated groups, the time-to-onset for reduction in sleep interference scores occurred within the first 3 days of treatment [&lt;ulink linkID="1285764" linkType="Reference"&gt;1285764&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2011, an 8-week, randomized, double-blind, multicenter, placebo-controlled, phase IV trial (&lt;ulink linkID="81763" linkType="Protocol"&gt;NCT01455428&lt;/ulink&gt;; A0081276) of pregabalin began in patients (expected n = 224) in China with postherpetic neuralgia. The primary endpoint was change from baseline in weekly mean pain score [&lt;ulink linkID="1585134" linkType="Reference"&gt;1585134&lt;/ulink&gt;]. In August 2014, topline data showed the trial met its primary endpoint with a significant treatment difference of -0.71 points compared with placebo [&lt;ulink linkID="1585077" linkType="Reference"&gt;1585077&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2009, results from a 254-patient study were presented at the 61st American Academy of Neurology (AAN) annual meeting in Seattle, WA. Patients with post-traumatic peripheral neuropathic pain were randomized to placebo or flexible dose pregabalin (150 to 600 mg/day) for 4 weeks of dose optimization, followed by fixed dose for another 4 weeks. Data demonstrated that compared to placebo, the pregabalin-treated patients had significant pain reduction (0.62 points lower on an 11-point scale) and reported less pain interference with sleep. At the end of the study, 64% of pregabalin-treated patients reported feeling "improved" compared to 41% for placebo. The most frequent adverse events reported included dizziness, somnolence, headache, fatigue  and xerostomia [&lt;ulink linkID="1004586" linkType="Reference"&gt;1004586&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Other studies&lt;/subtitle&gt;In December 2008, Pfizer initiated a US, phase IV, randomized, double-blinded, parallel-group, placebo-controlled study (&lt;ulink linkID="15741" linkType="Protocol"&gt;NCT00631696&lt;/ulink&gt;; A0081104), to evaluate the effect of pregabalin on sperm production in healthy male volunteers (n = 222). Subjects received placebo (n = 109) or pregabalin 600 mg/day (300 mg bid; n = 111, for 10 weeks after a 2-week titration that began at 50 mg bid). The primary endpoint was the proportion of subjects with a &amp;gt;/= 50% reduction in sperm concentration from baseline to week 26. The study was conducted as part of an FDA post-approval commitment, and was completed in February 2012 [&lt;ulink linkID="1310453" linkType="Reference"&gt;1310453&lt;/ulink&gt;]. In July 2012, Pfizer reported top-line results showing that the primary endpoint was met; pregabalin demonstrated no effect on the male reproductive function when compared to placebo [&lt;ulink linkID="1310321" linkType="Reference"&gt;1310321&lt;/ulink&gt;].&lt;/para&gt;&lt;/Postmarketing&gt;</value></Postmarketing><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Fibromyalgia&lt;/subtitle&gt;In November 2016, post-hoc analysis data from three randomized, double-blind, placebo-controlled, multicenter studies (Pfizer study number 1008-105; A0081056, NCT00645398; and A0081077, NCT00230776), which evaluated the safety and efficacy of pregabalin in patients with fibromyalgia were presented at the 80th ACR Annual Meeting in Washington DC. Patients received fixed dose of pregabalin (150 to 600 mg qd) or placebo (n = 505 and 1517, respectively) for 6 to 14 weeks. With higher pregabalin doses, the likelihood of fibromyalgia patients achieving&amp;gt;30 and &amp;gt;50% pain response incrementally increased in a dose-dependent manner; with incremental improvement in patient global impression of change score and sleep quality. Commonly reported AEs were dizziness and somnolence [&lt;ulink linkID="1873908" linkType="Reference"&gt;1873908&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2016, clinical data from two studies which evaluated the differential analgesic pharmacological effects of pregabalin and milnacipran in patients with fibromyalgia were presented at the 80th ACR Annual Meeting in Washington DC. Reduced clinical pain was associated with increased sgACC-IPL fcMRI. When directly compared fcMRI was significantly increased by milnacipran, and decreased by pregabalin between the right DLPFC seed and the precuneus [&lt;ulink linkID="1873846" linkType="Reference"&gt;1873846&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2016, pooled data from three 13 to14-week randomized, placebo-controlled, double-blind studies (NCT00645398, NCT00230776 and NCT00333866), which evaluated the efficacy of pregabalin, in patients with fibromyalgia, were presented at the 35th APS Annual Scientific Meeting in Austin, TX. Patients received at least single dose of pregabalin (300 to 600 mg/day; n = 1670) or placebo (n = 558). Compared with placebo, statistically significant efficacy for pain score reduction, fibromyalgia impact questionnaire, medical outcomes study-sleep scale, 30% or 50% responder and patient global impression of change scores was observed with all doses of pregabalin; irrespective of potential confounding effects included in the analysis or not. Pregabalin was generally well tolerated [&lt;ulink linkID="1800862" linkType="Reference"&gt;1800862&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In November 2015, pooled data were presented from four randomized, placebo-controlled, parallel group, double-blind, phase-III trials (A0081056/&lt;ulink linkID="16283" linkType="Protocol"&gt;NCT00645398&lt;/ulink&gt;, A0081077/&lt;ulink linkID="16090" linkType="Protocol"&gt;NCT00230776&lt;/ulink&gt;, A0081100/&lt;ulink linkID="16107" linkType="Protocol"&gt;NCT00333866&lt;/ulink&gt;, and A0081208/ &lt;ulink linkID="42322" linkType="Protocol"&gt;NCT00830167&lt;/ulink&gt;) which assessed the impact of prior use of antidepressants, gabapentin, or muscle relaxants on the response to pregabalin in patients (n = 2668) with fibromyalgia, were presented at the 79th ACR Annual Meeting in San Francisco, CA. The endpoint mean pain scores had comparable improvements observed for pregabalin irrespective of prior medication use. Least square mean pain score was improved by pregabalin compared with placebo in patients both with and without prior use of medication [&lt;ulink linkID="1709674" linkType="Reference"&gt;1709674&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In May 2015, clinical data were presented from two randomized, double-blind, two-way, placebo-controlled studies  (A0081165, A0081275, A0081268 and A0081269)  in patients with fibromyalgia  and neuropathy at the 34th APS Annual Scientific Meeting in Palm Springs, CA.								In all four studies, decreases in mean pain scores were less with pregabalin treatment in period 2 when compared with the treatment in period 1. Compared with placebo, the difference in mean pain score at study end for pregabalin was significant for the two fibromyalgia studies, but not the neuropathy studies [&lt;ulink linkID="1659906" linkType="Reference"&gt;1659906&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2014, data from a post-hoc analysis of a randomized, placebo-controlled, double-blind, 15-week trial of pregabalin (300 or 450mg/day) in patients (n = 498) with fibromyalgia were presented at the 33rd APS Annual Scientific Meeting in Tampa, FL. Somnolence and dizziness were the most common adverse events (46.4 and 29.6%, respectively) reported, with the greatest incidence of both observed in the first week of the trial (18.8 and 12.4%, respectively); the incidence declined over the first 6 weeks to 0 and 0.4%, respectively. The majority of new responders also emerged within this period [&lt;ulink linkID="1549047" linkType="Reference"&gt;1549047&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2014, data from  a pooled analysis of five placebo-controlled trials (protocols &lt;ulink linkID="53167" linkType="Protocol"&gt;1008105&lt;/ulink&gt;, &lt;ulink linkID="16283" linkType="Protocol"&gt;A0081056&lt;/ulink&gt;, &lt;ulink linkID="16090" linkType="Protocol"&gt;A0081077&lt;/ulink&gt;, &lt;ulink linkID="16107" linkType="Protocol"&gt;A0081100&lt;/ulink&gt;, &lt;ulink linkID="42322" linkType="Protocol"&gt;A0081208&lt;/ulink&gt;) in patients with fibromyalgia were presented at the  33rd APS Annual Scientific Meeting in Tampa, FL. Patients with moderate to severe pain intensity at baseline were treated with a fixed or flexible dose of pregabalin (n = 1623; 300 or 450 mg/day and 300 to 350 mg/day, respectively) or placebo (n = 937). At endpoint, a significantly greater proportion of patient in the pregabalin group had changed to a less severe pain category compared with those in the placebo group (p = 0.0001), with a change of one or two categories reported in 30.2 and 9.5% of patients, respectively, in the pregabalin group compared with 27.2 and 6.1% of patients, respectively, in the placebo group [&lt;ulink linkID="1549052" linkType="Reference"&gt;1549052&lt;/ulink&gt;]. In November 2014, further data  were presented at the 78th ACR Annual Meeting in Boston, MA.  At week 12, pregabalin  was found to be efficacious in reducing FM pain, improving sleep quality in all patients compared with placebo [&lt;ulink linkID="1611890" linkType="Reference"&gt;1611890&lt;/ulink&gt;]. In November 2015, further clinical data were presented at the 79th ACR Annual Meeting in San Francisco, CA. The incidence of treatment-related adverse events (AEs), severe intensity AEs and discontinuations due to AEs were higher with pregabalin when compared with placebo. Overall, the majority of AEs were mild and moderate and there was low incidence of SAEs and few subjects discontinued therapy due to AEs [&lt;ulink linkID="1709678" linkType="Reference"&gt;1709678&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A pooled analysis of four clinical trials of pregabalin in fibromyalgia patients (n = 2053) assessing the effect of prior opioid use on response to the drug was presented in May 2013 at the 32nd Annual Scientific Meeting of the APS in New Orleans, LA.  The treatment effect  of the drug was higher in patients without prior opioid use, but effect in patients with prior opioid use was higher than in placebo patients [&lt;ulink linkID="1431439" linkType="Reference"&gt;1431439&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2011, a phase IIIb, multicenter, double-blind, randomized, placebo-controlled, two-way crossover trial (&lt;ulink linkID="80713" linkType="Protocol"&gt;NCT01432236&lt;/ulink&gt;; A0081275) began in the US, Canada and Europe in fibromyalgia patients (expected n = 195) receiving antidepressant therapy for comorbid depression. The primary endpoint was mean pain score. At that time, the trial was expected to complete in July 2013 [&lt;ulink linkID="1489760" linkType="Reference"&gt;1489760&lt;/ulink&gt;]. In October 2013, topline data were reported from the 197-patient trial, showing that it met its primary endpoint of significant reduction in fibromyalgia pain compared with placebo [&lt;ulink linkID="1489391" linkType="Reference"&gt;1489391&lt;/ulink&gt;]. In October 2013,   data were presented at the 77th ACR/ARHP Annual Meeting in San Diego CA. Patients received pregabalin (150 to 450 mg/day) followed by placebo in period 1 (n = 96) and vice versa in period 2 (n = 97). When compared with the placebo (5.45), the least square mean pain score (primary endpoint) was significantly lower with pregabalin (4.84) [&lt;ulink linkID="1493909" linkType="Reference"&gt;1493909&lt;/ulink&gt;]. In May 2014, further data were presented at the 33rd APS Annual Scientific Meeting in Tampa, FL. The respective proportion of 30 and 50% pain responders was 45.3 and 26% for pregabalin compared with 27.7 and 15.8% for placebo (p = 0.0007 and 0.0205, respectively). Significant improvements in Hospital Anxiety and Depression  (HADS) - Depression and Anxiety scores, fibromyalgia Impact Questionnaire total and all subscale scores, and various sleep measures were also reported [&lt;ulink linkID="1549048" linkType="Reference"&gt;1549048&lt;/ulink&gt;]. Further data also presented at this conference demonstrated  that pregabalin resulted in significant decrease in pain scores regardless of the type if antidepressant coadministered [&lt;ulink linkID="1549050" linkType="Reference"&gt;1549050&lt;/ulink&gt;]. In June 2014, further  data were presented atÂ  EULAR 2014 Annual Meeting in Paris, Franceâ. In patients taking an SSRI, mean pain scores were significantly lower with pregabalin when compared with those in patients taking serotonin/norepinephrine reuptake inhibitor. At the end of period 1, 46.2% of pregabalin-treated patients and 30.1% of placebo recipients were patient global impression of change responders (very much/much improved)  [&lt;ulink linkID="1565228" linkType="Reference"&gt;1565228&lt;/ulink&gt;]. In November 2014, further data were presented from the 78th ACR Annual Meeting in Boston, MA. Pregabalin treatment was significantly better when compared with placebo irrespective of majority of patient baseline demographic and clinical characteristics including age, BMI, FM duration, depression duration, type of depression, pain severity, anxiety severity, sleep disruption severity and prior or no prior opioid use [&lt;ulink linkID="1609191" linkType="Reference"&gt;1609191&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2011, a 14-week, randomized, double-blind, placebo-controlled, phase III trial (&lt;ulink linkID="78974" linkType="Protocol"&gt;NCT01387607&lt;/ulink&gt;) began in patients (expected n = 324) in China with fibromyalgia. In October 2016, the trial was completed. In April 2018, results were reported; the least squares mean change from baseline in endpoint mean pain score during the double-blind treatment period at week 14 was -2.01 for pregabalin and -1.28 units for placebo (p&amp;lt;0.0001) [&lt;ulink linkID="1270332" linkType="Reference"&gt;1270332&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2011, clinical data were presented at the 30th Annual Scientific Meeting of the APS in Austin, TX from a double-blind, placebo-controlled, two-period crossover study evaluating the pain effect of the drug (300 to 450 mg/day) in patients with fibromyalgia and sleep disturbances (n = 119). Drug-treated patients showed improved daily pain scores, and total sleep time was increased by &amp;gt; 25 min, compared with placebo-treated patients [&lt;ulink linkID="1216244" linkType="Reference"&gt;1216244&lt;/ulink&gt;]. Further data were reported in May 2013 at the 32nd Annual Scientific Meeting of the APS in New Orleans, LA. Pregabalin increased sleep duration and decreased the frequency of waking [&lt;ulink linkID="1431282" linkType="Reference"&gt;1431282&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2009, a 52-week phase III multicenter, open-label, extension study (&lt;ulink linkID="42321" linkType="Protocol"&gt;NCT00830128&lt;/ulink&gt;; A0081209) of pregabalin (150 to 225 mg bid) was initiated in patients (n = 106) in Japan; the patients had completed study A0081208 without any serious adverse events. The primary endpoint was safety and efficacy; secondary outcomes included a pain visual analog (PVA) scale, a medical outcomes study sleep scale (MOS-sleep scale) and a fibromyalgia impact questionnaire (FIQ). The trial was completed in February 2011 [&lt;ulink linkID="1205765" linkType="Reference"&gt;1205765&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2009, a 16-week phase III multicenter, randomized, double-blind, placebo-controlled, parallel-group  study (&lt;ulink linkID="42322" linkType="Protocol"&gt;NCT00830167&lt;/ulink&gt;; A0081208) of pregabalin was initiated in patients (n = 501) in Japan. The primary endpoint was based on a numerical rating scale for pain; secondary outcomes included a PVA scale, a MOS-sleep scale, a quality of sleep (QOS) score from a daily sleep diary, and an FIQ. The trial was completed in February 2011 [&lt;ulink linkID="1205764" linkType="Reference"&gt;1205764&lt;/ulink&gt;]. In July 2011, top-line data from the trial were reported. A primary efficacy analysis showed a significant reduction in the endpoint mean pain score. The most common adverse events included somnolence, dizziness, weight increase and blurred vision [&lt;ulink linkID="1205686" linkType="Reference"&gt;1205686&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2007, data from a  14-week placebo-controlled study in 745  fibromyalgia patients showed that qualitative pain reductions of 2.05, 2.03 and 1.75 were obtained for those receiving pregabalin 600, 450 and 300 mg qd, respectively, compared with 1.04 for those on placebo. Of these, 30% on pregabalin 600 mg qd said their pain was improved by at least half on this scoring system, compared with 15% on placebo. The most common side effects were dizziness and somnolence [&lt;ulink linkID="789608" linkType="Reference"&gt;789608&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2006, a non-randomized, open-label, uncontrolled phase III trial (&lt;ulink linkID="16205" linkType="Protocol"&gt;NCT00346034&lt;/ulink&gt;, A0081101) was initiated in fibromyalgia patients (expected n = 500) in Canada, India, Korea and certain European countries. The subjects were to receive pregabalin for 12 weeks to determine the primary outcome of long-term safety. The study was completed in February 2008 [&lt;ulink linkID="784520" linkType="Reference"&gt;784520&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2006, a placebo-controlled, randomized, double-blind phase III trial (&lt;ulink linkID="16107" linkType="Protocol"&gt;NCT00333866&lt;/ulink&gt;) was initiated  in fibromyalgia patients (expected n = 740) in various countries worldwide. The subjects were to receive pregabalin twice-daily for 14 weeks to monitor daily pain scores. The study was completed in November 2007 [&lt;ulink linkID="789859" linkType="Reference"&gt;789859&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2002, phase III data presented from a double-blind, placebo-controlled monotherapy study in 529 fibromyalgia patients showed that 450 mg/day pregabalin significantly improved patient-characterized pain levels compared with placebo. In June 2003, phase III trials were reported to be complete [&lt;ulink linkID="500100" linkType="reference"&gt;500100&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Anxiety&lt;/subtitle&gt;In March 2009, phase III trials for generalized anxiety disorder were reported as ongoing [&lt;ulink linkID="1065713" linkType="Reference"&gt;1065713&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2006, a randomized, double-blind, placebo-controlled, parallel-assignment phase II trial (&lt;ulink linkID="32256" linkType="Protocol"&gt;NCT00245609&lt;/ulink&gt;; A0081072)  was initiated in Germany and UK, in patients (expected n = 90)  with anxiety prior to dental procedure, to evaluate the safety and efficacy of pregabalin  and alprazolam.  In October 2006, the trial was completed [&lt;ulink linkID="1453132" linkType="Reference"&gt;1453132&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In May 2002, data reported at the annual meeting of the American Psychiatric Association, showed that pregabalin was effective in reducing symptoms of anxiety and sustaining this improvement in patients with moderate to severe generalized anxiety disorder compared to two widely prescribed medicines. Data from two separate short-term studies demonstrated that pregabalin was more effective than placebo and as effective as &lt;ulink linkID="44259" linkType="Drug"&gt;alprazolam&lt;/ulink&gt; and &lt;ulink linkID="4648" linkType="Drug"&gt;venlafaxine&lt;/ulink&gt;  at reducing the symptoms of anxiety. Pregabalin also achieved significantly faster onset of sustained clinical improvement within the first week of treatment than placebo. Similar significant and sustained improvement within the first week was not achieved by either alprazolam or venlafaxine [&lt;ulink linkID="451917" linkType="reference"&gt;451917&lt;/ulink&gt;]. Additional data were presented in May 2003 at the annual meeting of the American Psychiatric Association in San Francisco, CA. Results from a combination of five placebo-controlled studies showed that pregabalin was effective in providing relief of both psychic and somatic anxiety symptoms as early as the first week of treatment [&lt;ulink linkID="490686" linkType="reference"&gt;490686&lt;/ulink&gt;], [&lt;ulink linkID="492385" linkType="reference"&gt;492385&lt;/ulink&gt;]. Similar data were presented at the 157th American Psychiatric Association meeting in New York, NY. Combined data from a number of phase II and III studies were presented. A total of 1282 patients receiving between 200 and 600 mg of pregabalin per day demonstrated a decrease of 12.7 points, compared to 9.3 in the placebo group [&lt;ulink linkID="539574" linkType="reference"&gt;539574&lt;/ulink&gt;].  In October 2004, similar data were presented at the 17th ECNP congress in Stockholm, Sweden [&lt;ulink linkID="568384" linkType="Reference"&gt;568384&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2000, the results of three double-blind, randomized, multicenter, controlled trials were reported at the annual CINP conference. Patients with GAD were administered placebo, pregabalin 50 mg tid, pregabalin 200 mg tid or lorazepam  2 mg tid. Following 4 weeks of treatment the dose was tapered over 1 week. Pregabalin (200 mg tid) and lorazepam were superior to placebo in reducing the symptoms of GAD. Overall, pregabalin was found to be effective and well tolerated [&lt;ulink linkID="377016" linkType="reference"&gt;377016&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A double-blind, placebo-controlled trial of 135 patients with social phobia compared pregabalin 150 mg/day and 600 mg/day with placebo [&lt;ulink linkID="377018" linkType="reference"&gt;377018&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Neuropathic pain&lt;/subtitle&gt;In January 2016, an investigator-led, randomized, cross-over assigned, placebo-controlled, double-blind phase II study (&lt;ulink linkID="326882" linkType="Protocol"&gt;NCT03407430&lt;/ulink&gt;; LCCC 1314) to evaluate the preventative effects of pregabalin in patients (expected n = 11) with pegfilgrastim-induced bone pain was initiated in the US by &lt;ulink linkID="1041077" linkType="Company"&gt;UNC Lineberger Comprehensive Cancer Center&lt;/ulink&gt; in collaboration with Pfizer. The primary endpoint was to determine the bone pain score-value. However in July 2017, the trial was terminated due to low patient accrual [&lt;ulink linkID="2046634" linkType="Reference"&gt;2046634&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2015, data were presented from a randomized, double-blind, placebo-controlled, phase III trial (NCT0145016)  of pregabalin in patients with oxaliplatin-induced painful neuropathy at the 51st ASCO meeting in Chicago, IL. Patients (n = 206) were randomized (1:1) to receive pregabalin (150 to 600 mg/day) or placebo for three days before and three days after each oxaliplatin infusion. Pregabalin treatment during oxaliplatin infusions was safe but didn't decrease the incidence of chronic or neuropathic pain related to oxaliplatin [&lt;ulink linkID="1664015" linkType="Reference"&gt;1664015&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2015, clinical data were presented from two randomized, double-blind, two-way, placebo-controlled studies (A0081268, A0081269, A0081165 and A0081275) in patients with fibromyalgia  and neuropathy at the 34th APS Annual Scientific Meeting in Palm Springs, CA.								In all four studies, decreases in mean pain scores were less with pregabalin treatment in period 2 when compared with the treatment in period 1. Compared with placebo, the difference in mean pain score at study end for pregabalin was significant for the two fibromyalgia studies, but not the neuropathy studies [&lt;ulink linkID="1659906" linkType="Reference"&gt;1659906&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2014, data from 16 placebo-controlled trials were presented at the 66th AAN Annual Meeting in Philadelphia, PA. In the pregabalin group, significantly greater proportion of patients shifted to a less severe pain category from baseline to endpoint, when compared with placebo [&lt;ulink linkID="1544715" linkType="Reference"&gt;1544715&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2014, data from two randomized, placebo-controlled, double-blind trials in patients with diabetic peripheral neuropathy or postherpetic neuralgia were presented at the 66th AAN Annual Meeting in Philadelphia, PA. In the 6-week analysis, 231 and 144 patients in the pregabalin arm and 87 and 51 patients in the placebo arm were 30 and 50% responders, respectively [&lt;ulink linkID="1544720" linkType="Reference"&gt;1544720&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;In May 2013, an analysis of data from two clinical trials showing the efficacy pregabalin for reducing neuropathic pain associated with spinal cord injury was presented at the 32nd Annual Scientific Meeting of the APS in New Orleans, LA. The proportion of patients reporting Patient Global Impression of Change and Modified Brief Pain Inventory responses increased with greater pain reduction [&lt;ulink linkID="1430868" linkType="Reference"&gt;1430868&lt;/ulink&gt;]. In May 2014, a further analysis presumed to be from these trials was presented at the 33rd APS Annual Scientific Meeting in Tampa, FL. In patients who reported moderate or severe pain at study onset, a significantly greater number  reported a less severe pain category at endpoint in the pregabalin group compared with placebo [&lt;ulink linkID="1549043" linkType="Reference"&gt;1549043&lt;/ulink&gt;] . Further data also presented at this conference showed that the majority of new responders and adverse events were reported within 3 weeks of treatment start [&lt;ulink linkID="1549053" linkType="Reference"&gt;1549053&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2012, a randomized, safety/efficacy, double-blind, parallel group, phase III trial (&lt;ulink linkID="93704" linkType="Protocol"&gt;NCT01701362&lt;/ulink&gt;; A0081279, 2012-003304-12) began in the US, Europe, Canada, South Korea,  Puerto Rico and South Africa in patients (n = 544) with chronic post-traumatic peripheral neuropathic pain. The primary endpoint was change from baseline of meanÂ painÂ score compared with placebo at week 15. The trial completed in August 2015Â [&lt;ulink linkID="1508008" linkType="Reference"&gt;1508008&lt;/ulink&gt;]; in November 2015, negative topline results from the study were reported, which showed that the primary endpoint was  not met [&lt;ulink linkID="1716101" linkType="Reference"&gt;1716101&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2012, Pfizer reported that the phase IIIb, multicenter, double-blind, randomized withdrawal, efficacy and safety, A0081242 trial for inadequately treated painful diabetic peripheral neuropathy failed to meet its primary endpoint of improving mean pain score relative to baseline. In the initial 6-week single-blind phase, pregabalin was administered to 665 patients, of whom 294 achieved a pain response of 30% or more and were then randomized to pregabalin or placebo for 13 weeks. At the end of the trial mean pain score improvement was 3.9 and 3.5 points for the two groups, respectively [&lt;ulink linkID="1287505" linkType="Reference"&gt;1287505&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2012, Pfizer halted the randomized, double-blind, placebo-controlled, parallel-group, multicenter, A0081244 trial for HIV neuropathy-associated neuropathic pain, following a planned interim analysis by the external data monitoring committee (E-DMC) that showed virtually identical improvements in pain scores in the drug and placebo arms [&lt;ulink linkID="1287502" linkType="Reference"&gt;1287502&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2011, a phase IIIb, multicenter, double-blind, randomized, cross-over, efficacy and safety trial (&lt;ulink linkID="82504" linkType="Protocol"&gt;NCT01474772&lt;/ulink&gt;; A0081269) began in the US, Europe and South Africa in patients (expected n = 288) with DPN. The primary endpoints were reduction in DPN pain and reduction in DPN pain on walking. At that time, the trial was expected to complete in July 2013 [&lt;ulink linkID="1489780" linkType="Reference"&gt;1489780&lt;/ulink&gt;]. In October 2013, topline data were reported from the 205-patient trial, showing that the drug did not meet the primary endpoints of significant difference in pain reduction between drug and placebo [&lt;ulink linkID="1489391" linkType="Reference"&gt;1489391&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2011, an 11-week randomized, double-blind, multicenter, placebo-controlled, phase III trial (&lt;ulink linkID="76229" linkType="Protocol"&gt;NCT01332149&lt;/ulink&gt;; A0081265) of pregabalin began in patients (expected n = 626) in China with diabetic peripheral neuropathy. The primary endpoint was mean pain score [&lt;ulink linkID="1585136" linkType="Reference"&gt;1585136&lt;/ulink&gt;]. In August 2014, topline data showed the trial failed to meet its primary endpoint, with a treatment difference of -0.28 points relative to placebo [&lt;ulink linkID="1585077" linkType="Reference"&gt;1585077&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2011, analytical clinical data were presented at the 30th Annual Scientific Meeting of the APS in Austin, TX. An analysis of 11 clinical studies found that for patients with painful diabetic neuropathy (PDN) or postherpetic neuralgia who experienced mild, moderate or severe sleep disturbances, pregabalin significantly improved pain. For PDN patients, the degree of pain improvement was proportional to degree of sleep interference   [&lt;ulink linkID="1216242" linkType="Reference"&gt;1216242&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By September 2008, a phase II/III trial had begun in Japan [&lt;ulink linkID="948614" linkType="Reference"&gt;948614&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2008, pooled clinical data were presented at the 68th ADA Scientific Sessions in San Francisco, CA.  The data suggested that  in patients with painful DPN, the pain-relieving effect of pregabalin was durable over a period of at least 2 years and that long-term use of pregabalin was generally well tolerated and not associated with clinically meaningful changes in HbA1c [&lt;ulink linkID="915214" linkType="Reference"&gt;915214&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2008, Pfizer was planning a randomized, double-blind, placebo-controlled, dose-escalation,  phase II trial (&lt;ulink linkID="13893" linkType="Protocol"&gt;NCT00599638&lt;/ulink&gt;, B0261002), of pregabalin in combination with &lt;ulink linkID="56702" linkType="Drug"&gt;PF-489791&lt;/ulink&gt;, in patients (n = 130), with post-herpetic neuralgia.  In the study, patients were to receive  pregabalin (75 to 150 mg bid), plus PF-489791 (4 mg to 10 mg qd), for  two weeks The primary endpoint was effective analgesia, as measured by the 11-point daily pain rating scale. This study was completed in December 2008 [&lt;ulink linkID="883058" linkType="Reference"&gt;883058&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2007, a global, multicenter, randomized, double-blind, parallel-group, phase III trial (&lt;ulink linkID="6849" linkType="Protocol"&gt;NCT00407745&lt;/ulink&gt;; A0081107) was initiated to evaluate the safety and efficacy of pregabalin in patients (n = 220) with chronic central neuropathic pain following spinal cord injury. The primary endpoint was the duration adjusted average change (DAAC) in pain scores during a 17-week treatment period. The study was completed in February 2011 [&lt;ulink linkID="1202342" linkType="Reference"&gt;1202342&lt;/ulink&gt;]. In June 2011, positive topline data were reported, which demonstrated that the study had met its primary endpoint. Central neuropathic pain was reduced in patients treated with pregabalin [&lt;ulink linkID="1201865" linkType="Reference"&gt;1201865&lt;/ulink&gt;]. In May 2012, clinical data were presented at the 31st Annual APS Meeting in Honolulu, HI. A total of 45.7 and 31.4% of patients receiving pregabalin and placebo, respectively, achieved a reduction in pain from baseline to endpoint of &amp;gt;/= 30%. Drug-treated patients also showed improvements over placebo in weekly sleep interference and patient global impression of change scores at endpoint [&lt;ulink linkID="1285699" linkType="Reference"&gt;1285699&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In September 2005, clinical data were presented at the European Federation of Neurological Societies Congress in Athens, Greece. The analysis included 45 patients with DPN and 36 patients with postherpetic neuralgia who had failed therapy or experienced intolerable side effects from amitryptyline, &lt;ulink linkID="3188" linkType="Drug"&gt;gabapentin&lt;/ulink&gt;   and one or more third-line neuropathic pain treatments. A total 46% of patients with diabetic peripheral neuropathy and 30% with postherpetic neuralgia achieved a 50% or greater reduction in pain after 3 months of pregabalin treatment. By 15 months, 36% and 32% of patients reported a similar reduction in pain, respectively [&lt;ulink linkID="623889" linkType="Reference"&gt;623889&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2005, several presentations on pregabalin were presented at the 65th ADA scientific sessions in San Diego, CA.  Four studies analyzed data from a pooled analysis of trials 014, 029, 040, 131, 149 and 155, which evaluated doses ranging from 75 to 600 mg/day of pregabalin, administered either twice or three times daily in patients with painful diabetic peripheral neuropathy. These studies found that pregabalin yielded significant pain reduction with favorable tolerability [&lt;ulink linkID="606629" linkType="Reference"&gt;606629&lt;/ulink&gt;], improved sleep disturbances associated with painful diabetic neuropathy [&lt;ulink linkID="606626" linkType="Reference"&gt;606626&lt;/ulink&gt;] and patients perceived a general significant clinical improvement in their health-related quality of life [&lt;ulink linkID="606631" linkType="Reference"&gt;606631&lt;/ulink&gt;]; pregabalin was also found to yield significant results compared to placebo after one day of treatment [ &lt;ulink linkID="606871" linkType="Reference"&gt;606871&lt;/ulink&gt;].   The most common treatment emergent  adverse events of dizziness (22%), somnolence (12.1%) were typically mild to moderate and transient in nature [&lt;ulink linkID="606871" linkType="Reference"&gt;606871&lt;/ulink&gt;].  Another presentation evaluated the long-term treatment of pregabalin in the first 15 months of an ongoing trial, in which pregabalin was administered from 150 to 600 mg/day with quarterly 'drug holidays' lasting from 3 to 28 days in 81 patients refractory to other treatments for neuropathy.  Pregabalin yielded significant reductions in VAS pain score and few subjects withdrew due to adverse events [&lt;ulink linkID="606632" linkType="Reference"&gt;606632&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2004, clinical data  were presented at the 64th ADA scientific sessions in Orlando, FL. A total of 217 patients who had at least a one-year exposure to pregabalin and who had VAS pain scores obtained during open-label phases were studied. Analysis of the VAS pain scores showed that the scores were consistent from quarter to quarter, indicating that the scores were stable over time [&lt;ulink linkID="542649" linkType="reference"&gt;542649&lt;/ulink&gt;], [&lt;ulink linkID="547999" linkType="reference"&gt;547999&lt;/ulink&gt;]. Further  data were presented from a 12-week, randomized, double-blind, placebo-controlled study in 338 patients with chronic neuropathic pain. 65 patients were randomized to placebo, flexible-dose (150 to 600 mg/day) and fixed-dose (300 mg/day for 1 week) pregabalin groups. Flexible- and fixed-doses significantly reduced mean pain score, and response to treatment was noted for 48% and 52% of patients in the flexible- and fixed-dose groups [&lt;ulink linkID="541478" linkType="reference"&gt;541478&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Also presented at the 64 ADA meeting, data from 974 subjects from 9 studies in adult patients with chronic pain were pooled with 4381 observations from healthy volunteer and renal impaired patients and epilepsy patients. Pharmacokinetics were well described in all patients by a one-compartment pharmacokinetic model with first-order absorption and a lag time [&lt;ulink linkID="544833" linkType="reference"&gt;544833&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In a further trial presented at the 64th ADA meeting, the pharmacokinetics of pregabalin were studied in healthy volunteers. Subjects received either single doses of 1 to 300 mg (n = 29), single or multiple doses of 25 to 300 mg every 8 h or 300 mg every 12 h  (n = 45), 300 mg every 8 h (n = 12), or single doses of 100 mg (n = 11) and 150 mg (n = 14). Pregabalin was rapidly absorbed with peak plasma concentrations at 0.7 to 1.4 h, oral bioavailability was approximately 90%, and it was shown that food reduced the absorption rate resulting in lower and delayed Cmax concentrations. Elimination half-life was approximately 6 h and steady-state was achieved within 1 to 2 days of repeated administration [&lt;ulink linkID="544828" linkType="reference"&gt;544828&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2003,  data were presented at the 7th EFNS congress in Helsinki, Finland. Data were pulled from six major studies in diabetic or post-herpetic neuropathic pain consisting of eight active treatment groups. The first 2 weeks of treatment were analyzed for all patients (923 on pregabalin and 506 on placebo), and a significant reduction of pain was observed on the first day for patients receiving 300 mg/day pregabalin, while doses from 75 to 150 mg/day generally produced pain reduction by day 2 or 3 [&lt;ulink linkID="505340" linkType="reference"&gt;505340&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2003,  data were presented at the Pharmacotherapy for Neuropathic Pain meeting in Surrey, UK. Pregabalin was found to be more potent than &lt;ulink linkID="3188" linkType="Drug"&gt;gabapentin&lt;/ulink&gt;  and could be administered twice a day [&lt;ulink linkID="500976" linkType="reference"&gt;500976&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2003,  data were presented at the 13th ENS meeting in Istanbul, Turkey. Three studies were carried out with pregabalin to treat painful diabetic neuropathy. These were 5 to 8 week studies with daily doses of drug between 75 and 600 mg; the primary endpoint was the score from the daily pain diary. The final study population included 729 patients, of whom 164 received 600 mg/day, 157 received 300 mg, 79 received 150 mg, 77 received 75 mg and 252 received placebo. Both the 300 and 600 mg/day doses were able to reduce the mean pain diary scores when compared to placebo; the efficacy of pregabalin was evident after one week and maintained to the study end. The drug was well tolerated, and 89% of the patients were able to complete the study. Dizziness and somnolence were the more frequent side effects [&lt;ulink linkID="498167" linkType="reference"&gt;498167&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2002, phase III data on pregabalin were presented at the 10th World Congress on Pain in San Diego, CA. A total of 1599 patients with DPN pain and post-herpetic neuralgia were used to explore relationships between pregabalin exposure and response. Pregabalin decreased neuropathic pain in a dose-dependent manner [&lt;ulink linkID="465885" linkType="reference"&gt;465885&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In June 2002,  data were presented at the 62nd ADA Scientific Sessions in San Francisco, CA. Two randomized, double-blind, 6-week trials (1008-14 and -29), involving a total of 583 patients with diabetic neuropathy, were conducted to evaluate the safety and efficacy of pregabalin at various doses up to 600 mg/day tid. In -014, pregabalin 150 and 600 mg/day versus placebo were studied, while -029 compared pregabalin 75, 300, and 600 mg/day against placebo. Pregabalin 300 and 600 mg/day were significantly better than placebo in reducing pain, with significant improvements in weekly mean pain scores, sleep interference scores and SF-McGill subscales beginning at week 1 and continuing until study end. These doses were also significantly better than placebo for clinical and patient global impressions of pain, and significantly more patients at these doses responded. The most common adverse events were dizziness and somnolence; 5.3% of patients withdrew due to adverse events. Among all treatment groups, 89% of patients completed the studies and the majority entered open-label treatment [&lt;ulink linkID="454539" linkType="reference"&gt;454539&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In March 2001, data on pregabalin were presented at the 102nd ASCPT meeting in Orlando, FL. A dose of 300 mg provided a decrease in pain score of approximately one unit from placebo. Further pain relief was observed when the daily dose was increased to 600 mg [&lt;ulink linkID="406243" linkType="reference"&gt;406243&lt;/ulink&gt;].   &lt;/para&gt;&lt;para&gt;In February 2001, the FDA advised Pfizer to halt its phase III trial of pregabalin in the treatment of neuropathic pain, following tumor incidence discovered in mice [&lt;ulink linkID="398726" linkType="reference"&gt;398726&lt;/ulink&gt;]. At this time, the company was to continue its phase III trials for the other indications and had initiated further preclinical studies in mice [&lt;ulink linkID="398785" linkType="reference"&gt;398785&lt;/ulink&gt;]. As of September 2002, the company was still working to characterize the mechanism behind this [&lt;ulink linkID="463312" linkType="reference"&gt;463312&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2001, an open-label, extension to the preceeding double-blind study, phase III study (&lt;ulink linkID="4247" linkType="Protocol"&gt;NCT00150423&lt;/ulink&gt;; 1008-165) was initiated in Germany to assess the safety and efficacy of pregabalin in patients (expected n = 384) with painful DPN. The primary endpoint was safety and efficacy. The  study completed in November 2005 [&lt;ulink linkID="1867191" linkType="Reference"&gt;1867191&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By January 2001, pregabalin was in phase II development in Japan for the potential treatment of neuropathic pain, with an anticipated approval date of 2005 [&lt;ulink linkID="394827" linkType="reference"&gt;394827&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In June 2000, the results of a phase III study of pregabalin were reported at the 60th American Diabetes Association meeting, in San Antonio, TX. In a 6-week randomized, double-blind parallel-group trial involving 246 patients with 1 to 5 years of pain associated with diabetic neuropathy, the percentage of responders was almost double the percentage in the placebo group. No analgesic effects were seen at a dose of 150 mg/day. Dizziness, somnolence and peripheral edema were the most commonly reported adverse events, of which the majority were mild-to-moderate and resolved during the study. It was concluded that pregabalin is effective and safe at doses of 600 mg/day in reducing the pain associated with diabetic neuropathy [&lt;ulink linkID="369802" linkType="reference"&gt;369802&lt;/ulink&gt;], [&lt;ulink linkID="413112" linkType="reference"&gt;413112&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Results were reported in 2000 of a double-blind, placebo-controlled trial of pregabalin in 337 patients with diabetic neuropathy in which pregabalin (75, 300 and 600 mg/day) was compared with placebo [&lt;ulink linkID="373643" linkType="reference"&gt;373643&lt;/ulink&gt;]. There were significant improvements in pain scores with both the 300 and 600 mg/day doses compared with placebo, beginning at week one and continuing through to study termination. Patients in the pregabalin 75 mg/day group did not show any significant improvements compared with placebo. Improvements of sleep scores were obtained for both 300 and 600 mg dosages. These data were in accordance with the results obtained with &lt;ulink linkID="3188" linkType="Drug"&gt;gabapentin&lt;/ulink&gt;  3600 mg/day [&lt;ulink linkID="349433" linkType="reference"&gt;349433&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Complex regional pain syndrome&lt;/subtitle&gt;In April 2006, a prospective, randomized, controlled, phase II trial (&lt;ulink linkID="49359" linkType="Protocol"&gt;NCT00558753&lt;/ulink&gt;; ABuv102007; PregTKA) of perioperative pregabalin in patients (n = 240) with late-onset complex regional pain syndrome after total knee arthroplasty, was initiated. The study was completed in June 2010 [&lt;ulink linkID="1771893" linkType="Reference"&gt;1771893&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Epilepsy: monotherapy&lt;/subtitle&gt;In April 2008, a phase III extension study (&lt;ulink linkID="7458" linkType="Protocol"&gt;NCT00596466&lt;/ulink&gt;) to  evaluate the long term safety and efficacy of pregabalin when      administered as monotherapy to epilepsy patients for      the treatment of partial seizures was initiated. The study was completed in December 2011 [&lt;ulink linkID="1262387" linkType="Reference"&gt;1262387&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2006, a randomized, double-blind, multicenter, parallel, phase III trial (&lt;ulink linkID="6722" linkType="Protocol"&gt;NCT00280059&lt;/ulink&gt;) of pregabalin monotherapy was initiated in patients ( n = 660) with newly diagnosed epilepsy with partial seizures in Europe, Asia, India and Mexico. Patients were randomized to receive pregabalin 150 to 600 mg/day bid or &lt;ulink linkID="6189" linkType="Drug"&gt;lamotrigine&lt;/ulink&gt; 100 to 500 mg/day bid. The primary endpoint was the proportion of patients who were seizure-free for 6 months. In April 2010, the trial was completed. Percentage of seizure-free responders was 51.6% for pregabalin vs 67.9% for lamotrigine [&lt;ulink linkID="1006001" linkType="Reference"&gt;1006001&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2007, a randomized, double-blind, multicenter, parallel, phase III trial (&lt;ulink linkID="7597" linkType="Protocol"&gt;NCT00524030&lt;/ulink&gt;), investigating pregabalin monotherapy for the treatment of partial seizures, was initiated in patients (expected n = 250) with epilepsy in the US. Patients were randomized to receive pregabalin 600 mg/day bid or 150 mg/day bid for 20 weeks. The primary endpoint was the percentage of patients who met at least one of the five pre-specified exit criteria, reflecting a decrease in seizure control. In April 2009, the expected completion date for this trial was March 2010, however, by  September 2011 the trial was terminated [&lt;ulink linkID="1005977" linkType="Reference"&gt;1005977&lt;/ulink&gt;]. In October 2011, an independent Data Monitoring Committee recommended the halting a phase III efficacy and safety monotherapy  trial for partial onset seizures,presumed to be  this trial,  based on positive primary efficacy endpoint findings [&lt;ulink linkID="1267519" linkType="Reference"&gt;1267519&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2007, a phase I/II placebo-controlled, escalating, multiple dose study (&lt;ulink linkID="8050" linkType="Protocol"&gt;NCT00437281&lt;/ulink&gt;; A0081074) was initiated to evaluate safety, tolerability and pharmacokinetics of pregabalin in pediatric patients with partial onset seizures (n =  65). At that time, the study was expected to complete in November 2012 [&lt;ulink linkID="1623726" linkType="Reference"&gt;1623726&lt;/ulink&gt;]. In May 2007, a 12-month, open-label extension study (&lt;ulink linkID="8049" linkType="Protocol"&gt;NCT00448916&lt;/ulink&gt;; A0081075; 2010-020731-39) began to evaluate safety and tolerability of flexible doses in this patient group (n = 54); the study was expected to complete in  October 2013 [&lt;ulink linkID="1623727" linkType="Reference"&gt;1623727&lt;/ulink&gt;].  In December 2014, data from the extension study were presented at the 68th Annual Meeting of the American Epilepsy Society in Seattle, WA. Doses &amp;lt;/= 10 mg/kg were well tolerated. Dizziness and somnolence was observed less commonly than in adult studies [&lt;ulink linkID="1621546" linkType="Reference"&gt;1621546&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Epilepsy: adjunctive therapy&lt;/subtitle&gt;In December 2016, a phase III trial as adjunctive therapy for pediatric epilepsy patients (4 to 16 years of age) met its primary endpoint. The study in 295 patients was a 12-week double-blind, placebo-controlled, randomized, parallel group, including two fixed pregabalin doses. Data showed for patients treated with pregabalin 10 mg/kg/day a significant reduction seizure frequency versus placebo, while a treatment with pregabalin 2.5 mg/kg/day resulted in a numerical reduction in seizure frequency, which was not statistically significant [&lt;ulink linkID="1879946" linkType="Reference"&gt;1879946&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2014, a randomized, double-blind, placebo-controlled, parallel-group assigned,  multicenter, phase III trial (&lt;ulink linkID="175526" linkType="Protocol"&gt;NCT02072824&lt;/ulink&gt;; A0081042  2013-003420-37) was initiated in the US, Europe,  Israel,  Asia,    South Africa and  Taiwan in children aged 1 month through &amp;lt;4 years of age (n = 179)  with partial onset seizures to assess the safety and efficacy of the drug as an adjunct therapy.  In June 2016, the trial was ongoing. At that time, the trial was expected to complete in August 2017 [&lt;ulink linkID="1774260" linkType="Reference"&gt;1774260&lt;/ulink&gt;]. Later that month, it was reported at the 13th EILAT Conference on New Antieplieptic Drugs and Devices in Madrid, Spain that the study continued to enroll patients [&lt;ulink linkID="1779590" linkType="Reference"&gt;1779590&lt;/ulink&gt;]. In May 2018, positive top-line data were reported from 175 patients with partial onset seizures not adequately controlled with one to three concomitant antiepileptic drugs who received pregabalin (7 and 14 mg/kg/day). The higher dose met the primary endpoint of a significant reduction in seizure frequency; a significant effect was not seen with the lower dose  [&lt;ulink linkID="2035450" linkType="Reference"&gt;2035450&lt;/ulink&gt;].  In December 2018, further data were presented at the 72nd American Epilepsy Society Annual Meeting in New Orleans, LA. Significant differences were not noted in responder rate with either pregabalin treatment (53.6 and 30.5% with 14 and 7 mg/kg/day, respectively) versus placebo (41.5%).  The adverse events (AEs) reported were all mild or moderate in intensity.Treatment-emergent serious AEs reported by five patients, including pneumonia, requiring hospitalization (n = 1 in 14 mg/kg/day group), acute rhinitis, increasing frequency of seizures, dehydration, choking (n = 4, placebo group), but none of these were considered treatment-related and all resolved without sequelae [&lt;ulink linkID="2121432" linkType="Reference"&gt;2121432&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2013, data were reported from a phase III, randomized, double-blind, parallel-group, multicenter, comparative, flexible-dose trial of adjunctive treatment with pregabalin (300, 450 or 600 mg/day) versus &lt;ulink linkID="5665" linkType="Drug"&gt;levetiracetam&lt;/ulink&gt; (1000, 2000 or 3000 mg/day) for reducing partial onset seizure frequency. Pregabalin met the primary endpoint of demonstrating a comparable proportion of patients achieving at least a 50% reduction in 28-day seizure rate compared with levetiracetam [&lt;ulink linkID="1385340" linkType="Reference"&gt;1385340&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2011, a double-blind, parallel group, multi-center, placebo-controlled, randomized, phase III study (&lt;ulink linkID="79112" linkType="Protocol"&gt;NCT01389596&lt;/ulink&gt;; PERIWINKLE; A0081041, 2010-020852-79, XALCORY 1014) was initiated in the US, Europe, Asia, Turkey and Korea to assess the safety and efficacy of the drug as an adjunct therapy in  children aged 4-16 years (n = 225) with partial onset seizures. At that time, the study was expected to complete in April 2016 [&lt;ulink linkID="1642994" linkType="Reference"&gt;1642994&lt;/ulink&gt;]. In June 2016, it was reported at the 13th EILAT Conference on New Antieplieptic Drugs and Devices in Madrid, Spain that enrollment of patients was completed [&lt;ulink linkID="1779590" linkType="Reference"&gt;1779590&lt;/ulink&gt;]. In December 2017, data were presented at the 71st American Epilepsy Society Annual Meeting in Washington DC. The seizure frequency reductions were tended to be more consistent for pregabalin 10 mg/kg/day dose when compared with 2.5 mg/kg/day.Â A small percentage of patients experienced a &amp;gt;/=25% increase in seizure frequency, with a numerically larger percentage of these patients in the placebo group (15.1%) than in either pregabalin group (7.8% in 2.5 mg/kg/day and 11.5% in 10mg/kg/day). Relatively few subjects were seizure-free (100% decrease) with any treatment.Â Pregabalin was well tolerated [&lt;ulink linkID="1992636" linkType="Reference"&gt;1992636&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2004,  data were presented at the seventh Eilat Conference on New Antiepileptic Drugs in Sardinia, Italy. In a 12-week, placebo-controlled, fixed-dose trial with pregabalin as an adjunctive therapy (up to 600 mg/day), 14 to 51% of patients showed at least a 50% decrease in seizure frequency and a clear dose-response relationship. The seizure-free rate was &amp;lt; 7%. The most common side effects were dizziness (29%), and somnolence (21%) and less than 1% of patients discontinued due to adverse effects. Weight gain (equal to or more than 7% increase from baseline) occurred in 40% of patients in the long-term study. The average weight gain was 6.4 kg in the 1-year cohort. After discontinuation of the drug, weight decreased [&lt;ulink linkID="540000" linkType="reference"&gt;540000&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2004, clinical data were presented at the 56th American Academy of Neurology Annual Meeting in San Francisco, CA. In a flexible dosing group (150 mg/day to 600 mg/day) seizure reduction rate was 35.4% compared to 40.3% for fixed dose (600 mg/day) and 10.6% for placebo. The compound was also found not to affect male fertility or efficacy of oral contraceptives in women [&lt;ulink linkID="538038" linkType="reference"&gt;538038&lt;/ulink&gt;], [&lt;ulink linkID="535701" linkType="reference"&gt;535701&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2002, clinical data were presented at the sixth Eilat Conference on New Antiepileptic Drugs in Sicily, Italy. Good tolerability was demonstrated at a dose of 300 mg three-times daily. The drug had linear kinetics and no food interactions were reported. The half-life of the compound was 6 h and no drug-drug interactions were expected based on in vitro studies [&lt;ulink linkID="451474" linkType="reference"&gt;451474&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2000, results of two trials involving 312 patients with partial seizures were presented at the 54th Annual Meeting of the American Epilepsy Society in Los Angeles, CA. When administered with other antiepileptic agents, pregabalin (600 mg, bid or tid) resulted in ~ 50% reduction in seizures. Both doses were well tolerated, with the most frequent (dose-related) adverse effects being dizziness, somnolence and ataxia. In similar trials, 50, 150, 300 and 600 mg pregabalin reduced seizures by 7, 12, 34 and 54%, respectively [&lt;ulink linkID="394531" linkType="reference"&gt;394531&lt;/ulink&gt;]. Similar data were reported in February 2005: pregabalin reduced seizure frequency by 53% when administered tid and by 44% when administered bid. Responder rates were 49% for pregabalin tid and 43% for pregabalin bid [&lt;ulink linkID="585067" linkType="Reference"&gt;585067&lt;/ulink&gt;], [&lt;ulink linkID="584873" linkType="Reference"&gt;584873&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2000, data were presented at the fifth Conference on New Antiepileptic Drugs in Eilat, Israel, showing the results of three multicenter, 12-week double-blind, placebo-controlled add-on studies, involving 1052 patients with partial seizures, which investigated dose-response relationships (50 to 600 mg/day), different dosing regimens (bid versus tid) and escalation rates. In all three trials, patients treated with pregabalin showed a significant reduction in seizure frequency compared with placebo. At interim analysis, effective dosages were 150 to 600 mg/day, with 34 to 44% of patients showing at least 50% seizure reduction. Pregabalin was well tolerated, with dizziness, somnolence and ataxia being the most commonly reported adverse events [&lt;ulink linkID="373379" linkType="reference"&gt;373379&lt;/ulink&gt;], [&lt;ulink linkID="406549" linkType="reference"&gt;406549&lt;/ulink&gt;], [&lt;ulink linkID="451474" linkType="reference"&gt;451474&lt;/ulink&gt;], [&lt;ulink linkID="468029" linkType="reference"&gt;468029&lt;/ulink&gt;]. At this time additional trials were planned to evaluate therapy use and pediatric indications [&lt;ulink linkID="373379" linkType="reference"&gt;373379&lt;/ulink&gt;]. In August 2003, further data were presented at the 7th EFNS congress in Helsinki, Finland. The addition of 512 de novo patients increased the numbers to 1480. Responder rates (defined as greater than or equal to 50% reduction of seizures versus baseline) were 44% in the 6-month cohort (n = 671), 49% in the 1-year cohort (n = 535) and 50.2 to 61.2% in the 2-year cohort (n = 201). In all cohorts, responder rates were maintained over time, and no new tolerability issues were identified with long-term treatment [&lt;ulink linkID="505340" linkType="reference"&gt;505340&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Tonic clonic epilepsy&lt;/subtitle&gt;In April 2013, a randomized, double-blind, placebo-controlled, parallel group, multicenter, phase III trial (&lt;ulink linkID="101538" linkType="Protocol"&gt;NCT01747915&lt;/ulink&gt;; A0081105; 2010-023263-18) of pregabalin as adjunctive therapy in pediatric and adult patients (expected n = 168) with primary generalized tonic-clonic seizures, was initiated in the US, Europe, Korea, Israel, Malaysia and India. In August 2018, the study was ongoing and expected to complete in July 2019 [&lt;ulink linkID="1759804" linkType="Reference"&gt;1759804&lt;/ulink&gt;]; in May 2019, negative topline data from the 12-week, 219-patient, phase III trial as part of a post-marketing commitment were reported, showing a non-statistically significant reduction in seizure frequency when compared with  placebo [&lt;ulink linkID="2155377" linkType="Reference"&gt;2155377&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In February 2012, an open-label, non-randomized, single-group assigned, phase III trial (&lt;ulink linkID="82023" linkType="Protocol"&gt;NCT01463306&lt;/ulink&gt;; A0081106; 2011-001412-65) was initiated in US, Europe, China, India, South Korea, Far East, Singapore, Taiwan, Israel and Lebanon in patients (expected n = 615) with primary generalized tonic-clonic seizures. The trial was expected to end in February 2018. In  March 2019, the trial was expected to complete in February 2020 [&lt;ulink linkID="1728755" linkType="Reference"&gt;1728755&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Other studies&lt;/subtitle&gt;In May 2016, pooled post-hoc data from a three fibromyalgia (FM) and three painful diabetic peripheral neuropathy (pDPN) placebo-controlled studies, which evaluate the safety and efficacy of pregabalin in patients with FM and pDPN were presented at the 35th APS Annual Scientific Meeting in Austin, TX. Patients with FM received pregabalin with starting dose of 150 mg/day and recommended dose of 300 to 450 mg/day; while patients with pDPN received pregabalin with starting dose of 150 mg/day and recommended dose of 300 mg/day. In FM patients, the likelihood of achieving a &amp;gt;/= 30% pain response incrementally increased from 27.5% with placebo to 31.5, 33.0 and 33.7% at 150, 300 and 450 mg/day, respectively. Dose-response was also observed in pDPN patients; 28.6% with placebo, and 41.9 and 49.0% at 150 and 300 mg/day, respectively. For both FM and pDPN patients, incremental improvements in patient global impression of change occurred with increasing doses. Commonly reported adverse events were dizziness and somnolence  [&lt;ulink linkID="1800837" linkType="Reference"&gt;1800837&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2015, clinical data were presented from a double-blind, placebo-controlled, two-period, crossover study in 40 older patients with type 2 diabetes at the 75th ADA Scientific Sessions in Boston, MA. Pregabalin significantly decreased the overall falls risk score and perception of pain, and improved gait speed significantly and reaction times for both the upper and lower limbs [&lt;ulink linkID="1667382" linkType="Reference"&gt;1667382&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2015, clinical data were presented from eight placebo-controlled trials in patients with neuropathic pain and previously treated with gabapentin at the 34th APS Annual Scientific Meeting in Palm Springs, CA.											Overall, patients who did not show a robust response to gabapentin or had difficulty in tolerating gabapentin exhibited clinically meaningful pain improvements when switched to pregabalin [&lt;ulink linkID="1659892" linkType="Reference"&gt;1659892&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2015, a double-blind, double dummy, randomized, placebo-controlled, five period cross-over phase I study (&lt;ulink linkID="221394" linkType="Protocol"&gt;NCT02349607&lt;/ulink&gt;; B3291010, 2014-004468-39) was planned to be initiated later that month, in Netherlands, to assess the effect of Â PF-05089771 alone and in combination with pregabalin on evoked pain endpoints in healthy male volunteers (expected n = 25) using pregabalin and  &lt;ulink linkID="69928" linkType="Drug"&gt;ibuprofen&lt;/ulink&gt; as positive controls. At that time, the study was expected to complete in March 2015 [&lt;ulink linkID="1632769" linkType="Reference"&gt;1632769&lt;/ulink&gt;]. In March 2015, the trial was initiated and in April 2015, the trial was completed [&lt;ulink linkID="1632769" linkType="Reference"&gt;1632769&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2014, an interventional, parallel, randomized phase II trial (&lt;ulink linkID="289661" linkType="Protocol"&gt;UMIN000026336&lt;/ulink&gt;) to assess the efficacy and safety of epidural anesthesia and pregabalin in patients (expected n=96) for perioperative pain control after thoracotomy. In March 2017, the study was completed [&lt;ulink linkID="1905723" linkType="Reference"&gt;1905723&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2013, data from a randomized (3:1), placebo-controlled, parallel-group, multiple dose, dose-escalation study were presented at the 2013 American Epilepsy Society Annual Meeting in Seattle, WA. Patients (n = 65) were categorized into four age cohorts   with four  dose  levels (2.5, 5, 10 and 15 mg/kg/day). When compared with the subjects &amp;gt;30 kg body weight, the AUC of pregabalin was approximately 30% lower and the clearance normalized per body weight was approximately 43% higher among subjects with &amp;lt;30 kg body weight.  Up to and including 10 mg/kg/day dose, pregabalin was well tolerated [&lt;ulink linkID="1522272" linkType="Reference"&gt;1522272&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Irritable bowel syndrome&lt;/subtitle&gt;In March 2010, an investigator-led, phase II, randomized, placebo-controlled, double-blind, efficacy study (&lt;ulink linkID="60354" linkType="Protocol"&gt;NCT00977197&lt;/ulink&gt;; 09-004404) of pregabalinÂ was initiated in patients (n = 97) withÂ irritable bowel syndrome; at that time, the study was expected to complete in November 2014. By September 2015, enrollment had been completed and  trial completion was expected in August 2016 [&lt;ulink linkID="1447005" linkType="Reference"&gt;1447005&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Restless leg syndrome&lt;/subtitle&gt;A study initiated in December 2009 (&lt;ulink linkID="60897" linkType="Protocol"&gt;NCT00991276&lt;/ulink&gt;; A0081185) demonstrated significant improvements in the primary endpoint, sleep maintenance, compared with placebo in adults with RLS [&lt;ulink linkID="1249468" linkType="Reference"&gt;1249468&lt;/ulink&gt;]. In June 2012, data from 85 subjects were presented from the double-blinded, triple-dummy, placebo-controlled, active-comparator, three-way crossover study  conducted in USA at the 16th International MDS Congress, in Dublin, Ireland.  Patients were randomized to receive pregabalin (300 mg/day), &lt;ulink linkID="4151" linkType="Drug"&gt;pramipexole&lt;/ulink&gt; (0.5 mg/day), or placebo for three 4-week periods. Pregabalin demonstrated improved sleep maintenance compared with pramipexole and placebo; in pregabalin versus placebo and pregabalin versus pramipexole groups, the least-square mean difference (LSMD) in wake after sleep onset (primary endpoint) was -27.1 and â25.9, respectively, and the LSMD in number of awakenings after sleep onset was -2.7 and â7.9, respectively; in the respective groups, the subjective total sleep time was increased with the LSMD value of 30.8 and 29.8 min, and pregabalin demonstrated improvement in the sleep architecture by increasing slow wave sleep with the LSMD value of 20.9 and 32.1 min. An improved RLS-next day impact total score was observed with pregabalin compared with placebo, and the score was comparable with pramipexole [&lt;ulink linkID="1302264" linkType="Reference"&gt;1302264&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2008, Pfizer initiated a randomized, double-blind, parallel, phase III trial (&lt;ulink linkID="38329" linkType="Protocol"&gt;NCT00806026&lt;/ulink&gt;; A0081186) in patients (expected n = 700) with idiopathic RLS in the US. Patients were randomized to receive 3 months placebo followed by 9 months treatment with pregabalin or pramipexole or 12 months treatment with pregabalin or pramipexole. Study doses were 300 mg/day pregabalin po administered od, 0.25 mg/day pramipexole po administered od, and 0.5 mg/day pramipexole po administered od. All drugs were administered 1-3 h before bedtime. Primary endpoints were RLS symptom severity, as measured by the International RLS Severity Scale, the proportion of patients responding to treatment, as measured by the Clinical Global Impression Scale, and the rate of augmentation. In April 2009, the scheduled completion date for this trial was March 2011 [&lt;ulink linkID="1005943" linkType="Reference"&gt;1005943&lt;/ulink&gt;]. Data were reported in December 2011.  The study met each of its three coprimary endpoints, showing significant benefit as compared with placebo and pramipexole. Patients treated with pregabalin experienced a significant improvement compared with placebo in RLS symptom severity as measured by the International Restless Leg Group Rating Scale following 12 weeks of treatment. The pregabalin group also demonstrated a significant improvement following 12 weeks of treatment in the proportion of patients responding to treatment compared with those on placebo as measured by the Clinical Global Impression Improvement scale. In addition, treatment resulted in a significant reduction in the rate of augmentation compared with pramipexole 0.5 mg/day over 12 months. At that time, Pfizer had no plans to pursue approval in this indication [&lt;ulink linkID="1249468" linkType="Reference"&gt;1249468&lt;/ulink&gt;]. In June 2012, similar data were presented at the 16th International MDS Congress, in Dublin, Ireland. Pregabalin significantly improved RLS symptoms compared to placebo and showed increased efficacy compared to pramipexole at 12 and 52 weeks. At 40/52 weeks, pregabalin significantly induced lower incidences of augmentation compared with pramipexole. Serious adverse events related to treatment were  lower for pregabalin patients. Over 12 weeks, assessment of several secondary endpoints such as improvement in limb pain visual analog scale (VAS), RLS-Quality of Life and subjective Wake After Sleep Onset (sWASO), were favorable for pregabalin [&lt;ulink linkID="1302543" linkType="Reference"&gt;1302543&lt;/ulink&gt;], [&lt;ulink linkID="1302570" linkType="Reference"&gt;1302570&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Chronic cervical pain&lt;/subtitle&gt;In September 2018, data from an 8-week, multicenter, prospective, non-interventional, observational study which evaluated the effectiveness of pregabalin, in chronic cervical pain patients with accompanying upper limb radiating pain was presented at  17th World Congress on Pain in Boston, MA. Patients (n = 369) received pregabalin 75 mg bid, titrating to 150 mg bid over one week. At week 8, change in treatment difference from baseline in PRSIS score was statistically significant (-0.898, confident interval -1.262 and p &amp;lt; 0.001). In patients treated with pregabalin and other analgesics, all causality adverse events (AEs) reported by 42 and 48, respectively [&lt;ulink linkID="2076702" linkType="Reference"&gt;2076702&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In October 2006, preclinical data were presented at the 36th Annual SFN Meeting in Atlanta, GA. In the Vogel test in wt mice, dose dependent anxiolytic-like effects were observed and the minimally effective dose (MED) was 10 mg/kg. In contrast, across the same dose range, anxiolytic-like effects of pregabalin were abolished in  knock-in mice. &lt;ulink linkID="51693" linkType="Drug"&gt;Phenobarbital&lt;/ulink&gt; produced robust anxiolytic-like effects in both genotypes (MED = 32 mg/kg; -30 min, ip). Similar effects were seen in wt and knock-in mice after treatment with Pregabalin  in the accelerating rotarod test; however, locomotor activity testing was shown to be ineffective for measuring side effects produced by pregabalin [&lt;ulink linkID="730381" linkType="Reference"&gt;730381&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2004, data were presented at the 227th ACS meeting in Anaheim, CA. The compound was found to be more potent than &lt;ulink linkID="3188" linkType="Drug"&gt;gabapentin&lt;/ulink&gt; in biological assays and showed linear pharmacokinetics. It had excellent oral bioavailability, high aqueous solubility and entered the brain effectively. Pregabalin was also effective in the rat model of anxiety. Mice with an arginine 217 residue that had mutated to an &lt;ulink linkID="18030" linkType="Company"&gt;alanine&lt;/ulink&gt; demonstrated reduced binding of the compound to the receptor in the neocortex and hippocampus, and pregabalin was found to be inactive in these animals. In a murine model of neuropathic pain, pregabalin was as efficacious as morphine in wild-type animals, but less effective in mutant animals [&lt;ulink linkID="532753" linkType="reference"&gt;532753&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By March 2004, pregabalin had been shown to be a substrate for the large neutral amino acid system L amino acid transporter with an IC50 of 158 +/-35 microM ([3H]leucine uptake inhibition in CHO cells) and to bind to alpha2-delta subunit of calcium channel with an IC50 value of 80 +/- 7 nM ([3H]gabapentin binding inhibition to pig brain membranes). SAR of pregabalin and analogs suggested that both activities are required for the observed pharmacological activity of pregabalin [&lt;ulink linkID="669802" linkType="Reference"&gt;669802&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2002, preclinical data were presented at the 32nd Neuroscience meeting in Orlando, FL. Results from studies in rotarod and water lick conflict rat models demonstrated a stereoselective mechanism of action for pregabalin. Benzodiazepines showed greater disruption of rotarod behavior than pregabalin [&lt;ulink linkID="468969" linkType="reference"&gt;468969&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2001, preclinical data were presented at Digestive Disease Week in Atlanta, GA, showing the drugs efficacy against visceral pain [&lt;ulink linkID="408789" linkType="reference"&gt;408789&lt;/ulink&gt;]. At the same meeting, studies on abdominal cramps were presented. Pregabalin delivered either orally or intrathecally to rats had antinociceptive effects, acting at a the postsynaptic level in the dorsal horn [&lt;ulink linkID="409558" linkType="reference"&gt;409558&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt; Pregabalin has an IC50 value of 80 nM and has been shown to be more effective than &lt;ulink linkID="3188" linkType="Drug"&gt;gabapentin&lt;/ulink&gt; at alleviating mechanical hyperalgesia (a model of neuropathic pain) at non-sedative doses [&lt;ulink linkID="296525" linkType="reference"&gt;296525&lt;/ulink&gt;], [&lt;ulink linkID="307238" linkType="reference"&gt;307238&lt;/ulink&gt;]. In rats treated to carrageenan treatment to the hind paw, pregabalin treatment (2.5 h after carrageenan) reduced each of static allodynia, dynamic allodynia and thermal hyperalgesia [&lt;ulink linkID="428636" linkType="reference"&gt;428636&lt;/ulink&gt;], [&lt;ulink linkID="493673" linkType="reference"&gt;493673&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><ExpertReview>&lt;para&gt;&lt;subtitle&gt;There are two evaluations of this drug&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Richard Huckle, &lt;ulink linkType="Company" linkID="27921"&gt;Axovan Ltd&lt;/ulink&gt;, Allschwil, Switzerland&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Submission date: 24 June 2003&lt;/subtitle&gt;&lt;subtitle&gt;Publication date: 28 August 2003&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Introduction&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="17814"&gt;Pregabalin&lt;/ulink&gt; (CI-1008) has been developed as a follow-up compound to &lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt; (Neurontin) for use in the treatment of epilepsy, pain, anxiety and social phobia. Both &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt; are analogs of gamma-aminobutyric acid (GABA), a neurotransmitter that is thought to play a major inhibitory role in the central nervous system (CNS). As with many other agents that act on or within the CNS, the exact mechanism of action of GABA is currently not fully understood. Impairment of GABA function can produce seizures [&lt;ulink linkType="reference" linkID="501345"&gt;501345&lt;/ulink&gt;], whereas enhancement results in an anticonvulsant effect [&lt;ulink linkType="reference" linkID="501345"&gt;501345&lt;/ulink&gt;]. Agents such as &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; act on the GABA inhibitory pathway, thereby decreasing abnormal neuronal hyperexcitability by modulating sodium and calcium channels, or by inhibiting the actions of excitatory amino acid [&lt;ulink linkType="reference" linkID="494489"&gt;494489&lt;/ulink&gt;]. The resulting inhibition of excess neuronal activity is thought to be the basis for the efficacy of anticonvulsants in epilepsy and neuropathic pain. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Synthesis and SAR&lt;/subtitle&gt;The synthesis and SAR of &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; have been discussed in a previous evaluation of this drug in 2001 [&lt;ulink linkType="reference" linkID="412900"&gt;412900&lt;/ulink&gt;]. A series of GABA analogs were prepared and, following the discovery that the anticonvulsant activity of racemic 3-isobutyl GABA resides in the (S)-enantiomer (&lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt;) [&lt;ulink linkType="reference" linkID="297247"&gt;297247&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="373673"&gt;373673&lt;/ulink&gt;], the abilities of the analogs to displace (3H)-&lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt; were compared in receptor binding studies. The (S)-enantiomer was again demonstrated to be the most potent [&lt;ulink linkType="reference" linkID="169739"&gt;169739&lt;/ulink&gt;], indicating a need for enantioselective synthesis. Analysis of the SAR suggested that size and substitution patterns at the 3-position of the GABA chain were not well tolerated [&lt;ulink linkType="reference" linkID="373673"&gt;373673&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The half-maximal concentrations of &lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; necessary to mediate GABA transport in dissociated hippocampal neurons were approximately 50 and 25 microM, respectively [&lt;ulink linkType="reference" linkID="501530"&gt;501530&lt;/ulink&gt;]. The enantioselectivity dependence on both pressure and catalyst loading have also been investigated to increase the enantiomeric excess for more efficient production [&lt;ulink linkType="reference" linkID="502720"&gt;502720&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Preclinical Development&lt;/subtitle&gt;Although &lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; were originally developed as anticonvulsants for epilepsy, serendipitous discoveries have demonstrated a wider application for their use in affective disorders (eg, bipolar depression), anxiety disorders and pain (especially neuropathic). The mechanisms by which these agents afford these effects are still not clearly understood.&lt;/para&gt;&lt;para&gt;The effects of &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; on cellular substances have been assessed. Nuclear magnetic resonance spectroscopy studies of the effects of &lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt;, &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="4651"&gt;vigabatrin&lt;/ulink&gt; on the levels of GABA, glutamate and glutamine were carried out in the brains of Long Evans rats [&lt;ulink linkType="reference" linkID="494489"&gt;494489&lt;/ulink&gt;]. No change was observed in cellular GABA and glutamine concentrations in rats treated with &lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt; or &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt;, while both significantly decreased cellular glutamate concentrations (4%, p &amp;gt; 0.05) in the healthy rat forebrain [&lt;ulink linkType="reference" linkID="494489"&gt;494489&lt;/ulink&gt;]. In rat brain slices, &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt; reduced glutamate release by 11 to 26% [&lt;ulink linkType="reference" linkID="373644"&gt;373644&lt;/ulink&gt;], whereas &lt;ulink linkType="Drug" linkID="4651"&gt;vigabatrin&lt;/ulink&gt; increased cellular GABA by 50% (p &amp;gt; 0.003) compared with saline-treated rats [&lt;ulink linkType="reference" linkID="494489"&gt;494489&lt;/ulink&gt;]. In a 3,4-diaminopyridine (DAP)-induced model of increased norepinephrine and dopamine release in the rat hippocampus and striatum, DAP-induced increases were dose-dependently antagonized by &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt;; &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; (100 mg/kg ip) did not alter basal synthesis [&lt;ulink linkType="reference" linkID="345734"&gt;345734&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The anticonvulsant profile of &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; has been extensively examined in animals [&lt;ulink linkType="reference" linkID="297247"&gt;297247&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="299344"&gt;299344&lt;/ulink&gt;]. These preclinical studies demonstrated that &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; is 3- to 10-fold more potent than &lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt;. For example, &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; is more potent than &lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt; in preventing maximal electroshock seizures (MES) in mice (ED50 = 20 versus 87 mg/kg po, respectively) and in rats (ED50 = 1.8 versus 10.3 mg/kg po, respectively). In addition, &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; is slightly more effective in blocking kindled hippocampal seizures in the rat model (30 mg/kg ip &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; produced a comparable effect to 100 mg/kg ip &lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt;).&lt;/para&gt;&lt;para&gt;Results from studies in rotarod and Vogel water lick conflict rat models demonstrated that benzodiazepines disrupted rotarod behavior to a greater extent than &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; [&lt;ulink linkType="reference" linkID="468969"&gt;468969&lt;/ulink&gt;]. Further data highlighted a 10-fold difference between the dose of &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; that produced an anxiolytic-like effect (10 mg/kg) and that which produced sedative side effects. There was no difference between the dose of diazepam that produced an anxiolytic-like effect and that which produced sedative side effects (3.2 mg/kg) [&lt;ulink linkType="reference" linkID="468951"&gt;468951&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In various animal models of pain, &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; has demonstrated efficacy at doses 2- to 4-fold lower than &lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt; [&lt;ulink linkType="reference" linkID="296525"&gt;296525&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="307238"&gt;307238&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="327542"&gt;327542&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="349416"&gt;349416&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="373667"&gt;373667&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="373676"&gt;373676&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="404124"&gt;404124&lt;/ulink&gt;]. Compared with morphine and amitriptyline, both &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt; possess a superior antiallodynic profile. In a rat model of hyperalgesia, &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; interacted synergistically with naproxen to reverse thermal hyperalgesia associated with the peripheral inflammation induced by injection of carrageenan into a hind paw [&lt;ulink linkType="reference" linkID="487499"&gt;487499&lt;/ulink&gt;]. Nociceptive thresholds were determined by the radiant heat paw-withdrawal test, while paw edema was measured by plethysmometry. Administration of &lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt;, &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; and naproxen alone reversed thermal hyperalgesia (ED50 = 19.2, 6.0 and 0.5 mg/kg, respectively) [&lt;ulink linkType="reference" linkID="487499"&gt;487499&lt;/ulink&gt;]. &lt;ulink linkType="Drug" linkID="17814"&gt;Pregabalin&lt;/ulink&gt; reduced static allodynia, dynamic allodynia, thermal hyperalgesia and normalized weight bearing between hind paws, but did not significantly reduce paw swelling [&lt;ulink linkType="reference" linkID="428636"&gt;428636&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="493673"&gt;493673&lt;/ulink&gt;]. Combinations of &lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt; and naproxen in fixed-dose ratios of 50:1, 10:1 or 1:1 interacted synergistically to reverse carrageenan-induced thermal hyperalgesia; however, a ratio of 1:50 &lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt; and naproxen produced only additive effects. None of the combinations of &lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt; and naproxen decreased paw edema in a manner greater than additive. The mixture of 10:1 of &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; and naproxen interacted synergistically to reverse thermal hyperalgesia on the inflamed hind paw, whereas mixtures of 1:1 or 1:10 produced only additive effects [&lt;ulink linkType="reference" linkID="487499"&gt;487499&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In a rat model of visceral pain [&lt;ulink linkType="reference" linkID="307227"&gt;307227&lt;/ulink&gt;], &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; demonstrated an antiallodynic effect against trinitrobenzene sulfonic acid (TNBS)-induced colitis. &lt;ulink linkType="Drug" linkID="17814"&gt;Pregabalin&lt;/ulink&gt; (30 to 200 mg/kg sc) and morphine (0.1 to 1 mg/kg sc) dose-dependently inhibited TNBS-induced colonic allodynia. However, as would be predicted, &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; did not inhibit the colonic inflammatory effect of TNBS [&lt;ulink linkType="reference" linkID="307227"&gt;307227&lt;/ulink&gt;]. Oral &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; decreased colorectal distension-induced pain and spinal neuronal activity, and blocked visceral hypersensitivity in rats [&lt;ulink linkType="reference" linkID="408789"&gt;408789&lt;/ulink&gt;]. In further studies in rats, rectal distension-induced abdominal contractions were inhibited dose-dependently in animals orally administered &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; [&lt;ulink linkType="reference" linkID="327542"&gt;327542&lt;/ulink&gt;]. Oral administration of 10 mg/kg was effective at reducing the intensity of the nociceptive response related to rectal distension [&lt;ulink linkType="reference" linkID="404124"&gt;404124&lt;/ulink&gt;]. &lt;ulink linkType="Drug" linkID="17814"&gt;Pregabalin&lt;/ulink&gt; administered at the spinal and supraspinal levels exhibited potent antinociceptive activity on inflammatory colonic pain [&lt;ulink linkType="reference" linkID="345658"&gt;345658&lt;/ulink&gt;]. The ability of &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; to block chronic colonic pain suggests a possible role in treating the symptoms of diseases such as irritable bowel syndrome. Similar results were obtained in a model of septic shock; &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; suppressed lipopolysaccharide (LPS)-induced hyperalgesia [&lt;ulink linkType="reference" linkID="327542"&gt;327542&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metabolism and Pharmacokinetics&lt;/subtitle&gt;The rat MES test revealed that following single intravenous doses of &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; (5 to 150 mg/kg), pharmacokinetics were dose-proportional, no dose-mobilization was observed and the half-life (t1/2) was 2.5 h [&lt;ulink linkType="reference" linkID="297246"&gt;297246&lt;/ulink&gt;]. A study in rats, mice, monkeys and dogs revealed that there was no racemization, and bioavailability was &amp;gt; 70%, with t1/2 of between 3.9 and 5.8 h. No gender difference and minimal metabolism (&amp;lt; 10%) was observed in rats and monkeys [&lt;ulink linkType="reference" linkID="297248"&gt;297248&lt;/ulink&gt;]. In human cytosolic and microsomal preparations, no metabolism was observed [&lt;ulink linkType="reference" linkID="297248"&gt;297248&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Blood-brain barrier (BBB) penetration was also assessed using microdialysis in rats [&lt;ulink linkType="reference" linkID="487507"&gt;487507&lt;/ulink&gt;]. BBB influx (Cl(in)) and efflux (Cl(out)) permeabilities for &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; were 4.8 and 37.2 microl/min/g brain, respectively, following an intravenous infusion of an efficacious dose to rats.&lt;/para&gt;&lt;para&gt;In a phase I study (n = 29), the pharmacokinetics of &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; were examined following a single rising dose. &lt;ulink linkType="Drug" linkID="17814"&gt;Pregabalin&lt;/ulink&gt; was rapidly absorbed with a Tmax of 1.3 h and an oral bioavailability of 90% [&lt;ulink linkType="reference" linkID="373639"&gt;373639&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="373679"&gt;373679&lt;/ulink&gt;]. In an additional study, the elimination t1/2 was approximately 6 h following multiple increasing doses of &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; (25 to 300 mg three-times daily and 300 mg twice-daily) for 14 days (n = 86); this was unaffected by dose. &lt;ulink linkType="Drug" linkID="17814"&gt;Pregabalin&lt;/ulink&gt; was rapidly absorbed and Cmax and AUC values were proportional to dose [&lt;ulink linkType="reference" linkID="373639"&gt;373639&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="494780"&gt;494780&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Another study examined the population pharmacokinetics of &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; in healthy volunteers, patients with renal impairment and patients with chronic pain. The results demonstrated that the pharmacokinetics of the drug were linear and that oral clearance was related to creatinine clearance in both healthy volunteers and patients with chronic pain. Dose adjustments did not appear necessary under conditions of concomitant administration of insulin, diuretics or oral antidiabetics [&lt;ulink linkType="reference" linkID="446895"&gt;446895&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="465963"&gt;465963&lt;/ulink&gt;]. Elimination t1/2 (~ 6 h) and urinary excretion (82 to 108%) were not affected by dose. &lt;ulink linkType="Drug" linkID="17814"&gt;Pregabalin&lt;/ulink&gt; can also be dosed with or without food and irrespective of gender [&lt;ulink linkType="reference" linkID="465890"&gt;465890&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In addition to healthy volunteers, &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; pharmacokinetics and safety have been evaluated in other likely patient groups, such as the renally impaired. Results from a single-dose (50 mg) pharmacokinetic study of &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; in individuals with various degrees of renal function impairment demonstrated that &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; was safe and cleared by hemodialysis. Supplemental &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; doses may be required for patients on chronic hemodialysis treatment after each hemodialysis to maintain steady-state plasma &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; concentrations [&lt;ulink linkType="reference" linkID="502723"&gt;502723&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt; &lt;ulink linkType="Drug" linkID="17814"&gt;Pregabalin&lt;/ulink&gt; undergoes negligible metabolism in healthy volunteers after oral administration. Approximately 92% of administered drug was recovered in urine and feces, urine being the primary route of elimination [&lt;ulink linkType="reference" linkID="405793"&gt;405793&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Toxicity&lt;/subtitle&gt;Following analysis by the FDA of a mouse study that demonstrated incidence of a specific tumor type, Pfizer announced that it was restricting the use of &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; in some patients [&lt;ulink linkType="reference" linkID="398726"&gt;398726&lt;/ulink&gt;], and halted phase II trials for neuropathic pain [&lt;ulink linkType="reference" linkID="398785"&gt;398785&lt;/ulink&gt;]. Although Pfizer submitted an application in Europe in March 2003, submission in the US was delayed until October 2003. The delay allowed for the inclusion of data from the requested toxicological mechanistic studies.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Clinical Development&lt;/subtitle&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="17814"&gt;Pregabalin&lt;/ulink&gt; was evaluated in hospitalized patients (n = 93) whose anti-epileptic medications had been discontinued for seizure monitoring [&lt;ulink linkType="reference" linkID="373662"&gt;373662&lt;/ulink&gt;]. In a double-blind study, patients were randomized to receive &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; (1800 mg/day; n = 42) or &lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt; (900 mg/day; n = 51) for up to 8 days; the primary efficacy parameter was the time point at which patients exit from the study ('time-to-exit'). The median time-to-exit for patients in the &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; group was 191 h, and 88 h for patients in the &lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt; group. Of the patients on &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt;, 57.1% completed the full 8 days of the monotherapy compared with 23.5% on &lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt; [&lt;ulink linkType="reference" linkID="373662"&gt;373662&lt;/ulink&gt;]. This is similar to previous efficacy reports for patients administered &lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt; (3600 mg/day), which demonstrated a mean time to exit of 151 h and a completion rate of 53% [&lt;ulink linkType="reference" linkID="404130"&gt;404130&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;&lt;subtitle&gt;Epilepsy&lt;/subtitle&gt;In addition to the placebo-controlled studies conducted in patients with partial epilepsy, the effect of &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; on adjunctive therapy in epilepsy patients maintained on valproate, &lt;ulink linkType="Drug" linkID="6189"&gt;lamotrigine&lt;/ulink&gt;, &lt;ulink linkType="Drug" linkID="44376"&gt;phenytoin&lt;/ulink&gt; or &lt;ulink linkType="Drug" linkID="44697"&gt;carbamazepine&lt;/ulink&gt; was examined in five open-label studies [&lt;ulink linkType="reference" linkID="501341"&gt;501341&lt;/ulink&gt;]. &lt;ulink linkType="Drug" linkID="17814"&gt;Pregabalin&lt;/ulink&gt; had no significant effect on the pharmacokinetics of other anti-epileptic drugs, suggesting that it can be safely used in combination with these agents. &lt;/para&gt;&lt;para&gt;Further reports [&lt;ulink linkType="reference" linkID="501342"&gt;501342&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="501343"&gt;501343&lt;/ulink&gt;] are an amalgamation of results from three multicenter, double-blind, randomized, placebo-controlled trials of &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; administered twice or three-times daily as an add-on therapy in patients with refractory partial seizures with or without secondary generalization (n = 1052). Patients received &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; at doses of 50 to 600 mg/day following an 8-week baseline period in which they experienced at least six partial seizures and no 4-week seizure-free period. &lt;ulink linkType="Drug" linkID="17814"&gt;Pregabalin&lt;/ulink&gt; treatment produced significant changes in both primary efficacy (percentage change in partial seizure frequency) and responder rate (patients with at least a 50% reduction in seizure frequency) during the first week of treatment compared with patients administered placebo. At interim analysis, effective dosages were 150 to 600 mg/day, with at least 50% seizure reduction observed in 34 to 44% of patients [&lt;ulink linkType="reference" linkID="373379"&gt;373379&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="406549"&gt;406549&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The efficacy, safety and tolerability of &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; (administered twice daily) in patients with partial seizures were also studied [&lt;ulink linkType="reference" linkID="494502"&gt;494502&lt;/ulink&gt;]. A total of 453 patients were included in the double-blinded, randomized, placebo-controlled, parallel-group study consisting of an 8-week baseline and 12-week double-blind phase. The median baseline seizure rate was 10/month, and seizure frequency reductions from baseline were 7% (placebo; n = 100), 12% (50 mg/day; n = 88), 34% (150 mg/day; n = 86), 44% (300 mg/day; n = 90), and 54% (600 mg/day; n = 89). Responder rates (&gt;/= 50% seizure reduction) were 14% (placebo), 15% (50 mg/day), 31% (150 mg/day), 40% (300 mg/day) and 51% (600 mg/day) [&lt;ulink linkType="reference" linkID="494502"&gt;494502&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;A mixed-effects model was used to characterize the relationship between monthly seizure frequency (over a 3-month period) and &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; daily dose (0, 50, 150, 300 and 600 mg) as add-on treatment in three double-blinded, parallel-group studies in patients with refractory partial seizures (n = 1042) [&lt;ulink linkType="reference" linkID="494504"&gt;494504&lt;/ulink&gt;]. An asymptotic decrease in seizure frequency was demonstrated by 75% of patients with increasing doses of &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt;, whereas 25% did not demonstrate a significant decrease in seizure frequency from baseline. In patients who demonstrated a dose-related decrease in seizure frequency from baseline, the maximal percentage of seizure reduction from baseline was 100% for women and 80% for men, with an ED50 value of 186 mg (daily) [&lt;ulink linkType="reference" linkID="494504"&gt;494504&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Pain&lt;/subtitle&gt;The clinical effects of &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; on certain types of pain have also been explored. &lt;ulink linkType="Drug" linkID="17814"&gt;Pregabalin&lt;/ulink&gt; was initially studied in patients with painful diabetic peripheral neuropathy [&lt;ulink linkType="reference" linkID="373643"&gt;373643&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="494778"&gt;494778&lt;/ulink&gt;]. Patients (n = 337) were randomized to receive &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; (75, 300 or 600 mg/day) or placebo for 5 weeks. Statistically significant improvements in mean pain score were recorded in patients receiving 300 or 600 mg/day of &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; compared with placebo. Significant improvements were also obtained on sleep interference scores, SF-McGill Pain Questionnaire scores and the Clinical and Patient Global Impressions of Change (CGIC and PGIC, respectively). In a further phase III, 5-week double-blind, placebo-controlled study comparing the efficacy of &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; (150 and 300 mg/day) and placebo in 246 patients with painful diabetic neuropathy, &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; (600 mg/day) was better than placebo for reduction of pain score, sleep interference score, CGIC and PGIC. Half of the patients on &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; reported improvement, compared with 15% on placebo [&lt;ulink linkType="reference" linkID="369802"&gt;369802&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="454539"&gt;454539&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In another study [&lt;ulink linkType="reference" linkID="487525"&gt;487525&lt;/ulink&gt;], the efficacy and safety of &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; was evaluated for reducing pain and associated symptoms in patients (n = 529) with fibromyalgia syndrome (FMS; a chronic musculoskeletal pain), in an 8-week randomized, double-blinded, placebo-controlled, parallel-group monotherapy trial. Patients administered &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; (150 mg three-times daily) demonstrated significant improvements in the endpoint mean pain score compared with placebo, and were significantly more likely to have a 50% reduction in pain from baseline. Of the patients administered 150 and 300 mg/day of &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt;, 29% experienced significant pain reduction, with significant improvements in sleep quality and fatigue [&lt;ulink linkType="reference" linkID="467950"&gt;467950&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In a similarly designed trial, &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; was examined for its effects on the pain associated with post-herpetic neuralgia (PHN). In 173 patients randomly assigned to receive &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; (300 or 600 mg/day administered to patients with creatinine clearance 30 to 60 or &amp;gt; 60 ml/min, respectively) or placebo, decreases in pain scores (SF-McGill Pain Questionnaire) were significantly greater in those administered &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; than in those on placebo. Significant reductions in pain were observed in patients administered &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; after the first full day of treatment and throughout the study period (8 weeks). Reductions in pain of at least 30% were observed in 63% of patients administered &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; and 25% of patients administered placebo [&lt;ulink linkType="reference" linkID="446712"&gt;446712&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="494497"&gt;494497&lt;/ulink&gt;]. It was found that an Emax model using average plasma concentration as the measure of exposure best described the efficacy of &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt;, which rapidly reduced pain in such patients in a dose- and concentration-dependent manner. &lt;/para&gt;&lt;para&gt;In August 2003, clinical data from six major studies in diabetic or post-herpetic neuropathic pain consisting of eight active treatment groups were studied. The first 2 weeks of treatment were analyzed for all patients (923 on &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; and 506 on placebo), and a significant pain reduction was observed on the first day for patients receiving 300 mg/day &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt;, while doses from 75 to 150 mg/day generally produced pain reduction by day 2 or 3 [&lt;ulink linkType="reference" linkID="505340"&gt;505340&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Generalized anxiety disorder&lt;/subtitle&gt;To test efficacy in generalized anxiety disorder (GAD), a multicenter, double-blinded, European study randomized 426 GAD patients to receive &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; (400 or 600 mg/day), &lt;ulink linkType="Drug" linkID="4648"&gt;venlafaxine&lt;/ulink&gt; (Efexor; 75 mg/day) or placebo for 6 weeks. All three active treatments were found to be safe, and better than placebo in improving the GAD symptoms. &lt;ulink linkType="Drug" linkID="17814"&gt;Pregabalin&lt;/ulink&gt; was associated with a more rapid onset of action and a lower percentage of patients withdrawing from the study due to adverse events [&lt;ulink linkType="reference" linkID="487522"&gt;487522&lt;/ulink&gt;]. In another study [&lt;ulink linkType="reference" linkID="487497"&gt;487497&lt;/ulink&gt;] comparing &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; (50 and 200 mg three-times daily, n = 77 and 66, respectively), &lt;ulink linkType="Drug" linkID="44362"&gt;lorazepam&lt;/ulink&gt; (2 mg three-times daily, n = 68) and placebo (n = 67), both &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="44362"&gt;lorazepam&lt;/ulink&gt; significantly reduced the total Hamilton Rating Scale for Anxiety (HAM-A), by 3.9 (p = 0.0013) and 2.35 (p = 0.0483), respectively, compared with placebo as early as the week 1 observation. In short-term treatment, &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; did not appear to have the same withdrawal symptoms associated with benzodiazepines such as &lt;ulink linkType="Drug" linkID="44362"&gt;lorazepam&lt;/ulink&gt; [&lt;ulink linkType="reference" linkID="518529"&gt;518529&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Long-term treatment with &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; for up to 26 weeks was also effective in preventing relapse of GAD [&lt;ulink linkType="reference" linkID="487510"&gt;487510&lt;/ulink&gt;]. In addition, among patients with depression and GAD, &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; helped to relieve symptoms of depression [&lt;ulink linkType="reference" linkID="494618"&gt;494618&lt;/ulink&gt;]. Five combined studies were presented with data from 1282 patients who received either &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; or placebo [&lt;ulink linkType="reference" linkID="490686"&gt;490686&lt;/ulink&gt;]. All treatment groups had similar baseline clinical and demographic characteristics. Psychic and somatic symptoms, as well as speed of onset, were assessed using HAM-A. &lt;/para&gt;&lt;para&gt;Results from a total of five double-blinded, randomized, placebo-controlled trials were analyzed for efficacy and safety of &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; in the management of patients with GAD. A total of 1367 patients with DSM-IV GAD were randomized to receive placebo or &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; at daily doses of 150 to 600 mg for 4 to 6 weeks. The mean HAM-A score improved in all patients treated with &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt;. The drug showed similar efficacy in improving the psychic and somatic symptoms of GAD at all dose levels [&lt;ulink linkType="reference" linkID="502743"&gt;502743&lt;/ulink&gt;]. The efficacy of &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; as an anxiolytic in patients with co-morbid depressive symptoms was significantly higher than placebo and was not affected by the baseline Hamilton Rating Scale for Depression (HAM-D) total score of the patients [&lt;ulink linkType="reference" linkID="502745"&gt;502745&lt;/ulink&gt;]. The onset of efficacy of the drug was slightly dose-dependent as the higher dose levels were associated with increases in the percentages of patients with at least a 30% improvement in their GAD symptoms after 1 week of treatment (30% with placebo, 44% with 150 to 200 mg and 54% with 600 mg) [&lt;ulink linkType="reference" linkID="502746"&gt;502746&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A double-blind, randomized, placebo-controlled clinical trial used the Endicott Work Productivity Scale (EWPS) to determine the effects of &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; on the work productivity of patients with GAD [&lt;ulink linkType="reference" linkID="502748"&gt;502748&lt;/ulink&gt;]. A total of 455 patients were included in the trial and randomized to receive &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; (600 mg/day), &lt;ulink linkType="Drug" linkID="44259"&gt;alprazolam&lt;/ulink&gt; (1.5 mg/day) or placebo for 4 weeks. The EWPS scores of the patients were significantly higher with a daily dose of &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; (600 mg/day) compared with placebo or &lt;ulink linkType="Drug" linkID="44259"&gt;alprazolam&lt;/ulink&gt;. The lower &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; doses also improved work productivity, although the differences did not reach statistical significance [&lt;ulink linkType="reference" linkID="502748"&gt;502748&lt;/ulink&gt;]. Data from the combination of studies, including phase II and pivotal phase III trials, suggest that &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; may offer broad and rapid efficacy for the acute treatment of GAD.&lt;/para&gt;&lt;para&gt;In a double-blind, placebo-controlled trial of 135 patients with social phobia comparing &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; (150 and 600 mg/day) with placebo, a trend towards significant differences was obtained for the &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; 600 mg/day group compared with placebo (p = 0.024) using the Liebowitz Social Anxiety Scale total score. These data were less encouraging than those obtained with &lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt; (900 to 3600 mg/day), which showed significant differences on all the major social phobia scales [&lt;ulink linkType="reference" linkID="404132"&gt;404132&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Side Effects and Contraindications&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="17814"&gt;Pregabalin&lt;/ulink&gt; is generally well tolerated, the most commonly reported adverse effects being mild-to-moderate dizziness, somnolence and ataxia. The side effects and contraindications of &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; have been described in a previous literature evaluation [&lt;ulink linkType="reference" linkID="412900"&gt;412900&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Current Opinion&lt;/subtitle&gt;In recent years, &lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt; has been yet another of Pfizer's success stories, generating sales of over US $1.7 billion in 2001, a 31.8% growth on the previous year's sales. The inevitable patent loss and subsequent erosion of market share due to generic &lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt; has spurred Pfizer to ensure that the revenue-generating potential of &lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt; is effectively transferred to its improved product &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt;. One key driving factor for the success of &lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt; is the off-label use (particularly for neuropathic pain, which accounts for approximately 70% of sales). Will &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; follow this same trend? So far, &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; has been evaluated for use in a number of CNS disorders, ranging from epilepsy to GAD, and offers a superior clinical profile to that of &lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt;, particularly in terms of kinetics. So, will the indication of neuropathic pain provide the greatest return on investment for Pfizer, as with &lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt;? The profile of &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; in various non-clinical models of pain suggests that &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; is superior to &lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt;, and clinical studies in FMS and PHN have shown that &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; certainly has activity against these types of pain. &lt;/para&gt;&lt;para&gt; &lt;ulink linkType="Drug" linkID="3188"&gt;Gabapentin&lt;/ulink&gt;'s perceived safety and relative clinical efficacy have made it a very successful drug. &lt;ulink linkType="Drug" linkID="17814"&gt;Pregabalin&lt;/ulink&gt; is 2- to 10-fold more potent than &lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt;, but unlike &lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt;, its linear pharmacokinetics means its pharmacological effects are more predictable, decreasing the need for dose titration in the clinic. How &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; will fare if other experimental compounds make it onto the market may be another story. For example, &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; may have competition from antagonists, such as Roche's NMDA NR2B antagonists, Ionix's Cav 2.2 and Nav 1.8 antagonists, and TrpV1; preclinical data appear quite promising for these agents.&lt;/para&gt;&lt;para&gt; &lt;ulink linkType="Drug" linkID="17814"&gt;Pregabalin&lt;/ulink&gt; is at least as efficacious as &lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt; in epilepsy as an add-on treatment in patients with refractory partial seizures. This, coupled with a good safety and superior pharmacokinetic profile, would lead us to believe that &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; is a worthy follow-up to &lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt;.&lt;/para&gt;&lt;para&gt;Ivan Selak, Department of Neurology, &lt;ulink linkType="Company" linkID="20605"&gt;University of Liege&lt;/ulink&gt;, B-4000 Liege and CNS Therapeutic Group, UCB Pharmaceuticals, Braine-L'Alleud, Belgium&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;26 January 2001&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Introduction&lt;/subtitle&gt;Gamma-aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the central nervous system. Impairment of GABA function produces seizures, whereas enhancement results in an anticonvulsant effect. Several anti-epileptic drugs have been developed on the basis of their ability to modulate GABA-mediated inhibitory synaptic transmission. Due to its widespread localization, GABA may be involved in the pathogenesis of various neurological conditions in which inhibition may be reduced. &lt;ulink linkType="Drug" linkID="17814"&gt;Pregabalin&lt;/ulink&gt; is an analog of GABA, which has been developed as a follow-up compound to &lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt; (&lt;ulink linkType="Company" linkID="18767"&gt;Pfizer Inc&lt;/ulink&gt;) for use in similar neurological conditions, ie, epilepsy, pain, anxiety and social phobia. Due to these similarities, it is important to consider the data obtained with &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; in comparison with that available for &lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt;.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Synthesis and SAR&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="17814"&gt;Pregabalin&lt;/ulink&gt; can be synthesized by several methods [&lt;ulink linkType="reference" linkID="373657"&gt;373657&lt;/ulink&gt;] and is the pharmacologically active (S)-enantiomer of 3-aminomethyl-5-methyl-hexanoic acid, developed as a 3-substituted GABA analog [&lt;ulink linkType="reference" linkID="169739"&gt;169739&lt;/ulink&gt;]. A series of GABA analogs were prepared and their ability to inhibit maximal electroshock-induced seizures (MES) in mice was studied [&lt;ulink linkType="reference" linkID="373673"&gt;373673&lt;/ulink&gt;]. The anticonvulsant activity of racemic 3-isobutyl GABA was found to reside in the (S)-enantiomer, &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt;. &lt;/para&gt;&lt;para&gt;In the mouse MES assay, &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; was more potent than &lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt;; ED50 = 87 mg/kg po for &lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt; versus 20 mg/kg po for &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; [&lt;ulink linkType="reference" linkID="297247"&gt;297247&lt;/ulink&gt;]. The abilities of the different analogs to displace (3H)-&lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt; were also compared [&lt;ulink linkType="reference" linkID="169739"&gt;169739&lt;/ulink&gt;]. Analysis of the structure/activity relationship suggests a narrow tolerance of size and substitution patterns at the 3-position of the GABA chain [&lt;ulink linkType="reference" linkID="373673"&gt;373673&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Pharmacology&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="17814"&gt;Pregabalin&lt;/ulink&gt; has been extensively tested in animal models of epilepsy [&lt;ulink linkType="reference" linkID="297247"&gt;297247&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="299344"&gt;299344&lt;/ulink&gt;]. It is more effective than &lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt; in preventing MES in mice (ED50 = 20 mg/kg po versus 87 mg/kg po) and in rats (1.8 mg/kg po versus 10.3 mg/kg po); it is also more effective in blocking seizures in the rat kindled hippocampal seizures model. However, &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; is less effective than &lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt; in blocking chemically-induced seizures (pentylene, tetrazole, bicuculline, picrotoxin and strychnine). As with &lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt;, &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; was ineffective in blocking absence seizures in the rat. Altogether, the analysis of these animal models suggests that &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; has a similar profile to that of &lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt;, but that active doses of &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; are 3- to 10-fold lower than those of &lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt;. &lt;/para&gt;&lt;para&gt; &lt;ulink linkType="Drug" linkID="17814"&gt;Pregabalin&lt;/ulink&gt; has been compared with &lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt; in different rat models of pain, eg, intrathecal substance P or NMDA, thermal injury, carrageenan-induced hyperalgesia, rat paw formalin test and rat post-operative pain [&lt;ulink linkType="reference" linkID="349416"&gt;349416&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="373667"&gt;373667&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="373676"&gt;373676&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="397542"&gt;397542&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="404124"&gt;404124&lt;/ulink&gt;]. In all of these models, &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; was effective at doses 2- to 4-fold lower than &lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt;. Compared with morphine and amitriptyline, both &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt; possess a superior antiallodynic profile, and may represent a novel class of therapeutic agents.&lt;/para&gt;&lt;para&gt;While it has been extensively explored, the mechanism of action of &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; is not completely understood. However, due to their similar preclinical profiles, results obtained with &lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt; can be compared with those obtained with &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt;. &lt;ulink linkType="Drug" linkID="17814"&gt;Pregabalin&lt;/ulink&gt; displaces (3H)&lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt; from its binding site on the alpha2delta subunit of calcium channels. &lt;ulink linkType="Drug" linkID="17814"&gt;Pregabalin&lt;/ulink&gt; does not interact with a wide range of neurotransmitter receptors (glutamate, GABA, monoamine, adenosine, acetylcholine or opiates) or with voltage-activated ion channels (sodium and calcium) [&lt;ulink linkType="reference" linkID="302823"&gt;302823&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="345734"&gt;345734&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="373644"&gt;373644&lt;/ulink&gt;]. As with &lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt;, &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; is expected to increase GABA content in the brain [&lt;ulink linkType="reference" linkID="345748"&gt;345748&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="404123"&gt;404123&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metabolism&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="17814"&gt;Pregabalin&lt;/ulink&gt; is rapidly absorbed (tmax = 1 h), has an oral bioavailability of 90%, and is not metabolized in humans (99% unchanged in urine) [&lt;ulink linkType="reference" linkID="373639"&gt;373639&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="373679"&gt;373679&lt;/ulink&gt;]. The plasma half-life = 5.8 h, and Cmax and area under the curve (AUC) are dose-proportional. Food delays both the tmax and Cmax, but AUC and half-life remain unchanged. &lt;ulink linkType="Drug" linkID="17814"&gt;Pregabalin&lt;/ulink&gt; is not bound to plasma protein. No drug interactions have been reported, but no data for special populations (renal or hepatic impairment) are available.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Toxicity&lt;/subtitle&gt;In animal studies, &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; causes ataxia at high doses, and neonatal death in rats is seen at doses greater than 250 mg/kg [&lt;ulink linkType="reference" linkID="297245"&gt;297245&lt;/ulink&gt;]. A lifetime study in mice has highlighted the incidence of a specific tumor type, although this effect has not been observed in rats, nor in any other toxicological screening study [&lt;ulink linkType="reference" linkID="398726"&gt;398726&lt;/ulink&gt;]. In normal human volunteers, &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; was well tolerated up to 900 mg/day [&lt;ulink linkType="reference" linkID="373639"&gt;373639&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Clinical Development&lt;/subtitle&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="17814"&gt;Pregabalin&lt;/ulink&gt; pharmacokinetics and safety over a dosage range of 1 to 300 mg (single dose) has been evaluated in 29 healthy volunteers [&lt;ulink linkType="reference" linkID="373679"&gt;373679&lt;/ulink&gt;], and additional data for doses up to 900 mg/day show good tolerability. The apparent elimination half-life was 6 h and independent of dose [&lt;ulink linkType="reference" linkID="373639"&gt;373639&lt;/ulink&gt;]. &lt;ulink linkType="Drug" linkID="17814"&gt;Pregabalin&lt;/ulink&gt; is rapidly absorbed, tmax = 1.3 h, the pharmacokinetics are linear, and the drug is not metabolized in humans.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;The efficacy of &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; as a monotherapy has been evaluated in hospitalized patients whose anti-epileptic medications had been discontinued for seizure monitoring [&lt;ulink linkType="reference" linkID="373662"&gt;373662&lt;/ulink&gt;]. A total of 93 patients (42 &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt;; 51 &lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt;) were randomized to receive &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; 600 mg tid or &lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt; 300 mg tid in a double-blind fashion for up to 8 days. The primary efficacy parameter was 'time to exit' (time point at which patients exit from the study). Median time to exit was 191 h for patients in the &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; group and 88 h for those in the &lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt; group. Overall, 57.1% of the patients on &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; and 23.5% on &lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt; completed the full 8 days of monotherapy. These data are in line with previously reported efficacy data, which demonstrated a mean time to exit of 151 h and a completion rate of 53% in patients receiving &lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt; 3600 mg/day [&lt;ulink linkType="reference" linkID="404130"&gt;404130&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;Double-blind, parallel group, placebo-controlled studies have been initiated to study the efficacy of &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; as an add-on treatment in patients with partial epilepsy. Preliminary data have been published in abstract form [&lt;ulink linkType="reference" linkID="404126"&gt;404126&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="404128"&gt;404128&lt;/ulink&gt;]. In one trial (n = 400), &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; (50, 150, 300 and 600 mg/day bid) was compared with placebo. In another trial, patients were randomized to &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; 300 mg/day bid, &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; 200 mg/day tid or placebo. Interim analyses show the effective dose range to be 150 to 600 mg/day, with responder rates (measured as a 50% seizure reduction) of 34 to 44% [&lt;ulink linkType="reference" linkID="373379"&gt;373379&lt;/ulink&gt;]. Efficacy data for &lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt; in trials of similar design have been published previously; the responder rate for &lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt; never exceeded 30%. Full data analysis of the &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; studies should be awaited before drawing further conclusions.&lt;/para&gt;&lt;para&gt;One long-term report of a followup study of ten patients has been reported [&lt;ulink linkType="reference" linkID="404129"&gt;404129&lt;/ulink&gt;] and suggests that &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; (average daily dose of 580 mg/day) remains efficacious for a mean duration of 10.4 months. Compared with the efficacy data reported for other new anti-epileptic drugs [&lt;ulink linkType="reference" linkID="404135"&gt;404135&lt;/ulink&gt;], &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; seems to have a better efficacy than &lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt;, and to be in the same efficacy range as &lt;ulink linkType="Drug" linkID="6189"&gt;lamotrigine&lt;/ulink&gt; (&lt;ulink linkType="Company" linkID="16453"&gt;Glaxo Wellcome plc&lt;/ulink&gt;), &lt;ulink linkType="Drug" linkID="4576"&gt;topiramate&lt;/ulink&gt; (&lt;ulink linkType="Company" linkID="17332"&gt;Johnson &amp;amp; Johnson&lt;/ulink&gt;/Janssen-Cilay Ltd/&lt;ulink linkType="Company" linkID="17724"&gt;Kyowa Hakko Kogyo Co Ltd&lt;/ulink&gt;) and levetiracetam (&lt;ulink linkType="Company" linkID="20452"&gt;UCB SA&lt;/ulink&gt;).&lt;/para&gt;&lt;para&gt;Following analysis by the FDA of a mouse study that showed incidence of a specific tumor type, Pfizer has announced that it is restricting the use of &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; in some clinical patients [&lt;ulink linkType="reference" linkID="398726"&gt;398726&lt;/ulink&gt;], and it has frozen its phase II trials for neuropathic pain [&lt;ulink linkType="reference" linkID="398785"&gt;398785&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Side Effects and Contraindications&lt;/subtitle&gt;Adverse events (AEs) have been monitored throughout the different phases of &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; development, and safety data are available for &amp;gt; 1000 patients with partial epilepsy. No serious AEs have been reported during phase I trials; the most commonly reported events were dizziness and somnolence, both of which were mild or moderate in intensity. Mild transient elevations in hepatic enzymes were observed sporadically in healthy subjects [&lt;ulink linkType="reference" linkID="373639"&gt;373639&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="373679"&gt;373679&lt;/ulink&gt;]. During phase III trials dizziness, somnolence and ataxia were the most frequently reported AEs; these were mild-to-moderate in intensity and increased with increasing dosages [&lt;ulink linkType="reference" linkID="373379"&gt;373379&lt;/ulink&gt;]. In other clinical conditions, dizziness and somnolence were the most frequent AEs reported [&lt;ulink linkType="reference" linkID="369802"&gt;369802&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="373643"&gt;373643&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="377016"&gt;377016&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="377018"&gt;377018&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;No drug interactions have been reported at this stage, and safety comparisons with other new anti-epileptic drugs [&lt;ulink linkType="reference" linkID="404135"&gt;404135&lt;/ulink&gt;] seem to show &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; to be advantageous.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Current Opinion&lt;/subtitle&gt;Analysis of published phase III trials in epilepsy shows that &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; is efficacious as an add-on treatment in patients with refractory partial seizures. Compared with its predecessor (ie, &lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt;), efficacy data for &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; seem to be more promising: responder rates of 34 to 44% for &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; (150 to 600 mg) versus 21% for &lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt; (1200 mg). Such efficacy data are in line with those reported for other new anti-epileptic drugs under similar conditions. In addition, its safety profile seems to be as good as that of &lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt;. At this stage, no information is available on the use of &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; in patients with generalized seizures, and this could be a limitation for its use as a widely effective anti-epileptic drug.&lt;/para&gt;&lt;para&gt;The second main indication for &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; seems to be its use in diabetic neuropathic pain. Efficacy and tolerability at 300 to 600 mg/day appears to be equivalent to 3600 mg/day of &lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt;. &lt;/para&gt;&lt;para&gt;As far as the use of &lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt; in psychiatric disorders is concerned, the results in GAD and social phobia are very promising and numerous other clinical indications are currently being investigated. The development of &lt;ulink linkType="Drug" linkID="17814"&gt;pregabalin&lt;/ulink&gt; appears to be almost identical to that of &lt;ulink linkType="Drug" linkID="3188"&gt;gabapentin&lt;/ulink&gt;, but data available at this time do not allow final statements regarding its use in the market of neurology and/or psychiatry.&lt;/para&gt;</ExpertReview><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-09-01T00:00:00.000Z</StatusDate><Source id="557408" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="119">Epilepsy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-09-01T00:00:00.000Z</StatusDate><Source id="557408" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2527">Fibromyalgia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-11-12T00:00:00.000Z</StatusDate><Source id="1647989" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-10-01T00:00:00.000Z</StatusDate><Source id="1387703" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="119">Epilepsy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-10-01T00:00:00.000Z</StatusDate><Source id="1387703" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-07-01T00:00:00.000Z</StatusDate><Source id="1350697" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="119">Epilepsy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-02-22T00:00:00.000Z</StatusDate><Source id="2007726" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-02-02T00:00:00.000Z</StatusDate><Source id="1411310" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2527">Fibromyalgia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-12-31T00:00:00.000Z</StatusDate><Source id="975021" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="119">Epilepsy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-07-01T00:00:00.000Z</StatusDate><Source id="1596623" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-09-01T00:00:00.000Z</StatusDate><Source id="557408" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-12-31T00:00:00.000Z</StatusDate><Source id="1270235" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="119">Epilepsy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-02-02T00:00:00.000Z</StatusDate><Source id="1411310" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="119">Epilepsy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-10-20T00:00:00.000Z</StatusDate><Source id="569658" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="UZ">Uzbekistan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="119">Epilepsy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-02-22T00:00:00.000Z</StatusDate><Source id="2007726" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="TM">Turkmenistan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="119">Epilepsy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-02-22T00:00:00.000Z</StatusDate><Source id="2007726" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-07-01T00:00:00.000Z</StatusDate><Source id="1596623" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-12-31T00:00:00.000Z</StatusDate><Source id="1514082" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="119">Epilepsy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-11-12T00:00:00.000Z</StatusDate><Source id="1647989" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="119">Epilepsy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-06-21T00:00:00.000Z</StatusDate><Source id="624422" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2527">Fibromyalgia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-06-30T00:00:00.000Z</StatusDate><Source id="945397" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-10-27T00:00:00.000Z</StatusDate><Source id="1142528" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2527">Fibromyalgia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-05-12T00:00:00.000Z</StatusDate><Source id="1008646" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2527">Fibromyalgia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-06-23T00:00:00.000Z</StatusDate><Source id="1303483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1937">Generalized anxiety disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-09-27T00:00:00.000Z</StatusDate><Source id="658057" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="KG">Kyrgyzstan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="119">Epilepsy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-02-22T00:00:00.000Z</StatusDate><Source id="2007726" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="KZ">Kazakhstan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="119">Epilepsy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-02-22T00:00:00.000Z</StatusDate><Source id="2007726" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="TR">Turkey</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="119">Epilepsy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-02-22T00:00:00.000Z</StatusDate><Source id="2007726" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-02-12T00:00:00.000Z</StatusDate><Source id="1006016" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2527">Fibromyalgia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-03-16T00:00:00.000Z</StatusDate><Source id="2130414" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2527">Fibromyalgia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-12-31T00:00:00.000Z</StatusDate><Source id="1514082" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="119">Epilepsy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-09-01T00:00:00.000Z</StatusDate><Source id="557408" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="119">Epilepsy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-12-31T00:00:00.000Z</StatusDate><Source id="975021" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3300">Postherpetic neuralgia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-09-21T00:00:00.000Z</StatusDate><Source id="624422" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-10-20T00:00:00.000Z</StatusDate><Source id="569658" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1937">Generalized anxiety disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-07-01T00:00:00.000Z</StatusDate><Source id="1596623" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-09-19T00:00:00.000Z</StatusDate><Source id="623889" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-12-31T00:00:00.000Z</StatusDate><Source id="975021" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="119">Epilepsy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-02-22T00:00:00.000Z</StatusDate><Source id="2007726" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="119">Epilepsy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-12-31T00:00:00.000Z</StatusDate><Source id="1514082" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-09-21T00:00:00.000Z</StatusDate><Source id="624422" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-11-12T00:00:00.000Z</StatusDate><Source id="1647989" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="119">Epilepsy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-07-01T00:00:00.000Z</StatusDate><Source id="1350697" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1937">Generalized anxiety disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-11-12T00:00:00.000Z</StatusDate><Source id="1647989" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="TJ">Tajikistan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="119">Epilepsy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-02-22T00:00:00.000Z</StatusDate><Source id="2007726" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2992">Tonic clonic epilepsy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-02-21T00:00:00.000Z</StatusDate><Source id="1728755" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2992">Tonic clonic epilepsy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-02-21T00:00:00.000Z</StatusDate><Source id="1728755" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="XH">Far East</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2992">Tonic clonic epilepsy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-02-21T00:00:00.000Z</StatusDate><Source id="1728755" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2992">Tonic clonic epilepsy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-02-21T00:00:00.000Z</StatusDate><Source id="1728755" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="IN">India</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2992">Tonic clonic epilepsy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-02-21T00:00:00.000Z</StatusDate><Source id="1728755" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="CN">China</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2992">Tonic clonic epilepsy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-02-21T00:00:00.000Z</StatusDate><Source id="1728755" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2992">Tonic clonic epilepsy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-02-21T00:00:00.000Z</StatusDate><Source id="1728755" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2992">Tonic clonic epilepsy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-02-21T00:00:00.000Z</StatusDate><Source id="1728755" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="LB">Lebanon</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2992">Tonic clonic epilepsy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-02-21T00:00:00.000Z</StatusDate><Source id="1728755" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2992">Tonic clonic epilepsy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-03-21T00:00:00.000Z</StatusDate><Source id="1728755" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="X2">Asia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="119">Epilepsy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-10-17T00:00:00.000Z</StatusDate><Source id="1642994" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-01-06T00:00:00.000Z</StatusDate><Source id="1905723" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1774">Restless legs syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-09-27T00:00:00.000Z</StatusDate><Source id="1134713" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><Indication id="2527">Fibromyalgia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-04-30T00:00:00.000Z</StatusDate><Source id="1005285" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1774">Restless legs syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-09-27T00:00:00.000Z</StatusDate><Source id="1134713" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1937">Generalized anxiety disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-01-06T00:00:00.000Z</StatusDate><Source id="1071167" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1774">Restless legs syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-09-27T00:00:00.000Z</StatusDate><Source id="1134713" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="2618">Complex regional pain syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-12-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="CN">China</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="119">Epilepsy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-10-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="CN">China</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-01-31T00:00:00.000Z</StatusDate><Source id="1202342" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-07-13T00:00:00.000Z</StatusDate><Source id="1270234" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2527">Fibromyalgia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-03-31T00:00:00.000Z</StatusDate><Source id="1205764" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="2527">Fibromyalgia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-10-31T00:00:00.000Z</StatusDate><Source id="1267519" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="CZ">Czech Republic</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-01-31T00:00:00.000Z</StatusDate><Source id="1202342" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="PH">Philippines</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-01-31T00:00:00.000Z</StatusDate><Source id="1202342" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="IN">India</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-01-31T00:00:00.000Z</StatusDate><Source id="1202342" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="HK">Hong Kong</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-01-31T00:00:00.000Z</StatusDate><Source id="1202342" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="CO">Colombia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-01-31T00:00:00.000Z</StatusDate><Source id="1202342" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="CL">Chile</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-01-31T00:00:00.000Z</StatusDate><Source id="1202342" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-01-31T00:00:00.000Z</StatusDate><Source id="1202342" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="IN">India</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2527">Fibromyalgia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-06-30T00:00:00.000Z</StatusDate><Source id="789859" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2527">Fibromyalgia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-06-30T00:00:00.000Z</StatusDate><Source id="789859" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="VE">Venezuela</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2527">Fibromyalgia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-06-30T00:00:00.000Z</StatusDate><Source id="789859" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-12-31T00:00:00.000Z</StatusDate><Source id="1489780" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2527">Fibromyalgia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-06-30T00:00:00.000Z</StatusDate><Source id="789859" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="2527">Fibromyalgia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-03-31T00:00:00.000Z</StatusDate><Source id="988354" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-03-24T00:00:00.000Z</StatusDate><Source id="1524464" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2527">Fibromyalgia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-03-24T00:00:00.000Z</StatusDate><Source id="1524464" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="119">Epilepsy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-03-24T00:00:00.000Z</StatusDate><Source id="1524464" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="119">Epilepsy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-07-31T00:00:00.000Z</StatusDate><Source id="618341" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="PR">Puerto Rico</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-10-31T00:00:00.000Z</StatusDate><Source id="1508008" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2618">Complex regional pain syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-04-30T00:00:00.000Z</StatusDate><Source id="1771893" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2527">Fibromyalgia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-06-22T00:00:00.000Z</StatusDate><Source id="1303483" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="TR">Turkey</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="119">Epilepsy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-10-17T00:00:00.000Z</StatusDate><Source id="1642994" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20787">Warner-Lambert Co</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1998-05-08T00:00:00.000Z</StatusDate><Source id="286516" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20787">Warner-Lambert Co</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="119">Epilepsy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1998-05-08T00:00:00.000Z</StatusDate><Source id="286516" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20787">Warner-Lambert Co</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1998-05-06T00:00:00.000Z</StatusDate><Source id="286425" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20787">Warner-Lambert Co</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1937">Generalized anxiety disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1998-05-06T00:00:00.000Z</StatusDate><Source id="286425" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20787">Warner-Lambert Co</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="724">Antisocial personality disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1998-05-06T00:00:00.000Z</StatusDate><Source id="286425" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20787">Warner-Lambert Co</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="119">Epilepsy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1998-05-06T16:36:11.000Z</StatusDate><Source id="286425" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="CN">China</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="119">Epilepsy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-01-08T00:00:00.000Z</StatusDate><Source id="1006001" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="119">Epilepsy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-11-12T00:00:00.000Z</StatusDate><Source id="1647989" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-11-12T00:00:00.000Z</StatusDate><Source id="1647989" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1937">Generalized anxiety disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-11-12T00:00:00.000Z</StatusDate><Source id="1647989" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2527">Fibromyalgia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-11-12T00:00:00.000Z</StatusDate><Source id="1647989" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20805">Parke-Davis &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="119">Epilepsy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1993-01-01T00:00:00.000Z</StatusDate><Source id="153816" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="CN">China</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2527">Fibromyalgia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-06-30T00:00:00.000Z</StatusDate><Source id="1270332" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2527">Fibromyalgia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-10-15T00:00:00.000Z</StatusDate><Source id="2082742" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20787">Warner-Lambert Co</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="724">Antisocial personality disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1999-11-06T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="119">Epilepsy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-04-22T00:00:00.000Z</StatusDate><Source id="486607" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-04-22T00:00:00.000Z</StatusDate><Source id="486607" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2527">Fibromyalgia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-09-20T00:00:00.000Z</StatusDate><Source id="399956" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-02-13T00:00:00.000Z</StatusDate><Source id="398785" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1937">Generalized anxiety disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2000-06-28T00:00:00.000Z</StatusDate><Source id="371470" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2000-06-28T00:00:00.000Z</StatusDate><Source id="371470" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="119">Epilepsy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2000-06-28T00:00:00.000Z</StatusDate><Source id="371470" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-10-31T00:00:00.000Z</StatusDate><Source id="511220" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="119">Epilepsy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-10-31T00:00:00.000Z</StatusDate><Source id="511220" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-10-22T00:00:00.000Z</StatusDate><Source id="565489" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="119">Epilepsy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-06-13T00:00:00.000Z</StatusDate><Source id="607051" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-12-31T00:00:00.000Z</StatusDate><Source id="577995" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1937">Generalized anxiety disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-07-20T00:00:00.000Z</StatusDate><Source id="613139" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2527">Fibromyalgia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2002-10-25T00:00:00.000Z</StatusDate><Source id="511220" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="2527">Fibromyalgia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-05-01T00:00:00.000Z</StatusDate><Source id="789608" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2527">Fibromyalgia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-06-30T00:00:00.000Z</StatusDate><Source id="789859" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2527">Fibromyalgia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-06-21T00:00:00.000Z</StatusDate><Source id="807325" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-07-31T00:00:00.000Z</StatusDate><Source id="618341" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2527">Fibromyalgia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-12-31T00:00:00.000Z</StatusDate><Source id="945907" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1774">Restless legs syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-07-31T00:00:00.000Z</StatusDate><Source id="819965" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="119">Epilepsy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-07-06T00:00:00.000Z</StatusDate><Source id="547687" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-07-06T00:00:00.000Z</StatusDate><Source id="547687" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-10-22T00:00:00.000Z</StatusDate><Source id="565489" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1937">Generalized anxiety disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-03-27T00:00:00.000Z</StatusDate><Source id="658057" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2527">Fibromyalgia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-06-30T00:00:00.000Z</StatusDate><Source id="789859" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2527">Fibromyalgia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-06-30T00:00:00.000Z</StatusDate><Source id="789859" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-09-29T00:00:00.000Z</StatusDate><Source id="948614" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1937">Generalized anxiety disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-12-24T00:00:00.000Z</StatusDate><Source id="1065711" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-05-31T00:00:00.000Z</StatusDate><Source id="988354" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-10-27T00:00:00.000Z</StatusDate><Source id="1142528" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1774">Restless legs syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-12-31T00:00:00.000Z</StatusDate><Source id="1005943" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1774">Restless legs syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-12-31T00:00:00.000Z</StatusDate><Source id="1005943" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1774">Restless legs syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-12-31T00:00:00.000Z</StatusDate><Source id="1005943" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1937">Generalized anxiety disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-09-02T00:00:00.000Z</StatusDate><Source id="557410" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2527">Fibromyalgia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-02-18T00:00:00.000Z</StatusDate><Source id="877891" type="SERIAL"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00782"><Name>GABA receptor</Name><SwissprotNumbers></SwissprotNumbers></Target><Target id="PTGT-04258"><Name>GABA A receptor alpha-2 subunit</Name><SwissprotNumbers><Swissprot>P10063</Swissprot><Swissprot>P23576</Swissprot><Swissprot>P26048</Swissprot><Swissprot>P47869</Swissprot></SwissprotNumbers></Target><Target id="PTGT-04268"><Name>GABA A receptor delta subunit</Name><SwissprotNumbers><Swissprot>O14764</Swissprot><Swissprot>P18506</Swissprot><Swissprot>P22933</Swissprot></SwissprotNumbers></Target><Target id="PTGT-09179"><Name>CACNA2D calcium channel subunit</Name><SwissprotNumbers></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1027030">Amneal Pharmaceuticals Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="15872">Eisai Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="17331">Jeil Pharmaceutical Co Ltd</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="18767">Pfizer Inc</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>5</CountTotal></Company><Company><Company id="20645">Northwestern University</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="DOL1000090">Royalty Pharma</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="5">Drug - Commercialization License</Type><CountActive>5</CountActive><CountInactive>0</CountInactive><CountTotal>5</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>CC(C)C[C@@H](CC(=O)O)CN</Smiles></StructureSmiles><Deals><Deal id="115508" title="Eisai and Pfizer to develop Alzheimer's therapies worldwide including donepezil, pregabalin and icopezil"></Deal><Deal id="130195" title="Impax to copromote Pfizer's Lyrica"></Deal><Deal id="135482" title="Royalty Pharma to acquire a portion of Northwestern University's Lyrica royalty"></Deal><Deal id="138370" title="Jeil to copromote certain Pfizer drugs in Korea"></Deal><Deal id="145972" title="Royalty Pharma to acquire Pfizer's Lyrica royalty stream "></Deal><Deal id="241262" title="Co-promotion of Lyrica to treat neuropathic pain in Japan"></Deal></Deals><PatentFamilies><PatentFamily id="1009384" number="WO-2009094563" title="Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use"></PatentFamily><PatentFamily id="1017219" number="WO-00155090" title="Asymmetric synthesis of pregabalin"></PatentFamily><PatentFamily id="1026038" number="WO-2006008612" title="Preparation of beta-amino acids having affinity for the alpha-2-delta protein"></PatentFamily><PatentFamily id="1028353" number="WO-2009147528" title="Improved process for preparing pregabalin"></PatentFamily><PatentFamily id="1066474" number="WO-03077902" title="Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof"></PatentFamily><PatentFamily id="1097034" number="WO-00191736" title="Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic"></PatentFamily><PatentFamily id="109837" number="WO-2008128775" title="Stabilised pharmaceutical composition containing pregabaline"></PatentFamily><PatentFamily id="1100385" number="CN-01827095" title="Pharmaceutical composition using pregabalin as active ingredient, its preparation method and use"></PatentFamily><PatentFamily id="1100582" number="WO-09908670" title="GABA analogs to prevent and treat gastrointestinal damage"></PatentFamily><PatentFamily id="1102804" number="WO-2009147434" title="A novel and efficient method for the synthesis of an amino acid"></PatentFamily><PatentFamily id="1109209" number="CN-101362696" title="New method for preparing 3-aminomethyl-5-methyl caproate-racemic pregabalin"></PatentFamily><PatentFamily id="1110865" number="CN-101914031" title="Pregabalin derivative and use thereof"></PatentFamily><PatentFamily id="1140185" number="US-06372792" title="Method for treating anxiety, anxiety disorders and insomnia."></PatentFamily><PatentFamily id="1140896" number="WO-2004052360" title="Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof"></PatentFamily><PatentFamily id="1141071" number="WO-2004084879" title="Methods for treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators"></PatentFamily><PatentFamily id="1141453" number="WO-2005027850" title="Treating or preventing restless legs syndrome using prodrugs of GABA analogs"></PatentFamily><PatentFamily id="1161796" number="WO-2007143113" title="The use of enzymatic resolution for the preparation of intermediates of pregabalin"></PatentFamily><PatentFamily id="1166180" number="WO-09209560" title="GABA and L-glutamic acid analogs for antiseizure treatment."></PatentFamily><PatentFamily id="1167552" number="WO-09638405" title="Methods of making (S)-3-(aminomethyl)-5-methylhexanoic acid."></PatentFamily><PatentFamily id="1173496" number="WO-00243763" title="Combination of GABA agonists and aldose reductase inhibitors"></PatentFamily><PatentFamily id="1177615" number="WO-2006108151" title="Crystalline forms of pregabalin"></PatentFamily><PatentFamily id="1182778" number="WO-2012003968" title="Novel gastro-retentive dosage forms comprising a GABA analog and an opioid"></PatentFamily><PatentFamily id="1188218" number="WO-2011076915" title="Novel method for the preparation of (S)-pregabalin"></PatentFamily><PatentFamily id="1208263" number="WO-00002545" title="Compositions comprising GABA analogs and a decongestant to relieve sinus headache pain."></PatentFamily><PatentFamily id="1208500" number="WO-00067742" title="Modulation of substance P by gaba analogs and methods relating thereto"></PatentFamily><PatentFamily id="1215474" number="WO-2005025675" title="Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors"></PatentFamily><PatentFamily id="1234537" number="WO-2004002462" title="Method of treating attention deficit hyperactivity disorder"></PatentFamily><PatentFamily id="1241911" number="WO-09323383" title="GABA and L-glutamic acid analogs for antiseizure treatment."></PatentFamily><PatentFamily id="1252594" number="CN-01962612" title="Pregabalin new crystalline form and its preparation method"></PatentFamily><PatentFamily id="125712" number="WO-2004058168" title="Methods of treating non-painful bladder disorders using alpha2"></PatentFamily><PatentFamily id="1262279" number="WO-2010086429" title="Intermediates in the enantioselective synthesis of 3-(aminomethyl)-5-methyl-hexanoic acid"></PatentFamily><PatentFamily id="1282261" number="WO-00002546" title="Method for the treatment of insomnia."></PatentFamily><PatentFamily id="1294670" number="WO-2009010554" title="Process for the enantioselective preparation of pregabalin"></PatentFamily><PatentFamily id="1322666" number="CN-01857244" title="Slow released pregabalin medicine composition"></PatentFamily><PatentFamily id="133825" number="WO-2010150221" title="Taste masked pharmaceutical compositions of pregabalin"></PatentFamily><PatentFamily id="1380185" number="WO-2009122215" title="Novel process"></PatentFamily><PatentFamily id="1381729" number="CN-101788542" title="Detaching and detecting method for pregabalin and chiral isomeride thereof"></PatentFamily><PatentFamily id="1386302" number="EP-01192944" title="Use of pregabalin for treating asthma"></PatentFamily><PatentFamily id="1391877" number="CN-01929922" title="C1-symmetric bisphosphine ligands and their use in the asymmetric synthesis of pregabalin"></PatentFamily><PatentFamily id="1437600" number="WO-2005018622" title="A pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss"></PatentFamily><PatentFamily id="1438837" number="WO-2006027681" title="Combination of a 5-HT(1) receptor agonist and an alpha-2-delta ligand for the treatment of migraine"></PatentFamily><PatentFamily id="147442" number="WO-2008111096" title="Novel prodrugs"></PatentFamily><PatentFamily id="1490413" number="IN-200901649" title="Extended release floating tablet of pregabalin"></PatentFamily><PatentFamily id="1504470" number="WO-00053225" title="Analgesic compositions comprising anti-epileptic compounds and methods of using same"></PatentFamily><PatentFamily id="1513138" number="WO-2006092691" title="Use of PDE7 inhibitors for the treatment of neuropathic pain"></PatentFamily><PatentFamily id="1526271" number="CN-100368803" title="Kinds of pregabalin chiral isomers separation and determination methods"></PatentFamily><PatentFamily id="1528517" number="EP-02116618" title="Diagnosis and treatment of Kawasaki disease"></PatentFamily><PatentFamily id="153430" number="EP-02389933" title="Controlled-release pregabalin compositions"></PatentFamily><PatentFamily id="1534609" number="WO-2012059798" title="Novel method for racemization of optically pure Î²-cyano ester to corresponding racemic Î²-cyano acid"></PatentFamily><PatentFamily id="1536222" number="WO-00023067" title="Method for the treatment of mania and bipolar disorder"></PatentFamily><PatentFamily id="1542397" number="CN-01634869" title="Novel pregabalin crystalline form and its preparing process"></PatentFamily><PatentFamily id="1545961" number="CN-01806800" title="Pharmaceutical composition making pregabalin as active ingredient, its preparation method and uses"></PatentFamily><PatentFamily id="1561093" number="WO-2012075451" title="Clonidine and GABA compounds in a biodegradable polymer carrier"></PatentFamily><PatentFamily id="1561794" number="WO-2012035559" title="Sustained release pharmaceutical compositions comprising pregabalin"></PatentFamily><PatentFamily id="156503" number="IN-200800929" title="Process for resolution of pregabalin by chiral acids, involves contacting racemic pregabalin with chiral acid to precipitate salt of chiral acid with one of enantiomer"></PatentFamily><PatentFamily id="1565130" number="CN-102464594" title="Preparation method of intermediate compound of pregabalin"></PatentFamily><PatentFamily id="157572" number="IN-200801375" title="Novel polymorph of pregabalin"></PatentFamily><PatentFamily id="1577526" number="DE-19802327" title="Synergistic Analgesic Composition Containing 1-Phenyl-Cyclohexene And Aminobutyric Acid Derivatives"></PatentFamily><PatentFamily id="1583795" number="WO-02094220" title="Liquid pharmaceutical composition"></PatentFamily><PatentFamily id="158544" number="IN-200702207" title="Novel synthetic process for racemic pregabalin"></PatentFamily><PatentFamily id="1586397" number="WO-2005105048" title="Process for the selective increase of a release rate of an active material from a pharmaceutical composition"></PatentFamily><PatentFamily id="1609732" number="WO-00002547" title="The treatment of renal colic with GABA analogs."></PatentFamily><PatentFamily id="1632948" number="CN-102115449" title="Novel preparation method for pregabalin racemic hydrochloride"></PatentFamily><PatentFamily id="1679449" number="WO-2005100580" title="Stereoselective bioconversion of aliphatic dinitriles into cyano carboxylic acids."></PatentFamily><PatentFamily id="1696286" number="US-20080014280" title="Amorphous pregabalin and process for the preparation thereof"></PatentFamily><PatentFamily id="1704438" number="WO-2011016052" title="Process for preparing pregabalin"></PatentFamily><PatentFamily id="1705132" number="WO-2010115612" title="Pregabalin compositions"></PatentFamily><PatentFamily id="1709411" number="IN-200901587" title="Improved process for preparation of pregabalin"></PatentFamily><PatentFamily id="1711066" number="IN-200800323" title="Novel process for synthesis of pregabalin from novel intermediates"></PatentFamily><PatentFamily id="1711115" number="CN-102648915" title="Medicine composition for treating or controlling neuropathtic pain"></PatentFamily><PatentFamily id="1726565" number="WO-00002562" title="Compositions comprising GABA analogs and caffeine."></PatentFamily><PatentFamily id="1749794" number="CN-100500644" title="Interconnected medicine precursor of gabapentin and pregabalin and its medicinal use"></PatentFamily><PatentFamily id="1751975" number="WO-00145714" title="Formulations of adenosine A1 agonists"></PatentFamily><PatentFamily id="1758609" number="WO-2009001372" title="A novel process for the preparation of pregabalin"></PatentFamily><PatentFamily id="1758817" number="WO-2004054559" title="Î±-2-Î´ ligands for different pharmaceutical uses"></PatentFamily><PatentFamily id="1807472" number="WO-2005027975" title="Combinations of alpha-2-delta ligands and acetylcholinesterase inhibitors"></PatentFamily><PatentFamily id="1838697" number="WO-2010143052" title="Novel pharmaceutical compositions containing pregabalin"></PatentFamily><PatentFamily id="184000" number="WO-2008118427" title="Synthesis of (S)-(+)-3-(aminomethyl)-5-methyl hexanoic acid"></PatentFamily><PatentFamily id="1845244" number="CN-101585778" title="Preparation method of pregabalin"></PatentFamily><PatentFamily id="1847349" number="US-08063244" title="Process for the synthesis of pregabalin"></PatentFamily><PatentFamily id="1848435" number="WO-2009127560" title="Intermediates for the preparation of pregabalin and process for their preparation"></PatentFamily><PatentFamily id="1851127" number="WO-2011151708" title="Gastroretentive dosage forms of GABA analogs"></PatentFamily><PatentFamily id="1869434" number="WO-09640617" title="Method of making (S)-3-(aminomethyl)-5-methylhexanoic acid."></PatentFamily><PatentFamily id="1873824" number="WO-00007568" title="Method for making coated gabapentine or pregabaline particles."></PatentFamily><PatentFamily id="1873923" number="WO-09959572" title="Gamma-aminobutyric acid derivatives containing, solid compositions and process for preparing the same."></PatentFamily><PatentFamily id="1880111" number="WO-03093220" title="Process for preparing highly functionalized gamma-butyrolactams and gamma-amino acids"></PatentFamily><PatentFamily id="1882767" number="WO-2006110783" title="Process for making (S)-pregabalin"></PatentFamily><PatentFamily id="1884242" number="WO-2007052125" title="Solid pharmaceutical compositions containing pregabalin"></PatentFamily><PatentFamily id="1899624" number="WO-03020273" title="Pharmaceutical composition comprising gabapentin or an analogue thereof and an alpha-aminoamide and its analgesic use"></PatentFamily><PatentFamily id="1901366" number="WO-2008007145" title="Novel process"></PatentFamily><PatentFamily id="1904123" number="WO-2012059830" title="Manufacturing process for (S)-pregabalin"></PatentFamily><PatentFamily id="1906990" number="WO-09803167" title="IsobutylGABA and its derivatives for the treatment of pain."></PatentFamily><PatentFamily id="1915353" number="WO-2005089872" title="Treatment of local pain"></PatentFamily><PatentFamily id="1927591" number="WO-2011124934" title="Industrial process for the synthesis of (S)-(+)-pregabalin"></PatentFamily><PatentFamily id="195677" number="WO-2009082861" title="New resolution process of (S)-3-aminomethyl-5-methylhexanoic acid"></PatentFamily><PatentFamily id="1971613" number="EP-02067768" title="A process for the preparation of (S)(+)-3-(aminomethyl)-5-methylhexanoic acid"></PatentFamily><PatentFamily id="1976943" number="WO-09912537" title="Analgesic compositions comprising  anti-epileptic compounds and methods using same."></PatentFamily><PatentFamily id="1977180" number="WO-2007027476" title="Treating premature ejaculation using gabapentin and pregabalin prodrugs"></PatentFamily><PatentFamily id="1995336" number="WO-2010004577" title="Preparation of enantiomerically enriched gamma-nitro acid and pregabalin"></PatentFamily><PatentFamily id="199955" number="WO-2006136087" title="Preparation method of pregabalin and its intermediate and the said intermediate"></PatentFamily><PatentFamily id="2005336" number="WO-2012093411" title="Process for the preparation of R-(-)-3-(carbamoylmethyl)-5-methylhexanoic acid and the intermediates"></PatentFamily><PatentFamily id="2029484" number="WO-2005018621" title="A pharmaceutical composition for the prevention and treatment of addiction in a mammal"></PatentFamily><PatentFamily id="2029529" number="WO-2005025563" title="Combination comprising an alpha-2-delta ligand and an ssri and/or snri for treatment of depression and anxiety disorders"></PatentFamily><PatentFamily id="203002" number="WO-03063845" title="Alpha 2 delta ligands to treat tinnitus"></PatentFamily><PatentFamily id="2031140" number="WO-2006078811" title="Pharmaceutical formulations and methods of use"></PatentFamily><PatentFamily id="2033716" number="WO-2008040935" title="New polymorphic forms of pregabalin"></PatentFamily><PatentFamily id="2034209" number="WO-2008117305" title="A novel process for preparing pregabalin and its acid addition salts"></PatentFamily><PatentFamily id="2047886" number="WO-00124792" title="Synergistic combinations of an NK&lt;sub&gt;1&lt;/sub&gt; receptor antagonist and a GABA structural analog."></PatentFamily><PatentFamily id="2049726" number="WO-2005063229" title="Pregabalin composition"></PatentFamily><PatentFamily id="2051121" number="WO-03066040" title="Medicinal compositions containing gabapentin or pregabalin and N-type calcium channel antagonist"></PatentFamily><PatentFamily id="2059071" number="WO-2007127309" title="Processes for the synthesis of 3-isobutylglutaric acid"></PatentFamily><PatentFamily id="2067515" number="CN-101230016" title="Pregabalin derivative and its preparation method and application in neuropathic pain treatment"></PatentFamily><PatentFamily id="2068806" number="WO-2011077463" title="Process for preparing pregabalin and its intermediate"></PatentFamily><PatentFamily id="2080880" number="WO-2012015027" title="Therapeutic agent or prophylactic agent for neuropathic pain"></PatentFamily><PatentFamily id="2103557" number="WO-2005018670" title="Pharmaceutical composition comprising an alpha2delta ligand and an opioid receptor antagonist for the prevention and treatment of addiction in a mammal"></PatentFamily><PatentFamily id="2126565" number="WO-2012059797" title="Process for synthesis of (S)-pregabalin"></PatentFamily><PatentFamily id="2136416" number="CN-01827590" title="Novel pregabalin crystalline form, its preparing process and pharmaceutical compositions thereof"></PatentFamily><PatentFamily id="2137872" number="WO-03070237" title="Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2"></PatentFamily><PatentFamily id="2156593" number="IN-200901648" title="Extended release bilayer tablet of pregabalin"></PatentFamily><PatentFamily id="222986" number="WO-09858641" title="Use of GABA analogs such as gabapentin in the manufacture of a medicament for treating inflammatory diseases."></PatentFamily><PatentFamily id="223121" number="WO-2010036937" title="Topical formulations for treatment of neuropathy"></PatentFamily><PatentFamily id="2263805" number="WO-2009053446" title="Novel pregabalin intermediates and process for preparing them and pregabalin"></PatentFamily><PatentFamily id="2271519" number="WO-2009087650" title="A novel process for synthesis of pregabalin from substituted cyclopropane intermediate and a process for enzymatic resolution of racemic pregabalin"></PatentFamily><PatentFamily id="227419" number="WO-2011141923" title="Improved synthesis of optically pure (S)-3-cyano-5-methyl-hexanoic acid alkyl ester, an intermediate of (S)-pregabalin"></PatentFamily><PatentFamily id="227577" number="WO-2011107812" title="Stabilized pharmaceutical composition"></PatentFamily><PatentFamily id="228248" number="EP-02343055" title="Pharmaceutical compositions of pregabalin"></PatentFamily><PatentFamily id="2294375" number="CU-00023562" title="Bioconversi??n estereoselectiva de dinitrilos alif??ticos en ??cidos cianocarbox??licos"></PatentFamily><PatentFamily id="2297890" number="RU-02446795" title="Method for preventing phantom pain syndrome following amputation of extremity"></PatentFamily><PatentFamily id="2299474" number="WO-2009141362" title="Process for the stereoselective enzymatic hydrolysis of 5-methyl-3-nitromethyl-hexanoic acid ester"></PatentFamily><PatentFamily id="2324813" number="WO-2004006901" title="Gastrointestinal compositions comprising gaba derivatives"></PatentFamily><PatentFamily id="2329521" number="WO-2008009897" title="Process for preparing pregabalin and its opposite enantiomer"></PatentFamily><PatentFamily id="2330002" number="WO-2008079720" title="Alpha-2b receptor agonist and anticonvulsant compositions for treatng chronic pain"></PatentFamily><PatentFamily id="2333809" number="WO-2009044409" title="Novel resolution process for pregabalin"></PatentFamily><PatentFamily id="2344938" number="WO-2005002585" title="Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor"></PatentFamily><PatentFamily id="2351228" number="WO-2007090661" title="Active substance combination"></PatentFamily><PatentFamily id="2369573" number="CN-101985609" title="Pseudomonas and method of implementing microbial transformation for pregabalin intermediate by using the pseudomonas"></PatentFamily><PatentFamily id="2369893" number="WO-2012016683" title="Oral dosage form of pregabalin"></PatentFamily><PatentFamily id="2376102" number="EP-00952156" title="Aluminium complex derivatives for chemical vacuum evaporation and the method of producing the same"></PatentFamily><PatentFamily id="2384695" number="IN-201003772" title="Improved method for preparation of (s)-pregabalin useful for treating epilepsy and neuropathic pain"></PatentFamily><PatentFamily id="2392018" number="KR-01306585" title="The manufacturing method of the pregabalin."></PatentFamily><PatentFamily id="2393067" number="CN-102743357" title="Pregabalin stomach effervescent floating slow release preparation and preparation method thereof"></PatentFamily><PatentFamily id="2425491" number="CN-102793685" title="Oral capsule containing pregabalin and preparation method thereof"></PatentFamily><PatentFamily id="2434761" number="EA-00017542" title="Stable pharmaceutical composition comprising pregabalin, capsule containing the same, method for producing and use thereof"></PatentFamily><PatentFamily id="2440903" number="WO-2013001516" title="Multilayered dosage form"></PatentFamily><PatentFamily id="2455178" number="WO-2013008182" title="Prodrugs of GABA analogs"></PatentFamily><PatentFamily id="2457026" number="CN-102863326" title="Preparation method of one kind of antiepileptic medicine intermediate"></PatentFamily><PatentFamily id="2467739" number="CN-102898320" title="(3R)-(-)-3-(2-acetylamino)-5-methylhexanoic acid preparation method"></PatentFamily><PatentFamily id="2474009" number="WO-02100347" title="Prodrugs of gaba analogs, compositions and uses thereof"></PatentFamily><PatentFamily id="2474131" number="WO-03104184" title="Methods for synthesis of acyloxyalkyl derivatives of GABA analogs"></PatentFamily><PatentFamily id="2474187" number="WO-2004052844" title="Prodrugs of GABA analogs, compositions and uses thereof"></PatentFamily><PatentFamily id="2478652" number="WO-09959573" title="Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivatives and process for preparing the same."></PatentFamily><PatentFamily id="2513034" number="WO-2013054285" title="Gastroretentive dosage system and process of preparation thereof"></PatentFamily><PatentFamily id="2526005" number="CN-103073443" title="Pregabalin preparation method"></PatentFamily><PatentFamily id="2526006" number="CN-103073442" title="Splitting the pregabalin"></PatentFamily><PatentFamily id="2530602" number="WO-2013074320" title="Î±-2B receptor agonist and anticonvulsant compositions for treating chronic pain"></PatentFamily><PatentFamily id="2532338" number="WO-2013076225" title="Process for the preparation of gamma amino acids and intermediates used in said process"></PatentFamily><PatentFamily id="2532780" number="WO-2013076339" title="Combined preparations and compositions for the treatment of fibromyalgia"></PatentFamily><PatentFamily id="2533388" number="CN-103114054" title="Zjb-09277 of arthrobacter and application in preparing (s)--3-cyano--5-methylhexanoic acid"></PatentFamily><PatentFamily id="2543216" number="WO-2013162114" title="Sustained-release preparation using gastroretentive drug delivery system"></PatentFamily><PatentFamily id="2549172" number="WO-2013088410" title="Antineuritic pharmaceutical combination and compositions"></PatentFamily><PatentFamily id="2557012" number="WO-2013100873" title="Pharmaceutical formulation of pregabalin (particle size 300-2500 micrometer)"></PatentFamily><PatentFamily id="2557047" number="WO-2013100874" title="Effervescent pregabalin formulation"></PatentFamily><PatentFamily id="2560641" number="WO-2013103826" title="Anti-inflammatory compounds in combination with hydrogen for the treatment of inflammation"></PatentFamily><PatentFamily id="2566585" number="CN-102952057" title=".. 4-butyl pyridine or a.-2-a is one."></PatentFamily><PatentFamily id="2572955" number="WO-2013114281" title="Pregabalin GR tablets"></PatentFamily><PatentFamily id="2573433" number="WO-2013114283" title="Gastroretentive tablets"></PatentFamily><PatentFamily id="2600661" number="CN-103045559" title="Hydrophobic cotton-like silk spore bacteria thermophilic lipase, coding gene and application thereof"></PatentFamily><PatentFamily id="2611196" number="CN-102375037" title="Method for separating and determining pregabalin chiral isomer with electrophoretically mediated microanalysis technology"></PatentFamily><PatentFamily id="2631541" number="WO-2013168019" title="Compositions and methods for the treatment of neuropathic pain"></PatentFamily><PatentFamily id="2636847" number="WO-2013170966" title="Pharmaceutical composition comprising (1R,4R)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and a gabapentinoid"></PatentFamily><PatentFamily id="2640342" number="CN-103271888" title="Pregabalin orally disintegrating tablet and dispersible tablet and preparation method thereof"></PatentFamily><PatentFamily id="2661487" number="WO-2014108807" title="Formulations, methods and procedures for reducing or preventing the development, or the risk of development, of neuropathology as a result of trauma"></PatentFamily><PatentFamily id="2663960" number="WO-2014005494" title="Method of preparing lactam compound"></PatentFamily><PatentFamily id="2674044" number="CN-103385870" title="Medicine use of pregabalin"></PatentFamily><PatentFamily id="2675397" number="WO-2014016776" title="An improved process for racemization of (S)-3-(carbamoylmethyl)-5-methylhexanoic acid"></PatentFamily><PatentFamily id="2685522" number="IN-00272002" title="Process for racemisation"></PatentFamily><PatentFamily id="2686236" number="CN-103450045" title="Synthetic method of pregabalin intermediate 2-carboxethyl-3-cyano-5-methylethyl caproate"></PatentFamily><PatentFamily id="2694159" number="CN-103494796" title="Pregabalin and steady medicine composition and its preparation method"></PatentFamily><PatentFamily id="2702646" number="CN-103626668" title="Splitting chemistry preparation method of one kind s-configuration pregabalin"></PatentFamily><PatentFamily id="270478" number="WO-2009158343" title="Stereoselective enzymatic synthesis of (S) or (R)-iso-butyl-glutaric ester"></PatentFamily><PatentFamily id="2716213" number="CN-103585098" title="Pregabalin controlled release preparation and its preparation method"></PatentFamily><PatentFamily id="2733200" number="RU-2012144244" title="Method for enantioselective synthesis of (s)-pregabalin"></PatentFamily><PatentFamily id="2733836" number="WO-2014072785" title="A process for the preparation of pregabalin"></PatentFamily><PatentFamily id="2744360" number="WO-2014080345" title="Improved process for the preparation of pregabalin"></PatentFamily><PatentFamily id="2747819" number="CN-103695385" title="Esterase, gene, vector and engineering bacterium derived from &lt;i&gt;Thermomyces lanuginosus&lt;/i&gt; as well as application"></PatentFamily><PatentFamily id="2751724" number="IN-201200459" title="Enantiomeric enrichment of (r)-(-)-3-(carbamoylmethyl)-5-methylhexanoic acid, to form pregabalin involves treating (+/-)-3-(carbamoylmethyl)-5-methylhexanoic acid with (r)-(+)-alpha-phenylethylamine, hydrolyzing and triturating by water"></PatentFamily><PatentFamily id="2773430" number="WO-2014112152" title="Medicine for treatment of neuropathic disease"></PatentFamily><PatentFamily id="2779107" number="CN-103833562" title="A one asymmetric synthesis of pregabalin preparation method"></PatentFamily><PatentFamily id="2780968" number="WO-2014119984" title="Pharmaceutical composition comprising a biphasic immediate-release system for controlling convulsive seizures and pain"></PatentFamily><PatentFamily id="2785583" number="CN-103981160" title="Hydrophobic cotton-like silk spore bacteria thermophilic lipase, coding gene and application thereof"></PatentFamily><PatentFamily id="2785894" number="CN-103980144" title="A pregabalin intermediate mother liquor indiscriminately method"></PatentFamily><PatentFamily id="2789662" number="US-20140243412" title="Process for preparation of pregabalin"></PatentFamily><PatentFamily id="2806833" number="WO-2014155291" title="Process and intermediates for the preparation of pregabalin"></PatentFamily><PatentFamily id="2812970" number="WO-2014168228" title="Composition for topical use"></PatentFamily><PatentFamily id="2816377" number="CN-103922950" title="A pregabalin preparation method"></PatentFamily><PatentFamily id="2819541" number="CN-103948564" title="One of pregabalin capsule and its preparation method"></PatentFamily><PatentFamily id="2826745" number="WO-2014181359" title="A process for the preparation of an anticonvulsant agent pregabalin hydrochloride"></PatentFamily><PatentFamily id="2828149" number="CN-104130987" title="Cordyceps sinensis enzyme ester/lipase, coding gene, carrier, engineering fungus and its application"></PatentFamily><PatentFamily id="2842799" number="CN-104030870" title="Preparation of Â Î²-cyanoketone"></PatentFamily><PatentFamily id="2854423" number="WO-2014205654" title="Compound pharmaceutical compositions for treating pain"></PatentFamily><PatentFamily id="2856397" number="CN-104086439" title="A pregabalin intermediate resolving (r)-(+) -&amp;#945; - phenylethylamine recycling method"></PatentFamily><PatentFamily id="285676" number="WO-00243762" title="Combination of GABA agonists and sorbitol dehydrogenase inhibitors"></PatentFamily><PatentFamily id="2860842" number="CN-104193630" title="Splitting chemistry preparation method of one s-configuration of pregabalin"></PatentFamily><PatentFamily id="2871401" number="CN-104140375" title="Method for preparation of pregabalin"></PatentFamily><PatentFamily id="2887103" number="CN-104293744" title="Derived from thermophilic lipase mutant and application of ankle joint"></PatentFamily><PatentFamily id="2908539" number="CN-104288107" title="Floating sustained-release pellet, the pellet containing medicine composition and preparation method thereof"></PatentFamily><PatentFamily id="2908540" number="CN-104288106" title="Floating sustained-release pellet, the pellet containing medicine composition and preparation method thereof"></PatentFamily><PatentFamily id="2921582" number="CN-104402743" title="A pregabalin preparation method"></PatentFamily><PatentFamily id="2932996" number="CN-104473910" title="Pregabalin sustained-release pellets and preparation method thereof"></PatentFamily><PatentFamily id="2945014" number="CN-104592049" title="Pregabalin drug substances and preparation"></PatentFamily><PatentFamily id="2946765" number="CN-104557577" title="High purity (+)-pregabalin and (-)-pregabalin and preparation method"></PatentFamily><PatentFamily id="2946766" number="CN-104557576" title="High purity pregabalin and preparation method"></PatentFamily><PatentFamily id="2948436" number="CN-104546817" title="Pregabalin sustained-release preparations"></PatentFamily><PatentFamily id="2954106" number="CN-104649919" title="Preparation method of small particle pregabalin"></PatentFamily><PatentFamily id="295934" number="WO-2008077599" title="Combination therapy of lower urinary tract disorders with Î±2Î´ ligands and nsaids"></PatentFamily><PatentFamily id="2961781" number="WO-2015091505" title="Gabapentinoids and sigma receptor ligands combinations"></PatentFamily><PatentFamily id="2965571" number="RU-02544859" title="Method of producing (s)-3-aminomethyl-5-methylhexanoic acid (pregabalin)"></PatentFamily><PatentFamily id="2969044" number="CN-104710320" title="Method for preparing pregabalin"></PatentFamily><PatentFamily id="29752" number="WO-03061656" title="Pharmaceutical composition and method for treating disorders of the central nervous system"></PatentFamily><PatentFamily id="29753" number="WO-03062185" title="Methods for producing substituted acrylic acid esters and use of the latter for producing substituted gamma-amino acids"></PatentFamily><PatentFamily id="2981521" number="CN-104803871" title="Preparation method of pregabalin intermediate"></PatentFamily><PatentFamily id="2981523" number="WO-2016155566" title="Method for preparing pregabalin intermediate, 3-carbamoymethyl-5-methylhexanoic acid, using solvent-free reaction"></PatentFamily><PatentFamily id="2981524" number="CN-104803868" title="Recycling method of 3-isobutyl glutaric acid monoamide"></PatentFamily><PatentFamily id="3000405" number="CN-104829515" title="Pregabalin impurity preparation methodÂ "></PatentFamily><PatentFamily id="3014066" number="CN-104840443" title="Pharmaceutical composition containing active ingredient of pregabalin"></PatentFamily><PatentFamily id="3033071" number="CN-104892441" title="Method for preparing R- isomer of pregabalin"></PatentFamily><PatentFamily id="3042753" number="CN-104906064" title="A pregabalin stomach floating sustained-release tablet and preparation method thereof"></PatentFamily><PatentFamily id="3050970" number="WO-2015156581" title="Pharmaceutical composition containing pregabalin with improved stability and method for preparing same"></PatentFamily><PatentFamily id="3063773" number="US-20150313892" title="Pharmaceutical compositions for treating pain associated with dysmenorrhea"></PatentFamily><PatentFamily id="3069159" number="CN-105001147" title="Preparing method of pregabalin intermediate impurity"></PatentFamily><PatentFamily id="3074202" number="CN-105055371" title="Pregabalin oral administration preparation"></PatentFamily><PatentFamily id="3075382" number="CN-105037183" title="Preparation method of pregabalin impurities"></PatentFamily><PatentFamily id="3087384" number="CN-105085302" title="Pregabalin intermediate"></PatentFamily><PatentFamily id="3087396" number="CN-105085290" title="A pregabalin synthesis method"></PatentFamily><PatentFamily id="3091777" number="WO-2015189068" title="Method for the preparation of beta-substituted gamma-amino carboxylic acids"></PatentFamily><PatentFamily id="3093880" number="CN-105130832" title="Synthesis process of pregabalin"></PatentFamily><PatentFamily id="3098686" number="CN-105152954" title="Method of no solvent recoverying 3-isobutyl glutaric acid monoamide"></PatentFamily><PatentFamily id="3106518" number="WO-2016005897" title="Combination of pregabalin and meloxicam for the treatment of neuropathic pain"></PatentFamily><PatentFamily id="3115998" number="WO-2016009303" title="Pharmaceutical combinations comprising gabapentin or pregabalin with Na&lt;sub&gt;v&lt;/sub&gt;1.7 inhibitors"></PatentFamily><PatentFamily id="3133247" number="CN-105315363" title="A lyrica artificial antigen preparation method"></PatentFamily><PatentFamily id="3135519" number="WO-2016028238" title="A pH responsive hybrid hydrogel and method of synthesis thereof"></PatentFamily><PatentFamily id="3135857" number="WO-2016028237" title="A novel pH responsive hydrogel and method of synthesis"></PatentFamily><PatentFamily id="3141561" number="CN-105348126" title="&lt;para&gt;Method of synthesis of pregabalin using chloroacetonitrile and isobutyraldehyde&lt;/para&gt;"></PatentFamily><PatentFamily id="3141562" number="CN-105348125" title="Method of synthesis of pregabalin using isovaleraldehyde"></PatentFamily><PatentFamily id="3141563" number="CN-105348124" title="Method of synthesis of pregabalin using oxopyrrolidine as intermediate"></PatentFamily><PatentFamily id="3141564" number="CN-105348123" title="&lt;para&gt;Method of synthesis of pregabalin using Î³-isobutyl glutaric anhydride as intermediate&lt;/para&gt;"></PatentFamily><PatentFamily id="3158219" number="CN-105367434" title="Method of using isobutyraldehyde as raw material synthesis pregabalin"></PatentFamily><PatentFamily id="3159019" number="CN-105362335" title="Medicine composition for inhibition of pain and preparation method thereof"></PatentFamily><PatentFamily id="3163826" number="CN-105434395" title="Lyrica capsule and preparation method thereof"></PatentFamily><PatentFamily id="3167753" number="CN-105463037" title="Butylaluminum dinitrile as intermediate in the synthesis of pregabalin"></PatentFamily><PatentFamily id="3178407" number="CN-105481801" title="Preparation method of pregabalin chiral intermediate"></PatentFamily><PatentFamily id="3178493" number="CN-105481712" title="Racemic recycling method of pregabalin intermediate resolution mother liquid"></PatentFamily><PatentFamily id="3178497" number="CN-105481708" title="Method for synthesizing pregabalin with methyl cyanoacetate, or pentanenitrile ce as raw material"></PatentFamily><PatentFamily id="3183912" number="CN-105520918" title="Lyrica capsule"></PatentFamily><PatentFamily id="3203885" number="WO-2016094567" title="Linear polysaccharide based film products"></PatentFamily><PatentFamily id="3236585" number="WO-2016111357" title="Prevention and/or therapeutic agent for fibromyalgia"></PatentFamily><PatentFamily id="3246820" number="UA-00091650" title="Pharmaceutical composition of gamma-aminobutiric acid derivatives for hard gelatinous capsules"></PatentFamily><PatentFamily id="3279060" number="CN-105753726" title="A preparation method of asymmetric synthesis pregabalin"></PatentFamily><PatentFamily id="3353481" number="WO-2016140799" title="Pregabalin immunoassays"></PatentFamily><PatentFamily id="3361296" number="EP-03067700" title="Immunoassay for pregabalin"></PatentFamily><PatentFamily id="3428206" number="CN-106008242" title="Asymmetric alcohol amine salt catalysis of chiral thiourea solution"></PatentFamily><PatentFamily id="3433854" number="WO-2016173960" title="Optimized synthesis of pregabalin and 4-aminobutane acid using an improved method for producing conjugated nitroalkenes"></PatentFamily><PatentFamily id="3443049" number="WO-2018001148" title="Method for preparing pregabalin intermediate 3-isobutylglutaric acid monoamide"></PatentFamily><PatentFamily id="345847" number="WO-00101983" title="A synergistic combination; gabapentin and pregabalin"></PatentFamily><PatentFamily id="3459711" number="WO-2016190638" title="Medicament comprising carisbamate, and use thereof for prevention, alleviation or treatment of pain or epilepsy"></PatentFamily><PatentFamily id="3508994" number="LV-00015168" title="Method for synthesis of (s)-3-aminomethyl-5-methylhexanoic acid"></PatentFamily><PatentFamily id="3513813" number="CN-106278931" title="3-isobutylglutaricacid monoamide preparation method"></PatentFamily><PatentFamily id="3533836" number="WO-2017019791" title="Synthesis of (S)-pregabalin"></PatentFamily><PatentFamily id="3538590" number="IN-201502812" title="Pharmaceutical composition useful for treating neuropathic pain and related disorders, comprises component comprising nortriptyline or its salt and excipients, and another component comprising pregabalin or its salt, and excipients"></PatentFamily><PatentFamily id="3538591" number="IN-201502811" title="Preparation of pharmaceutical composition used for treating neuropathic pain and related disorders, by preparing component comprising nortriptyline and excipients, and preparing another component comprising pregabalin and excipients"></PatentFamily><PatentFamily id="35548" number="EP-01977744" title="Polymorphic form alpha of (S)-pregabalin and process for its preparation"></PatentFamily><PatentFamily id="356537" number="EP-01178034" title="Alkyl amino acid derivatives useful as pharmaceutical agents"></PatentFamily><PatentFamily id="356889" number="WO-2007139933" title="Processes for the preparation of R-(+)-3-(carbamoyl methyl)-5-methylhexanoic acid and salts thereof"></PatentFamily><PatentFamily id="3604399" number="WO-2017064192" title="Pregabalin compositions"></PatentFamily><PatentFamily id="3628392" number="CN-106606495" title="A pregabalin sustained release tablet pharmaceutical composition and preparation method thereof"></PatentFamily><PatentFamily id="364040" number="EP-01992609" title="A process for the preparation of a (S)(+)-3-(aminomethyl)-5-methylhexanoic acid"></PatentFamily><PatentFamily id="3647365" number="CN-106676084" title="A lipase mutant derived from ankle joint, encoding gene and application thereof"></PatentFamily><PatentFamily id="366932" number="KR-2010015014" title="The pharmaceutical composition which prevents the spinal cord injury including pregabalin and cured."></PatentFamily><PatentFamily id="3674388" number="CN-106748850" title="A preparation method of pregabalin"></PatentFamily><PatentFamily id="3692695" number="RU-02619212" title="Method of prophylaxis of post-traumotomic pain syndrome in oncosurgery"></PatentFamily><PatentFamily id="3788212" number="JP-2017160158" title="Optically active 4-nitro butane acid ester and the manufacturing method of a pregabalin"></PatentFamily><PatentFamily id="378894" number="EP-02418194" title="Process for the preparation of pregabalin"></PatentFamily><PatentFamily id="379158" number="WO-2011071520" title="Processes for the preparation of (S)-3-(aminomethyl)-5-methylhexanoic acid"></PatentFamily><PatentFamily id="3808996" number="WO-2017172603" title="Topical formulation"></PatentFamily><PatentFamily id="3842762" number="MX-2016002508" title="Process and pharmaceutical composition of a pregabalin-etoricoxib combination for the treatment of pain."></PatentFamily><PatentFamily id="3878875" number="CN-107400075" title="Method for preparing pregabalin intermediate"></PatentFamily><PatentFamily id="3913556" number="IN-201304068" title="A process for synthesis of pregabalin"></PatentFamily><PatentFamily id="3929526" number="CN-107602402" title="A method of using ion exchange method for preparing pregabalin"></PatentFamily><PatentFamily id="3946217" number="CN-107641093" title="A method for preparing 4 - (s) - isobutyl -2 - pyrrolidone"></PatentFamily><PatentFamily id="4004175" number="CN-107857710" title="A method for preparing antiepileptic is pregabalin"></PatentFamily><PatentFamily id="4004176" number="CN-107857709" title="A method for preparing antiepileptic is pregabalin"></PatentFamily><PatentFamily id="4021568" number="WO-2018069687" title="Treatment of osteoarthritis"></PatentFamily><PatentFamily id="4042544" number="CN-107961225" title="A lyrica micro-osmotic pump tablet and preparation method thereof"></PatentFamily><PatentFamily id="4046909" number="CN-107976489" title="A method for measuring residual pyridine of pregabalin"></PatentFamily><PatentFamily id="4054584" number="CN-107998074" title="Pregabalin, oral solution and preparation method thereof"></PatentFamily><PatentFamily id="4095793" number="WO-2018111060" title="Combinations and methods for the treatment of neuropathic pain"></PatentFamily><PatentFamily id="4097430" number="JP-2018095567" title="The 4-amino-3- butane acids related object containing solid preparation"></PatentFamily><PatentFamily id="4099454" number="CN-108159011" title="Lyrica stomach detention slow release of double-phase release tablet and preparation method thereof"></PatentFamily><PatentFamily id="4116251" number="CN-108218649" title="Pregabalin and synthesis method of intermediate thereof"></PatentFamily><PatentFamily id="4135258" number="WO-2018134682" title="Method and system for predicting refractory epilepsy status"></PatentFamily><PatentFamily id="4136207" number="WO-2018138579" title="Method and system for predicting optimal epilepsy treatment regimes"></PatentFamily><PatentFamily id="4138614" number="JP-2018118909" title="Pregabalin containing pharmaceutical composition"></PatentFamily><PatentFamily id="415430" number="CA-02530904" title="Pharmaceutical agents for the treatment of pain associated with spinal cord injury"></PatentFamily><PatentFamily id="4162158" number="CN-108358799" title="Preparation method of pregabalin"></PatentFamily><PatentFamily id="4171411" number="WO-2018154337" title="Biomarkers"></PatentFamily><PatentFamily id="4185849" number="CN-108456144" title="A small grain crystalline pregabalin, composition and its preparing method"></PatentFamily><PatentFamily id="4185850" number="CN-108456143" title="Asymmetric preparing (s)--3 - aminomethyl - -5 - methylhexanoic acid"></PatentFamily><PatentFamily id="4196890" number="CN-108478537" title="A containing osmotic pump controlled release tablet of pregabalin"></PatentFamily><PatentFamily id="420203" number="WO-2004020424" title="Process for preparing functionalized -butyrolactiones from mucohalic acid"></PatentFamily><PatentFamily id="4206734" number="JP-2018150287" title="Oral pharmaceutical composition by which the unpleasant taste was masked"></PatentFamily><PatentFamily id="422297" number="WO-2009068967" title="Processes for preparing a substituted gamma-amino acid"></PatentFamily><PatentFamily id="423727" number="WO-00061188" title="Sodium channel blocker compositions and the use thereof"></PatentFamily><PatentFamily id="4250493" number="EP-03395336" title="Transdermal absorption preparation"></PatentFamily><PatentFamily id="4258674" number="CN-108715881" title="A zone, stereo-selective bio-catalytic synthesis of pregabalin chiral intermediate method"></PatentFamily><PatentFamily id="4304969" number="IN-00303996" title="Controlled release gastroretentive composition"></PatentFamily><PatentFamily id="4308735" number="CN-108912004" title="A synthesis method of pregabalin intermediate"></PatentFamily><PatentFamily id="4321663" number="WO-2018237009" title="Hydrogel prodrug for treatment"></PatentFamily><PatentFamily id="4324021" number="CN-108997128" title="A pregabalin intermediate 3-nitric acid methyl -5 - methyl caproic acid ethyl ester preparation method"></PatentFamily><PatentFamily id="4335050" number="CN-109044981" title="A pregabalin stomach floating sustained-release tablet and its preparation method"></PatentFamily><PatentFamily id="434229" number="WO-2006008640" title="Non-aqueous suspension containing a drug having an unpleasant taste"></PatentFamily><PatentFamily id="434743" number="WO-2005018645" title="A pharmaceutical composition for the prevention and treatment of addiction in a mammal"></PatentFamily><PatentFamily id="4358717" number="CN-109125287" title="Pregabalin tablet and its preparation method"></PatentFamily><PatentFamily id="4366056" number="CN-109232311" title="A environment-friendly high-effective pregabalin synthesis method"></PatentFamily><PatentFamily id="4400184" number="CN-109320430" title="Method for synthesizing pregabalin intermediate"></PatentFamily><PatentFamily id="440236" number="WO-2009149928" title="Processes for making pregabalin and intermediates therefor"></PatentFamily><PatentFamily id="4436903" number="CN-109456246" title="Pregabalin lactam methylene dimer and its preparation method"></PatentFamily><PatentFamily id="4445357" number="CN-109503403" title="Splitting method of pregabalin"></PatentFamily><PatentFamily id="4445358" number="CN-109503402" title="Preparation method of green chelating agent"></PatentFamily><PatentFamily id="4445359" number="CN-109503401" title="Preparation method of pregabalin"></PatentFamily><PatentFamily id="445051" number="SK-00005966" title="Stable composition of pregabalin"></PatentFamily><PatentFamily id="445550" number="WO-2010070593" title="Malonate esters"></PatentFamily><PatentFamily id="445557" number="WO-2011086565" title="Method for preparation of enantiomerically enriched and/or racemic gamma-amino acids"></PatentFamily><PatentFamily id="44556" number="CZ-00297970" title="Process for preparing (s)-3-(aminomethyl)-5-methyl-hexanoic acid (pregabalin)"></PatentFamily><PatentFamily id="4455604" number="WO-2019067403" title="Compositions and methods for assessing painful demyelinating and nondemyelinating diseases"></PatentFamily><PatentFamily id="4455710" number="WO-2019067768" title="Fixed dose combination formulations for treating pain"></PatentFamily><PatentFamily id="4456830" number="JP-2019052147" title="The pregabalin containing orally disintegrating tablet in which chemical stability was improved"></PatentFamily><PatentFamily id="4461830" number="WO-2019070641" title="Acetaminophen-pregabalin combinations and methods of treating pain"></PatentFamily><PatentFamily id="4466538" number="CN-109554358" title="Polypeptide, dna molecule, recombinant vector, transformant and application thereof"></PatentFamily><PatentFamily id="4480558" number="JP-06504638" title="A tablet and its manufacturing method"></PatentFamily><PatentFamily id="449254" number="WO-2010017498" title="Methods of synthesizing N-hydroxysuccinimidyl carbonates"></PatentFamily><PatentFamily id="4495006" number="KR-2019045026" title="The pregabalin refining manufacture method in which the stability is improved."></PatentFamily><PatentFamily id="4496752" number="WO-2010025931" title="Pharmaceutical combination"></PatentFamily><PatentFamily id="4498928" number="CN-109678737" title="A preparation method of pregabalin"></PatentFamily><PatentFamily id="4506766" number="WO-2019093631" title="Method for screening pain inhibiting substance"></PatentFamily><PatentFamily id="4506875" number="JP-2019073478" title="The 4-amino butane acids related object containing solid preparation and its manufacturing method"></PatentFamily><PatentFamily id="4531991" number="CN-109761838" title="A method for preparing pregabalin intermediates and recycling the resolving agent"></PatentFamily><PatentFamily id="45403" number="NZ-00543762" title="Use of an alpha2delta subunit calcium channel modulator such as gabapentin or pregabalin in a medicament for treating non-painful disorders of the bladder"></PatentFamily><PatentFamily id="455006" number="IN-00283092" title="An improved process for the preparation of enantiomerically pure pregabalin"></PatentFamily><PatentFamily id="4562347" number="WO-2019124358" title="Method for improving chemical stability of pregabalin by particle size control"></PatentFamily><PatentFamily id="46931" number="WO-2009066325" title="Controlled release pharmaceutical compositions of pregabalin"></PatentFamily><PatentFamily id="473858" number="WO-02078747" title="Pregabalin lactose conjugates"></PatentFamily><PatentFamily id="476190" number="WO-2005102389" title="Combinations comprising alpha-2-delta ligands"></PatentFamily><PatentFamily id="493266" number="WO-2010061403" title="Process to prepare highly pure (S)-pregabalin"></PatentFamily><PatentFamily id="493953" number="AR-00064949" title="A process for the preparation of pregabalin"></PatentFamily><PatentFamily id="494194" number="WO-2005041923" title="Compositions and dosage forms for enhanced absorption of metformin"></PatentFamily><PatentFamily id="514895" number="WO-2008004044" title="Process for the preparation of (R)-(-)-3-(carbamoylmethyl)-5-methylhexanoic acid and of pregabalin and synthesis intermediates"></PatentFamily><PatentFamily id="52031" number="WO-2007107835" title="Stable liquid formulations of antiepileptic agents"></PatentFamily><PatentFamily id="53267" number="WO-00061234" title="Combinations of GABA analogs and tricyclic compounds to treat depression"></PatentFamily><PatentFamily id="552061" number="WO-2007035789" title="Chiral 3-carbamoylmethyl-5-methyl hexanoic acids, key intermediates for the new synthesis of (S)-pregabalin"></PatentFamily><PatentFamily id="553194" number="WO-2008062460" title="Crystalline forms of pregabalin"></PatentFamily><PatentFamily id="567444" number="WO-00188101" title="Cell line for the expression of an Î±2Î´2 calcium channel subunit"></PatentFamily><PatentFamily id="572088" number="US-08044227" title="Preparation of pregabalin and related compounds"></PatentFamily><PatentFamily id="593775" number="WO-2009080365" title="Pregabalin salts"></PatentFamily><PatentFamily id="602702" number="CN-102465157" title="A biological enzyme method for preparing pregabalin chiral intermediate"></PatentFamily><PatentFamily id="614786" number="WO-09908667" title="Methods for treating physiological conditions associated with the use, or sequelae of use, of cocaine or other psychomotor stimulants."></PatentFamily><PatentFamily id="624354" number="WO-2008060572" title="Use of gabapentin and pregabalin prodrugs for treating tinnitus"></PatentFamily><PatentFamily id="628021" number="WO-2008137512" title="Process for preparing pregabalin"></PatentFamily><PatentFamily id="663847" number="WO-2009087674" title="Improved process for the preparation of (S)-pregabalin"></PatentFamily><PatentFamily id="701847" number="WO-2008138874" title="Process for preparing (S)-pregabalin by optical resolution of racemic pregabalin"></PatentFamily><PatentFamily id="713754" number="US-08686040" title="Method for treating anal pruritis and other perianal disorders"></PatentFamily><PatentFamily id="713785" number="WO-2009125427" title="Process for preparing (S)-3-(aminomethyl)-5-methylhexanoic acid"></PatentFamily><PatentFamily id="715678" number="WO-2005095424" title="Preparation of p-chirogenic phospholanes and their use in asymetric synthesis"></PatentFamily><PatentFamily id="722239" number="WO-2006000904" title="Preparation of pregabalin and related compounds"></PatentFamily><PatentFamily id="722349" number="WO-00061135" title="Method for the treatment of incontinence"></PatentFamily><PatentFamily id="740275" number="WO-2009087005" title="Composition comprising a nitrooxyderivative of acetaminophen and a anticonvulsant drug for the treatment of neuropathic pain"></PatentFamily><PatentFamily id="741699" number="WO-2009081208" title="Processes to pregabalin"></PatentFamily><PatentFamily id="775951" number="US-20090062393" title="Deuterium-enriched pregabalin"></PatentFamily><PatentFamily id="78567" number="CN-102115439" title="Preparing method of pregabalin intermediate 3-isobutyl glutarate"></PatentFamily><PatentFamily id="792063" number="WO-2005092318" title="Combinations comprising alpha-2-delta ligands"></PatentFamily><PatentFamily id="814984" number="CR-00007060" title="Pregabalin lactose conjugate"></PatentFamily><PatentFamily id="81846" number="IN-200602096" title="Extended release tablet of pregabalin comprises pregabalin, rate controlling polymer and excipients"></PatentFamily><PatentFamily id="823273" number="WO-2011053003" title="Gastric-retentive sustained release formulation containing pregabalin, polyethyleneoxide and PVA-PEG graft copolymer"></PatentFamily><PatentFamily id="843823" number="HU-200203768" title="Combination containing cGMPe inhibitor and gabapentine or pregabaline"></PatentFamily><PatentFamily id="844190" number="WO-2004016259" title="Synergistic combination of an alpha-2-delta ligand and a PDEV inhibitor for use in the treatment of pain"></PatentFamily><PatentFamily id="848484" number="WO-2007102058" title="Alpha-2-delta ligands for non-restorative sleep"></PatentFamily><PatentFamily id="865838" number="WO-2009046309" title="Pregabalin -4-eliminate, pregabalin 5-eliminate, their use as reference marker and standard, and method to produce pregabalin containing low levels thereof"></PatentFamily><PatentFamily id="868015" number="WO-2005082372" title="Combination of gamma-aminobutyric acid modulators and 5-HT&lt;sub&gt;1B&lt;/sub&gt;&lt;sub&gt;&lt;/sub&gt;"></PatentFamily><PatentFamily id="923752" number="WO-2008132589" title="Combinations comprising pregabalin"></PatentFamily><PatentFamily id="924053" number="WO-2009022839" title="Novel method for preparing pregabalin"></PatentFamily><PatentFamily id="937287" number="WO-00107037" title="Method of treating symptoms of hormonal variation, including hot flashes"></PatentFamily><PatentFamily id="939701" number="WO-2006121557" title="Pregabalin free of Lactam and a process for preparation thereof"></PatentFamily><PatentFamily id="965909" number="CU-00023651" title="Preparaci??n de pregabalina y compuestos relacionados"></PatentFamily><PatentFamily id="96752" number="EP-00974351" title="Medicament for preventing and treating gastrointestinal damage."></PatentFamily><PatentFamily id="968444" number="WO-2012025861" title="Process for the preparation of (S)-3-cyano-5-methylhexanoic acid derivatives of adn pregabalin"></PatentFamily><PatentFamily id="971448" number="IN-00295333" title="Efficient process for synthesis of pregabalin"></PatentFamily><PatentFamily id="997920" number="WO-2009004643" title="An improved process for preparation of (S)-pregabalin and intermediates thereof"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="1">Analyte</Type><Count>3</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>115</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="11">Process (Intermediate)</Type><Count>60</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>3</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>16</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="2">Drug Target</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>67</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="4">Delivery device</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>125</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>7</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>28</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ohara Pharmaceutical Co Ltd" id="1000882"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Chiral Quest Inc" id="1002505"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="FDC Ltd" id="1003015"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="CrystalGenomics Inc" id="1003254"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Agency For Science Technology &amp; Research" id="1006569"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Qilu Pharmaceutical Co Ltd" id="1006577"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hikal Ltd" id="1008476"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Aquestive Therapeutics Inc" id="1008765"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="KT&amp;G Corp" id="1008780"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Kunming Baker Norton Pharmaceutical Co Ltd" id="1008863"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Lunan Pharmaceutical Co Ltd" id="1009275"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sanofi SA" id="1009547"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Chongqing University of Technology" id="1010449"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Emcure Pharmaceuticals Ltd" id="1010536"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sanovel Ilac Sanayi Ve Tic-Aret Anonim Sirketi" id="1010709"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Astellas Pharma Inc" id="1013295"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Rubicon Research Private Ltd" id="1014536"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zhejiang University" id="1014561"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ark Diagnostics" id="1015191"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="SK Biopharmaceuticals" id="1015501"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shanghai Fosun Pharmaceutical (Group) Co Ltd" id="1015871"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Divis Laboratories Ltd" id="1015911"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Kemphys Ltd" id="1016653"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pharmed Medicare Private Ltd" id="1016896"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zhejiang University of Technology" id="1017337"></CompanyLink><CountAsOwner>8</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>8</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Laboratorios Liomont Sa De Cv" id="1017445"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Dishman Pharmaceuticals &amp; Chemicals Ltd" id="1020925"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="PharmaNova Inc" id="1022099"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Quay Pharmaceuticals Ltd" id="1022100"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="KHS AG" id="1023812"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="MSN Laboratories Ltd" id="1025511"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Changzhou Pharmaceutical Co Ltd" id="1025584"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Amneal Pharmaceuticals Inc" id="1027030"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Anjan Drugs Pvt Ltd" id="1027054"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Changzhou Sunlight Fine Chemical Co Ltd" id="1027342"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="HEC Pharm Co Ltd" id="1028084"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Indoco Remedies Ltd" id="1028190"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Laboratorios Senosiain" id="1028281"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Micro Labs Ltd" id="1028350"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="PMC Global Inc" id="1029646"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zhejiang Huahai Pharmaceutical Group Co Ltd" id="1030330"></CompanyLink><CountAsOwner>20</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>20</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zhejiang Jiuzhou Pharmaceutical Co Ltd" id="1030338"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zhejiang NHU Company Ltd" id="1030344"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Fogangren Bio-Pharma Ltd" id="1030649"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Industry-Academic Cooperation Foundation Dankook University" id="1031908"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Arbor Pharmaceuticals Inc" id="1035265"></CompanyLink><CountAsOwner>11</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>11</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sun Pharmaceutical Advanced Research Co Ltd" id="1035705"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Competence Centre for Cancer Research" id="1036334"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Chemo Iberica SA" id="1041486"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Trinity Laboratories Inc" id="1043169"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Protia LLC" id="1043660"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Jiangsu Nhwa Pharmaceutical Group Co Ltd" id="1048457"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Lianhe Chemical Technology Co Ltd" id="1048639"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Northwest Normal University" id="1049231"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Emma Childrenâs Hospital" id="1050716"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hengdian Group Ltd" id="1050881"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Taraxos Inc" id="1053265"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Enaltec Labs Pvt Ltd" id="1053716"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="BioPlus Life Sciences Pvt Ltd" id="1053891"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Up Chemical Co Ltd" id="1055045"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Edusa Pharmaceuticals Inc" id="1055630"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hankuk University of Foreign Studies" id="1055885"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shanghai Chenpon Pharmaceutical Technology Co Ltd" id="1056437"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hainan Poly Pharm Co Ltd" id="1056749"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zhejiang Tiantai Aurisco Pharmaceutical Co Ltd" id="1057544"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zhejiang Huayi Pharmaceutical Co Ltd" id="1057906"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Servicio Andaluz De Salud" id="1058089"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="RDD Pharma Ltd" id="1058840"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Helvetica Industries Pvt Ltd" id="1060251"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shanghai Pharmaceuticals Holding Co Ltd" id="1060612"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Beijing Rundekang Medical Technology Co Ltd" id="1061262"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Dissymmetrix Pvt Ltd" id="1062962"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shasun Pharmaceuticals Ltd" id="1063142"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Invent Farma ehf" id="1063377"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Haisco Pharmaceutical Group Co Ltd" id="1063506"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Krisani Biosciences (P) Ltd" id="1066295"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ningbo Meinuohua Pharmaceutical Co Ltd" id="1068475"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Skyview Enterprises Ltd" id="1068513"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Beijing Huaxi United Technology Development Co Ltd" id="1069839"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Henan Normal University" id="1069855"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Taicang Yuntong Chemical Factory" id="1069858"></CompanyLink><CountAsOwner>9</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>9</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Drug Process Licensing Associates LLC" id="1069945"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Koc University" id="1069946"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Optimus Pharma Pvt Ltd" id="1072625"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Northeast Pharmaceutical Group Co Ltd" id="1073084"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Kaiyuan Hengtai Pharma Co Ltd" id="1074711"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Heilongjiang Province Zhicheng Medicine Technology Co Ltd" id="1075883"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nanjing Yiheng Pharmaceutical Co Ltd" id="1076218"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Guangzhou Analysis &amp; Test Center" id="1078090"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Alpha Pharmaceutical Co Ltd, Jiangsu Province" id="1079121"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Huadong Medicine Co Ltd" id="1080476"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Neutec Pharmaceuticals" id="1084359"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Beijing Wanquan Dezhong Pharmaceutical Biotechnology Co Ltd" id="1085766"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Qingdao Central Hospital" id="1086921"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Allergan plc" id="1088700"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Endo International plc" id="1089706"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="AC Pharmaceuticals Co Ltd" id="1091493"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Huizhou Raffles Pharmatech Co Ltd" id="1091665"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Knight Therapeutics Inc" id="1093663"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Gansu Agricultural University" id="1094301"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shanghai Aucta Pharmaceuticals Co Ltd" id="1097080"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Medtronic plc" id="1097361"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sapna Life Sciences Corp" id="1098324"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="PPTM International SARL" id="1098372"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hebei Chengxin Co Ltd" id="1100319"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hebei Fine Chemical Co Ltd" id="1101739"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Huateng Pharmaceutical Co Ltd" id="1102441"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Cheer Fine Pharmaceutical (Anhui) Co Ltd" id="1111189"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hangzhou Alltest Biotech Co Ltd" id="1114390"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Chengdu Aibike Biotechnology Co Ltd" id="1121148"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hunan Linuo Biological Pharmaceutical Co Ltd" id="1123627"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Advent International" id="1123769"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nevakar LLC" id="1127235"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Immunial Enterprises Limited" id="1128000"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zhejiang Hongguan Biological Pharmaceutical Co Ltd" id="1143043"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Suzhou Yingnuoxin Pharmaceutical Technology Co Ltd" id="1143722"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Alliance Medical Group" id="1148001"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Viking Scientific Inc" id="1150064"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Syncozymes (Shanghai) Co. Ltd" id="1152307"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Tioga Research Inc" id="1154775"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="DowDuPont Inc" id="1155603"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zhejiang Huahai Zhicheng Pharmaceutical Co Ltd" id="1157287"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Guizhou Normal University" id="1164536"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Jiangxi Kewei Collaborative Innovation Pharmaceutical Co Ltd" id="1166068"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Cidat Sa De Cv" id="1166509"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Finanziaria Industriale Mobiliare ed Immobiliare SPA" id="1167241"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hainan Boao Ruida Medicell International Medical Center" id="1173494"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Guangzhou Daguang Pharmaceutical Co Ltd" id="1174187"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Langfang Zekang Pharmaceutical Technology Co Ltd" id="1182991"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Teva Takeda Pharma Ltd" id="1183994"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Wuxi Griffin Pharmaceutical  co Ltd" id="1185127"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ajinomoto Co Inc" id="13794"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Chinese Academy of Medical Military Sciences" id="14168"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Laboratorio Chimico Internazionale SpA" id="15383"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="CJ Corp" id="15473"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Cipla Ltd" id="15503"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Council of Scientific and Industrial Research (India)" id="15561"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Newron Pharmaceuticals SpA" id="15914"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Laboratorios Dr Esteve SA" id="16074"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Grunenthal GmbH" id="16587"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Western Australia" id="16842"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Johnson &amp; Johnson" id="17332"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sanford-Burnham Medical Research Institute" id="17746"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Maruho Co Ltd" id="17950"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Merck KGaA" id="18101"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mylan NV" id="18439"></CompanyLink><CountAsOwner>6</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>8</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nippon Chemiphar Co Ltd" id="18524"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nitto Denko Corp" id="18574"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ono Pharmaceutical Co Ltd" id="18681"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Orion Corp" id="18693"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pfizer Inc" id="18767"></CompanyLink><CountAsOwner>76</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>76</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Gedeon Richter Ltd" id="19441"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Servier" id="19863"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Siegfried Holding Ltd" id="19908"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Teva Pharmaceutical Industries Ltd" id="20348"></CompanyLink><CountAsOwner>19</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>21</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Toray Industries Inc" id="20406"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Towa Pharmaceutical Co Ltd" id="20423"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="UCB SA" id="20452"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of London" id="20607"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Northwestern University" id="20645"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Oklahoma" id="20650"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Rochester" id="20669"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Tokyo" id="20686"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"></CompanyLink><CountAsOwner>37</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>37</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="China Pharmaceutical University" id="21231"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="McMaster University" id="21238"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Texas System" id="21864"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Lupin Ltd" id="21932"></CompanyLink><CountAsOwner>7</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>9</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ethypharm SA" id="21952"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Apotex Inc" id="22353"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Suzuken Co Ltd" id="22959"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Novartis AG" id="23137"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Texas A&amp;M University System" id="23290"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="NicOx SA" id="23741"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Purdue Pharma LP" id="24191"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Trinity College Dublin" id="24704"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Russian Academy of Sciences" id="24837"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Panacea Biotec Ltd" id="25333"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Granada" id="25460"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Korea Advanced Institute of Science and Technology" id="25540"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Synthon BV" id="26145"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Dinamite Dipharma SpA" id="26954"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sun Pharmaceutical Industries Ltd" id="27561"></CompanyLink><CountAsOwner>8</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>9</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Wockhardt Ltd" id="27614"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="P Hertzen Moscow Cancer Research Institute" id="28172"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="GlaxoSmithKline plc" id="28355"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Natco Pharma Ltd" id="28692"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zydus-Cadila Group" id="29062"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Glenmark Pharmaceuticals Ltd" id="29326"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Dr Reddy's Laboratories Ltd" id="29387"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Royal College of Surgeons in Ireland" id="29655"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Alembic Ltd" id="29955"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Cadila Pharmaceuticals Ltd" id="30025"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Dynogen Pharmaceuticals Inc" id="30151"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Aurobindo Pharma Ltd" id="30215"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Medichem SA" id="30595"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ind-Swift Ltd" id="31515"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Randox Laboratories Ltd" id="31531"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Catholic University of Korea" id="DOL1000277"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Fudan University" id="DOL1000375"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>Y</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>